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ABSTRACT
It is now well-established that certain regions in the human genome show allelic non-
equivalence, depending on their maternal or paternal origin. This phenomenon,
known as genomic imprinting, violates the classical Mendelian assumption of
equivalent parental genetic contributions at autosomal loci. Imprinting occurs through
the action of epigenetic mechanisms during gametogenesis, which lead to parent-of-
origin specific transcriptional regulation of a subset of genes in the offspring.
This thesis describes work that arose from studies of the imprinting of GNAS1, on
human chromosome 20ql3. Null mutations in GNAS1 cause the hormone-resistance
syndrome pseudohypoparathyroidism type la (PHPla). It was demonstrated that
GNAS1 is imprinted, as predicted from the anomalous inheritance of PHP la, but that
its allele-specific regulation is highly complex. This gene is shown to encode several
protein products: (i) the alpha subunit of the stimulatory G protein Gs; this protein is
biallelically derived; (ii) NESP55, a neuroendocrine secretory protein, expressed
exclusively from the maternal allele; (iii) XLas, a Golgi-specific G protein that is
expressed exclusively from the paternal allele.
Many known imprinted genes lie in clusters that may span several hundred of kb, and
may be co-ordinately regulated by an imprinting control region. To assess whether
GNAS1 is part of such an imprinted gene cluster, genomic clones were analysed for
the presence of other nearby transcripts. This resulted in the identification of two
novel genes, CTSZ and CGI107, as well as a number ofputative transcripts that lie
within GNAS1. One of the latter forms part of a spliced polyadenylated antisense
transcript that spans the upstream region ofNESP55.
The CTSZ gene was shown to comprise 6 exons and 5 introns, spanning -12 kb. It
encodes cathepsin Z, a cysteine protease whose precise function is undefined. The
CGI107 gene was shown to comprise 6 exons and 5 introns, spanning -10 kb,
encoding a 194 amino acid protein of unknown function, but showing sequence
similarity to the kisir protein in Drosophila. Four chromosomally dispersed processed
pseudogenes ofCGI107 were identified.
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Expressed sequence polymorphisms were identified within both genes and used to
assess the allelic origin of transcripts in a range ofhuman tissues. Biallelic expression
was demonstrated for both genes, making it unlikely that they are imprinted. Together
with the biallelic expression of another neighbouring gene, TH1, these results suggest
the possibility that GNAS1 may not after all be part of an extensive cluster of
imprinted genes. This has implications for further studies of the mechanism of
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CHAPTER 1
THE GENOMIC IMPRINTING MECHANISM
CHAPTER 1. THE GENOMIC IMPRINTING MECHANISM
1.1 INTRODUCTION
Based on observations ofhis famous breeding experiments in the plant Pisum
sativum, Gregor Mendel, in 1865, concluded the existence of several rules that
govern the patterns by which genes are passed from one generation to the next. One
of the cornerstones ofMendel's "laws" is the idea that each parent makes a similar
contribution of genetic material to their offspring (Hall, 1990). In accordance with
this, most genes in humans are inherited in two copies, one from each parent (the
clear exceptions being sex-linked genes in males and mitochondrial genes) (Nicholls,
2000).
However, since the 1980s, evidence has emerged that cuts across these Mendelian
principles, since it has been found that certain regions in the genome are functionally
non-equivalent, depending on their maternal or paternal allelic origin. This
phenomenon, known as genomic imprinting, is believed to depend on epigenetic
modifications of the genome. Imprinting may be defined as a gametic process, which
leads to a parent-of-origin specific transcriptional silencing of a subset of genes in
the offspring (Barlow, 1995, Greally, 1998, Caspary et ah, 1998). It has been
estimated that there are 100-200 imprinted genes in the mammalian genome (Barlow,
1995).
Genomic imprinting is considered to be an epigenetic process in the sense that two
alleles that may be identical in DNA sequence are regulated differently within the
same nucleus. Also, the process is entirely reversible, the silent allele becoming
reactivated when passed through the germ line of the opposite parental sex and
conversely the active allele becoming silenced (Feil and Kelsey, 1997).
Empirical evidence that reflects the existence of genomic imprinting was gathered in
ancient times, probably more than 3000 years ago, among the mule breeders of Asia
Minor (Savory, 1970, Morison and Reeve, 1998). It is still a familiar fact that there
are phenotypic differences in the offspring obtained from crossing horses and
donkeys, depending on the sex of the parents. A cross between a male donkey and a
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female horse produces a mule, whereas the offspring of the reciprocal cross, between
a female donkey and a male horse, is known as a hinny (Savory, 1970). Fertility
studies have led to the general conclusion that the male hinny and mule are both
sterile. In contrast, fertile cases of female mule and hinny have both been
documented (Rong et al., 1988). It is thought that the structural and numerical
differences between the parental chromosomal sets (2n=64 or 62, in horse and
donkey respectively) result in abnormal pairing during male meiosis, and that the
resulting meiotic failure underlies the sterility observed (Chandley et al., 1974). This
example conforms to the Haldane Rule regarding interspecific hybrids, that states
that the heterogametic sex is the one more likely to be sterile.
A formal demonstration of unequal genetic contributions from parents to their
offspring came first from the observations made by Dawson (1965) on the outcomes
of interspecific crosses between Peromyscus maniculatus (the deer mouse) and
Peromyscus polionotus (the oldfield mouse). It was observed that the F1 hybrid from
the female P. maniculatus/m'd\e P. polionotus cross was significantly smaller on
average than P. polionotus, the smaller parental form. On the other hand, the F1
hybrid from the reciprocal cross was generally larger than either parent,
demonstrating a clear non-equivalence in the parental influence on the size of
offspring. Recent reinvestigation of this phenomenon has resulted in the
identification of both genetic and epigenetic factors that contribute to the Peromyscus
hybrid phenotypes. These include alterations in X chromosome inactivation and loss
of imprinting ofmaternally and paternally imprinted genes in both species (Vrana et
al., 2000).
The term parental "imprinting" was first used in this genetic context in reference to
whole chromosomes, originally to refer to the selective elimination of paternal
chromosomes in the insect Schiara (Crouse, 1960). Later, this term was used to
describe the selective inactivation of paternally derived X chromosomes in
extraembryonic membranes in the mouse (Lyon and Rastan, 1984).
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During the 1970s and 1980s, several different lines of experimental and clinical
evidence were accumulated to support the existence of genomic imprinting in
mammals. These may be grouped as follows (Hall 1997):
i) Pronuclear transplantation and parthenogenesis experiments in mice
ii) Differing phenotypes of triploids in humans
iii) Expression of chromosomal uniparental disomies in humans and mice
iv) Expression of chromosomal deletions in humans
v) Parental origin-specific expression of trangenes in mice
vi) Expression of specific genes in humans and mice, particularly related to
growth, development and behaviour
Examples of each type of evidence are summarized in the following sections.
1.1.1 PRONUCLEAR TRANSPLANTATION AND PARTHENOGENESIS
EXPERIMENTS IN MICE
In the 1980's, several series of pronuclear transplantation experiments were carried
out, with the aim of investigating differences between the roles played by the
maternal and paternal genomic contributions to the offspring. McGrath and Sober
(1984a) transplanted single pronuclei between one-cell-stage mouse embryos.
Removal of one pronucleus, followed by the introduction of a second from another
embryo, was used to construct biparental diploid gynogenetic, androgenetic and
control (one male and one female pronucleus) embryos. It was found that both
gynogenetic and androgenetic embryos were unable to complete normal
embryogenesis, whereas control embryos sometimes did complete normal
development. This indicated a requirement for both a maternal and a paternal genetic
contribution to allow normal development, at least in the mouse.
Similar experiments were carried out by Surani et al. (1984). These workers showed
that while 40-50% ofheterozygous reconstituted eggs with a male and a female
pronucleus developed to term, none of the eggs with two male pronuclei did so.
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Embryos in the latter case were very retarded, although the trophoblast developed
relatively well, compared with embryos having two female pronuclei. It was
concluded that the paternal genome was essential for the normal development of the
extraembryonic tissues, while the maternal genome was essential for embryogenesis
(Barton et al., 1984, Mann and Lovell-Badge, 1984).
McGrath and Solter (1984b) performed further pronuclear transplants between
mouse embryos carrying the Ihp mutation in the T-associated maternal effect (True)
locus on chromosome 17. The effects of this mutation are determined by the sex of
the parent from which it is inherited; when inherited from the female parent it is
lethal, but embryos that inherit it from the male parent survive. The authors noted
that the maternal-lethal effect persisted when Thp/+ pronuclei were transplanted into
+/+ cytoplasm, suggesting that the epigenetic defect underlying the anomalous
inheritance pattern was localized to the nucleus. They therefore suggested that a
specific gene(s) on chromosome 17 is inherited in a functional form from one parent
but in a non-functional form from the other. Later on, Barlow et al. (1991)
demonstrated that the imprinted gene Igf2r was indeed linked to the Tme locus.
Naturally-occurring human equivalents of the pronuclear transplantation experiments
in mice have been studied. These are two proliferative disorders that result from
uniparental conceptions, ovarian teratomas and complete hydatidiform moles.
Teratomas are embryonic tumours that contain tissues from all three embryonic germ
layers but completely lack placental tissue. Ovarian teratomas have been
demonstrated to have two maternally-derived haploid chromosome sets, in other
words to be parthenogenetic (Linder et al., 1975, Partington et al., 1984).
In complete hydatiform moles, in contrast, no embryo is formed and there is an
abundance of abnormal placental tissue. These complete moles are almost always
androgenetic in origin, the most frequent mechanism probably being the fertilisation
of an oocyte that lacks a maternal pronucleus, followed by a duplication of the
paternal chromosomes (Kajii and Ohama, 1977, Devriendt, 2000).
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1.1.2 PHENOTYPES OF TRIPLOIDS IN HUMANS
Somewhat less extreme imprinting effects are also observed in the phenotypes of
triploid human embryos. These differ depending on the paternal origin of the extra
haploid set of chromosomes, a fact first recognised by McFadden and Kalousek
(1991) and McFadden et al. (1993). These authors used DNA polymorphisms to
show whether the triploidy in 9 human fetuses was maternal or paternal in origin.
They described two phenotypes. The type I phenotype was characterised by a well-
grown fetus with proportionate head size or slight microcephaly; the placenta was
large and had the appearance of a partial hydatiform mole. In these type I cases, the
extra set of chromosomes was paternal. In contrast, the type II phenotype showed a
very growth retarded fetus with relative macrocephaly; the placentas were very small
and did not have molar characteristics. In these cases, the extra set of chromosomes
was maternal. No significant differences were observed between the two groups
regarding other malformations seen in triploidy, such as syndactyly and neural tube
defects (McFadden et al., 1993).
1.1.3 EXPRESSION OF CHROMOSOMAL UNIPARENTAL DISOMIES IN
HUMANS AND MICE
Uniparental disomy (or UPD) refers to the circumstance in which both of a pair of
chromosomal homologues are inherited from one parent, the total number of
chromosomes being normal (Hall, 1997). The origin ofUPD individuals depends
mostly on nondisjunction (ND) events, that can occur either in meiosis I (MI) or
meiosis II (Mil). There are three subsequent likely routes that lead to UPD (Soler et
al., 2000):
i) Trisomic zygote rescue- the origin of a trisomic fetus followed by the loss of
one chromosome.
ii) Gametic complementation- the fertilisation of a disomic egg by a nullisomic
sperm or vice versa.
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iii) Postzygotic duplication - compensatory UPD, a somatic event leading to
replacement of an abnormal or absent chromosome with the normal.
In mice, UPD can be experimentally induced. Cattanach and Kirk (1985)
intercrossed mice that were heterozygous for robertsonian translocations of
chromosomes 2, 11, and 13, such that UPD was the only viable outcome of specific
crosses. They showed that the offspring had different phenotypes depending on the
chromosomal disomy involved. Mice with disomy 13 were normal, but in contrast
the maternal duplication/paternal deficiency for chromosome 2 was lethal. Disomy
11 mice showed differences in size: when their chromosomes 11 were ofmaternal
origin they were consistently smaller and when these chromosomes were ofpaternal
origin they were consistently larger than normal.
These experiments show that the differential functioning of the maternal and paternal
genomes results from the combined effects of parental non-equivalence for several
chromosomal regions. They also show that imprinting affects gene activity in a
selective but reproducible way. Finally, since there were examples of normal
development among the uniparental disomies studied, it seemed that some
chromosomes were probably devoid of imprinted genes with important
developmental functions (Cattanach and Kirk, 1985, Cattanach, 1986).
In humans, UPD has been observed for most of the chromosomes, and the
pathological effects of some of these are well-defined. The most notable example is
UPD of chromosome 15, which results in two distinct clinical disorders, depending
on its parental origin: PraderWilli syndrome (PWS) results when both chromosome
15s are maternal (matUPD), while conversely patUPD15 results in Angelman
syndrome (AS) (Ledbetter et al., 1981, Nicholls et al., 1989, Mascar et al., 1992,
Smith et al., 1997).
The consequences ofUPD do not necessarily result from imprinting effects, since
isodisomy (in which two copies of a single parental chromosomal homologue are
inherited) also conveys the risk of unmasking an autosomal recessive disease, if the
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chromosome in question carries an abnormal allele (Hall, 1997). However, an
imprinting effect may be safely assumed if three or more cases ofUPD produce a
similar phenotype, not attributable to other known causes (recessive trait or
mosaicism). On the other hand, even a single case ofUPD with a normal phenotype
constitutes relatively strong evidence against a major imprinting effect for that
specific chromosome (Ledbetter and Engel, 1995).
1.1.4 PARENTAL ORIGIN-SPECIFIC EXPRESSION OF TRANSGENES IN
MICE
The first opportunity to study individual imprinted loci arose from the observation of
parental origin-specific expression of some mouse transgenes (Swain et al., 1987,
Sapienza et al., 1987, Reik et al., 1987). Swain et al. (1987) produced a transgenic
mouse in which an activated c-myc transgene was autosomally inherited but showed
parent-specific expression. When inherited from the male parent, the transgene was
expressed in the heart but no other tissue; on the other hand, when maternally
inherited, the same transgene was not expressed at all. Furthermore, the imprinted
pattern of expression also correlated with a parent-of-origin specific methylation
state (the maternal allele being methylated).
Sapienza et al. (1987) and Reik et al. (1987) further demonstrated that the
methylation pattern of transgenes could be changed by switching their gamete of
origin in successive generations. This is a requirement that must be satisfied if
methylation is postulated to play the key role in genomic imprinting, of establishing
the parent-specific epigenetic mark; see section 1.1.8.1.
1.1.5 DIFFERENTIAL EXPRESSION OF CHROMOSOMAL DELETION IN
HUMANS
Once again, PWS and AS represent the best-defined examples of differential
expression of chromosome deletions in humans. Almost 70% of individuals with
PWS have a deletion of chromosome 15q 11-13, and it is always the paternal
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chromosome that is deleted. On the other hand, about 70% ofAS individuals have a
similar del(15)(ql 1-13), but in this case it is always maternally derived. These
observations complement those on whole-chromosome UPD15 (see above). They
demonstrate that a common region (at least at the Mb resolution of the deletion
analysis) is involved in both disorders, and that this critical region functions
differently on the paternal and the maternal chromosome 15 (Ledbetter et al., 1981,
Knoll et al., 1989, Cassidy, 1997, Hall, 1997, Christian et al., 1998).
1.1.6 EXPRESSION OF SPECIFIC IMPRINTED GENES IN HUMANS AND
MICE
There are several examples of clinical disorders that appear to be inherited more
frequently from one parent than from the other, or with a difference in phenotype,
suggesting the possibility that genomic imprinting affects the chromosome regions
(and genes) involved in these conditions. Some of these loci are listed in Table 1.1
(Mannens et al., 1994, Morison and Reeves, 1998, Morison et al., 2001).
In addition, it should be mentioned that there are other conditions (such as fragile X
syndrome and Huntington disease) in which a parent-of-origin effect is apparent on
transmission of the disease allele. Both these disorders result from trinucleotide
repeat expansions, though their disease mechanisms are very different (Verkerk et
al., 1991, Huntington's Disease Collaborative Research Group, 1993). In fragile X, it
is the very different risk of repeat expansion on maternal vs. paternal transmission
that determines the anomalous inheritance pattern of the disorder (Fu et al., 1991). In
Huntington disease, there is again a greater risk of allele expansion on transmission
through a parent of one sex (male in this case). However, this manifests in a
quantitative difference in the phenotype (particularly age of onset) rather than an
altered inheritance pattern (Kremer et al., 1995, Squitieri et al., 2000). Neither of
these examples of unstable mutation is considered to fall within the usual definition
of genomic imprinting. Implicit in the concept of imprinting is that the parent-
specific effects operate through postzygotic differences in gene expression or
regulation that depend solely on parent of origin (Reik, 1989). In the case of the
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trinucleotide disorders, in contrast, it is the genetic (rather than epigenetic) change
that has occurred during gametogenesis that dictates the subsequent course of events.
1.1.7 CHARACTERISTICS OF IMPRINTED GENES
Several human chromosomes have had regions identified within them that are
imprinted or are suspected to be so. This may be based on evidence from UPD cases,
or from parent-of-origin-effects in single-gene disorders. It may also be deduced
from the analysis of regions orthologous to those containing known imprinted genes
in the mouse. More recently, some imprinted human genes have also been identified
through systematic screens for differential expression or methylation (Hatada et al.,
1991). To date, -40 imprinted human genes are known, some ofwhich are listed in
Table 1.1.
Table 1.1. Mapped parent-of-origin effects in humans. Some of the genes identified
as imprinted are listed. The chromosomal regions marked by an asterisk are further
described in the text (modified from Morison and Reeve, 1998 and Morison et al.,
2001).
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CHROMOSOME LOCATION GENE/PARENT-OF ORIGIN-EFFECT
1* lp36 p73 monoallelic expression has been identified in fetal
thymus and pancreas; biallelic expression (or LOI) has been
observed in renal and ovarian carcinomas (Mai et al., 1998,
Chen et al., 2000a)
5 5q22-q31 U2AFBPL appears not to be imprinted in humans although its
murine homologue (U2afbp-re) is imprinted
6* 6q25.3 IGF2R is imprinted in mice, and may be polymorphically
imprinted in humans
6q24-25 Transient neonatal diabetes, ZAC1, HYMAI
7* 7pl 1.2-p 12 Silver-Russell syndrome, GRB10, CIT1
7q32 PEG1/MEST
11* 1 lp 15 Beckwith-Wiedemann syndrome; HI9, IGF2, KCNQ1,
CDKN1C and others - see below
11 q 13
Ilq22.3-q23.3
Familial glomus tumours; tumour susceptibility is always
inherited from carrier fathers
13 13q 14 Serotonin receptor-2A (5-HTR2A) or HTR2A\ expressed
biallelically in normal tissues but in fibroblasts of some
retinoblastoma patients is paternally expressed (Kato et al.,
1996, Bunzel et al., 1998)
14 14q32 PEG9/DLK1 is paternally expressed; MEG3/GTL2 is
maternally expressed (Kobayashi et al., 2000, Wylie et al.
2000)
15* 15q 11 -ql 3 Prader-Willi and Angelman syndromes. Among the
imprinted genes identified are: NDN, SNRPN, PAR4, IPW,
UBE3A
18 18q The IMPACT gene appears not to be imprinted in humans
though its murine homologue (Impact) is imprinted






Turner syndrome patients with a maternally retained X (45,
Xm) showed poorer verbal and higher order executive skills
that those with 45,Xp
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The genes described so far as imprinted may represent between 20 to 40% of their
total number in the mammalian genome (Barlow, 1995). This estimate was based on
the consideration that only 1 in 400 mouse loci analysed by phenotype and 2 in 263
mouse loci analysed by gene inactivation exhibit parental restriction. Other studies
have shown similarly that only about 1 in 400 CpG islands in the mouse shows
differential methylation (Shibata et al., 1995). Although these estimates may not in
all cases reflect random sampling, extrapolation from a gene number of 60 000
suggests that between 100 and 200 mammalian genes may be imprinted.
Their growing number has allowed the delineation of some features that may be
common to imprinted genes, as follows:
i) Differences in DNA methylation between the parental alleles
") Differences in histone acetylation between the parental alleles
iii) Differences in DNase sensitivity between the parental alleles
iv) Asynchronous replication of the two alleles
v) Imprinting regulation centres
vi) Repetitive sequences
vii) Antisense strand transcripts
viii) Clustering of imprinted genes
These aspects are considered further in the following paragraphs.
1.1.7.1 Differential methylation of imprinted genes
DNA methylation certainly has an important role in genomic imprinting. Not only do
imprinted genes display different methylation patterns on their maternal and paternal
alleles, correlated with differences in gene transcription, but these methylation states
are also heritable through cell division, and are therefore capable of acting as an
epigenetic mark (Shemer et al., 1996, Feil and Kelsey, 1997). The rather contrived
neologism "methylome" has even been proposed recently, to refer to the complete set
ofDNA methylation modifications within a cell. This would include a description of
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individual sites ofDNA methylation and regional subchromosomal variations, not
just global levels ofmethylation (Feinberg, 2001).
The DNA 5-cytosine methyltransferases are enzymes that catalyse the transfer of a
methyl group from S-adenosyl methionine to the 5 position of cytosines, almost
exclusively those within the dinucleotide sequence CpG (Bonfils et al., 2000). The 5-
methyl groups do not affect base pairing, but can influence protein-DNA interactions
by protruding into the major groove of the DNA helix, thus altering the binding
affinity of sequence-specific transcription factors (Jones and Laird, 1999). To date,
three distinct families ofDNA methyltransferase genes have been identified, they
have been termed DMNTl/Dnmtl, DNMT2/Dnmt2 and DNMT3/Dnmt3 (Xie et al.,
1999).
The DNMT1 gene maps to human chromosome 19pl3.2-pl3.3; it codes for a large
enzyme, DNMT1, of 193 kDa (Bestor et al., 1988, Robertson et al., 1999). The
mouse Dnmtl gene has 4 promoters and several spliced forms, including one,
Dnmtlo, which is present only in the oocyte (Bestor, 2000, Bigey et al., 2000).
DNMT1B is a minor isoform of the human protein, (resulting from a 48 nt insertion
between exons 4 and 5 of the DNMT1 mRNA). It is ubiquitously expressed in
human cells, but constitutes only 2-5% of the total amount ofDNMT1 (Hsu et al.,
1999, Bonfils et al., 2000).
The importance ofDnmtl for CpG methylation of imprinted genes was directly
demonstrated by the generation ofmice carrying a targetted mutation in the Dnmtl
gene. Embryos homozygous for the mutated allele exhibited genome-wide
hypomethylation and loss of the allele-specific expression of the imprinted genes
Igf2 and H19 (Li et al., 1992 and 1993, Reik et al., 1999, Sasaki et al., 2000). These
mice failed to develop beyond the stage characteristic for normal day 9.5 embryos,
and died at day 11 (Li et al., 1992). Further studies ofDnmtl were carried out by
Jackson-Grusby et al. (2001). These authors conditionally inactivated Dntml,
demonstrating that the loss ofDnmtl from somatic cells causes p53-dependent
apoptosis and also causes a global induction of gene expression, either directly or by
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interaction with histone deacetylases and/or by changes in chromatin structure.
Dnmtl has a 5 to 30-fold preference for hemimethylated substrates, and it has
therefore been attributed a role in maintenance ofmethylation patterns through
successive rounds of semiconservative DNA replication (Reik et ah, 1999, Bonfils et
ah, 2000).
From the point of view of imprinting, one of the most interesting characteristics of
the mouse Dnmtl gene is that it has alternative sex-specific promoters and is subject
to both transcriptional and posttranscriptional regulation within germ cells
(particularly oocytes). Three alternative 5' exons have been identified, which in 5' to
3' order are specific to oocytes (Dnmtl o, mRNA 5.1 kb), to somatic cells of both
sexes (Dnmtls, mRNA 5.2 kb), and to pachytene spermatocytes (Dnmtlp, mRNA
6.0 kb) (Mertineit et ah, 1998). The most 5' exon (the non-coding 157 nt exon lo)
directs synthesis of a mRNA that encodes an N-terminally truncated (but active)
oocyte-specific Dnmtl o isoform (Gaudet et ah, 1998, Mertineit et al., 1998).
Mertineit et al. (1998) demonstrated that Dmntl (mRNA 5.2 kb) is present at high
levels in spermatogonia and spermatocytes until the pachytene stage, when it falls to
undetectable levels, but then an increase of the largermRNA (Dnmtlp, 6.0 kb) is
noted. In the oocyte, Dnmtlo accumulates during the growth phase, with a nuclear
localisation, but later becomes cytoplasmic; it is found only at the oocyte cortex in
ovulated oocytes, but re-enters the nucleus at the four-cell stage after fertilization
(Gaudet et al., 1998, Mertineit et al., 1998).
The differential expression of these three DNMT1 isoforms may have important
consequences in the context of genomic imprinting. From nuclear transplantation
experiments, it is known that the nuclei of growth-stage oocytes are more effective in
supporting the development of biparental embryos than the nuclei of less mature
non-growing oocytes (Kono et al., 1996). This indicates that the biparental
developmental potential of such embryos is acquired during oocyte growth. As
Dnmtlo is present in both growing oocytes and preimplantation embryos, this
isoform of the enzyme could have an important role in epigenetic modification of the
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growing oocyte nucleus, and/or in the maintenance of imprinted methylation patterns
during early development (Gaudet et al., 1998).
It became clear that DNA methyltransferases other than DNMT1 are involved in
modifying mammalian DNA when further investigations of the de novo methylation
and maintenance methylation mechanisms were carried out. As previously
mentioned, the experiments of Li et al. (1992) showed that ES cells homozygous for
the null Dnmtl mutation were viable. However, it later appeared that some residual
Dnmtl activity may have been present in these lines. Lei et al. (1996) therefore
created a new truly null allele ofDnmtl, Dnmf. In homozygous mutant ES cells,
they measured i) the levels of de novo methylation (by introducing a foreign DNA,
the murine retrovirus MoMuLV) and ii) the maintenance ofmethylation. They
observed stable low levels of both methylcytosine and methyltransferase activity.
Furthermore, the methylation was maintained after more than 20 cell generations.
They also found that the newly integrated MoMuLV DNA was almost completely
methylated in both wild-type cells (controls) and mutated cells 8 days after infection.
These results clearly indicated the existence of another enzyme(s) able both to
maintain methylation of endogenous loci and to account for the de novo methylation
activity observed in the ES cells.
A second DNMT gene, DNMT2 was then identified by Yoder and Bestor (1998); its
gene is on human chromosome 1 Op 15 (Vilain et al., 1998, Yoder and Bestor, 1998).
Dnmt2 has 3 transcripts (1.6, 2.6 and 4 kb) the 1.6 kb transcript being the most
abundant and ubiquitously expressed, although at very low levels. There is 81%
amino acid sequence identity between human and mouse Dnmt2 enzymes (Okano et
al., 1998). Interestingly, Dnmt2 is more similar to a putative DNA methyltransferase
of the fission yeast (S. pombe) than to Dnmtl (Yoder and Bestor, 1998), probably
reflecting divergence very early in evolution.
By creating a Dnmt2 null allele, Okano et al. (1998) demonstrated not only that ES
cells homozygous for the mutation appeared to be normal in growth and morphology,
but also that an endogenous virus maintained its methylation level and a newly
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integrated retrovirus was de novo methylated. Their results suggested that Dnmt2 is
not essential either to maintain methylation or to perform de novo methylation. In
fact, the biological function ofDnmt2 remains undefined.
The DNMT3 family consist of two related genes, DNMT3A (2p23) and DNMT3B
(20ql 1.2). DNMT3A (912 aa) and DNMT3B (853 aa) share respectively 98% and
94% of amino acid sequence identity with their orthologous mouse enzymes.
DNMT3A is ubiquitously expressed and has three major transcripts of 4.0, 4.4, and
9.5 kb; it is not known if all of these can encode functional proteins (Robertson et al.,
1999, Xie et al., 1999, Ramsahoye et al., 2000). At least four different transcripts of
Dnmt3b have also been identified (Robertson et al., 1999).
Dnmt3a can methylate not only CpG residues but also CpA and CpT. Given their
close sequence similarity, it seems possible that Dnmt3b, too, may methylate non-
CpG dinucleotides (Ramsahoye et al., 2000).
By infecting ES cells lacking either or both enzymes with a recombinant retrovirus
(MoMuLvsup-l), Okano et al. (1999) demonstrated that Dnrntdd'Ax Dnmt3b'A single
mutants methylated proviral DNA normally, whereas the double mutant cells
completely lacked de novo methylation activity. Furthermore, it was also
demonstrated that both enzymes are required for de novo methylation during
embryonic development. Doubly heterozygous mice (Dnmt3a+/~or Dnmt3b+/~) were
normal and fertile, but Dnmt3a/~mice died early (4 weeks) after birth. The Dnmt3b~A
mutation was lethal in utero, the embryos presenting multiple malformations (such as
neural tube defects) and growth impairment. Similar conclusions regarding the role
ofDnmt3a as a de novo methyltransferase were reached by Lyko et al. (1999), using
a transgenic Drosophila model.
Since Dnmtl failed to de novo methylate retroviral DNA and various repetitive
sequences in the Dnmt3a" 7Dnmt3b_/" ES cells and embryos, it would appear that by
itself, Dnmtl probably cannot initiate de novo methylation (Okano et al., 1999 ). It
was also observed that the methylation ofH19 and Igf2r is retained in Dnmt3a
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/Dnmt3b7" ES cells, thus supporting the idea that the main role ofDnmtl is
maintaining parental methylation imprints once that they are introduced into the
germline (Okano et al., 1999, Reik et ah, 1999).
Mutations in DNMT3B cause the ICF syndrome (OMIM #242860), characterised by
/mmunodeficiency, Centromere instability of chromosomes 1, 9 and/or 16, Facial
anomalies (epicanthal folds, telecanthus, flat nasal bridge, macroglossia and mild
micrognathia), and recurrent respiratory infections (Wijmenga et al., 1998). By
homozygosity mappingWijmenga et al. (1998) localized the ICF syndrome gene to a
9 cM region on chromosome 20ql 1 -ql 3. The DNMT3B gene was also shown to map
to 20ql 1.2 (Xieetal., 1999).
Okano et al. (1999) noted that one of the main characteristics of ICF syndrome (the
hypomethylation of satellites II and III, major components of the constitutive
heterochromatin) was similar to the hypomethylation of centromeric minor satellite
repeats demonstrated in the Dnmt3bmutant mice. This, added to the known genetic
linkage data, suggested DNMT3B as a good ICF syndrome candidate gene.
Homozygosity or compound heterozygosity for DNMT3B mutations were found in
six ICF patients (Okano et al., 1999, Xu et al., 1999). It appears clear from these
studies that DNMT3B has a specific role in the methylation of certain centromeric
repeats, which in turn is important for the maintenance of chromosome stability.
1.1.7.2 Histone acetylation
Histone acetylation contributes to the formation of a transcriptionally competent
environment by "opening" chromatin and allowing general transcription factors to
gain access to the DNA. Conversely, histone deacetylation contributes to a "closed"
chromatin state and transcriptional repression. Histone acetylation is carried out by
histone acetyltransferases (HATs) and histone deacetylation by histone deacetylases
(HDACs). Several HATs can also acetylate non-histone proteins such as p53 (Pazin
and Kadonaga, 1997, Eden et al., 1998, Cheung et al., 2000).
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The lysine residues at the N-terminal tails of the core histones are acetylated
particularly within nucleosomes associated with transcribed genes. On the other
hand, inactive genomic regions (such as the silent X chromosome and constitutive
heterochromatin) are associated with hypoacetylated histones. It has been suggested
that acetylation alters the nucleosome conformation either by decreasing the affinity
ofhistones for DNA or by causing a change in the higher-order chromatin structure
by interfering with internucleosomal contacts (Pedone et al., 1999).
The functional link between histone acetylation and DNA methylation has been
found to include close interactions between the enzymatic machineries that regulate
these two aspects of chromatin structure. Thus, the methylcytosine binding protein
MeCP2 physically interacts with the transcriptional corepressor protein Sin3A, and
in doing so recruits an HDAC to chromatin that contains methylated DNA (Amir et
al., 1999). MeCP2 is a member of a family of proteins that mediate transcriptional
regulation, and is mutated in patients suffering from Rett syndrome, an X-linked
neurodegenerative disorder (Amir et al., 1999). MeCP2 has affinity for heavily
methylated DNA rich in CpG. This direct link between methylation and histone
acetylation explains previous observations that methylated DNA templates
microinjected into cell nuclei are initially actively transcribed, but only until the
DNA is packaged into chromatin (Jones et al., 1998, Tycko, 2000). The close
functional relationship between methylation and HDAC activity is further shown by
the fact that DNMT1 forms transcriptionally repressive multiprotein complexes with
both HDAC1 and HDAC2 (Fuks et al., 2000, Robertson et al., 2000, Rountree et al.,
2000). The interacting effects ofhistone deacetylation and DNA methylation are also
shown by the need for a combination ofboth trichostatin A (a potent HDAC
inhibitor) and 5 aza-dC (a methylation inhibitor) to reactivate the silent paternal H19
allele in culture (Pedone et al., 1999, Cheung et al., 2000).
1.1.7.3 DNase sensitivity
A DNasel hypersensitive site corresponds to a region where nucleosomes are either
absent or are partially disrupted due to the binding of non-histone proteins (Feil and
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Khosla, 1999). In many genes, DNasel hypersensitivity marks the sites of regulatory
sequences such as enhancers or locus control regions, reflecting the altered
chromatin structure that results from binding of transcriptional regulators to such
sites (Schweizer et ah, 1999).
Not surprisingly, altered DNasel sensitivity accompanies the differential expression
state of the alleles of some imprinted genes, too. In the case of U2afl-rsl, the silent
maternal allele is hypermethylated in a CpG-rich region in which the expressed
paternal allele is unmethylated. DNase I hypersensitivity of a putative promoter
region, indicative of an "open" chromatin conformation, was seen only on the
paternal allele of this gene (Shibata et al., 1996).
DNase I hypersensitivity has also been assessed within the differentially methylated
regions (DMRs) of the mouse H19 locus (Hark and Tilghman, 1998). Two regions of
nuclease hypersensitivity were identified on the maternal chromosome, which
corresponded to the most heavily methylated regions on the paternal allele. The more
distal hypersensitive region (or HS1) is <500 bp in length and is centred at -3.8 kb
from the H19 promoter, whereas the promoter-proximal region (HS2) extends from
approximately-2.0 to -2.7 kb (Hark and Tilghman, 1998, Ben-Porath and Cedar,
2000). Regulation ofH19 is further discussed in section 1.1.10.3.
1.1.7.4 Asynchronous replication, homologous pairing and meiotic
recombination frequencies of imprinted genes
1.1.7.4.1 Replication timing
Replication timing can be assessed by in situ hybridisation to interphase nuclei.
Nuclei in which a given gene has not yet replicated show two single hybridisation
dots, whereas those in which both alleles have already replicated reveal two sets of
doublets. Thus in an asynchronous cell-cycle population, the relative time of
replication can be measured, since the higher the proportion of double-spotted nuclei,
the earlier that gene replicates in S-phase. Most genes replicate synchronously on the
two chromosomal homologues, with only -10% of nuclei showing an asynchronous
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(single-double) hybridisation pattern (Kitsberg et al., 1993). In contrast, 25 to 35% of
nuclei display asynchronous replication of the imprinted genes Ig/2, Igf2r and HI9,
in each case the paternal allele being early replicating (Kitsberg et ah, 1993, Greally
et ah, 1998). It has been suggested that replication timing may be controlled by cell-
cycle dependent trans-acting factors that bind to recognition sites on the DNA
exclusively at the time they undergo replication. Once an initial allele-specific target
site for such factors has been set up in the gametes, the differential replication timing
will be preserved, representing a primary epigenetic difference between the parental
alleles (Simon et ah, 1999).
1.1.7.4.2 Homologuepairing
Homologue pairing refers to the preferential spatial association ofhomologous loci
in meiotic and somatic cells. In studies of imprinted genes, it has been demonstrated
that an association between the two homologous 15q 1 l-ql3 chromosomal regions
occurs during the late S-phase of the somatic cell cycle. Cells from PWS and AS
patients were demonstrated to be deficient in this association, suggesting that normal
imprinting may also involve mutual recognition and preferential association between
maternal and paternal chromosomes (LaSalle and Lalande, 1996). The precise nature
of the interactions that occur between the homologous chromosomal regions,
however, remain unclear.
1.1.7.4.3 Recombination frequencies
Large sex-specific differences in meiotic recombination frequencies have been
observed in imprinted regions. The 1 lpl5.5 and 15ql 1 -ql3 regions both recombine
with very high frequency during male meiosis and very low frequency in female
meiosis. It has been suggested that this phenomenon may be related to region-
specific differences in accessibility ofDNA to the recombination machinery (Paldi et
ah, 1995).
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1.1.7.5 Repetitive sequences in imprinted genes
Neumann et al. (1995) described the presence of direct tandem repeats embedded in
the CpG-rich differentially-methylated regions of imprinted genes. Although these
repeats tend to be G-rich, no specific recurring sequence motifs have been identified
between different genes. The repeat units vary in length and location with respect to
their genes. The exact role of these sequences is unknown, but it has been suggested
that they may form specific secondary structures that attract de novo methylation
either in the gametes or soon after fertilisation.
1.1.7.6 Antisense transcription at imprinted loci
Antisense transcripts have been described within or closely associated with several
imprinted genes. It is believed from various lines of evidence that these antisense
transcripts may play a role in regulating the imprinted genes with which they are
associated. In general, these antisense RNAs do not have an open reading frame and
hence probably exert their effects directly within the nucleus at the RNA level.
The antisense transcript that is best characterised functionally is the one associated
with the mouse Igf2r gene, named Air. This originates from a differentially
methylated promoter region in intron 2 of Ig2r, and is transcribed exclusively from
its unmethylated paternal allele. Since Igf2r expression is maternally monoallelic, it
was suspected thatAir is involved in the suppression in cis of transcription from the
sense Igf2r promoter. This idea received direct support from transgenic experiments
in which deletion of theAir promoter region result in biallelic Igf2r expression (Wutz
et al., 1997). Thus, transcription ofAir across the paternal Igf2r promoter may have
the effect of somehow "occluding" the sense gene promoter, perhaps locally
inactivating the chromosome by physically "coating" the chromatin (as has been
proposed for the X chromosome inactivation, see below). Alternatively, the cis
suppressive effect may result from sharing of transcription factors that are in limiting
supply or from competition in cis for shared enhancers (Reik and Constancia, 1997,
Constancia et al., 1998).
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Several imprinted antisense transcripts (Igfas a, b, c) have also been described in the
upstream region of the Igf2 gene. However, in contrast to the Igf2r situation, these
are expressed, at low levels, from the same allele as Igf2. Their role is unclear,
although it has been suggested that the overlapping antisense transcripts may
influence the activity of sense promoters, and/or may be involved in regulating Igf2
in a tissue-specific manner (Moore et al., 1997).
1.1.7.7 Clusters of imprinted genes and regulation by imprinting centres
One feature that has repeatedly emerged from studies of the chromosomal regions
containing imprinted genes is that such genes tend to be grouped together in clusters
(Lee et ah, 1999b). Detailed analysis of these has revealed complex regulatory
mechanisms that often indicate coordinated regional control of the imprinted domain.
The two most intensively studied imprinted gene clusters are on human
chromosomes 11 and 15 (with syntenic homology to mouse chromosome 7, distal
and central respectively) (Nicholson et ah, 2000). However, other regions of
clustering of imprinted genes have been identified on human chromosomes 7 and 14,
and there are also some other examples in the mouse (Caspary et ah, 1998).
A related and important feature ofboth of the above two imprinted chromosomal
regions is the so-called imprinting centre or IC (these are discussed further in
sections 1.1.9 and 1.1.10). The IC can be conceptualised as a cis-acting control
element that exists in two alternative structural forms. Imprint switching is postulated
to occur during gametogenesis when the maternal IC allele is set up in one
conformation, whereas the paternal allele adopts the alternative structure. Once
established, each of these structures is maintained through fertilisation and
embryonic development. Following implantation, the IC can act as a regional
organiser which sets up imprinted patterns ofmethylation, chromatin structure and
gene expression across large genomic intervals (Ben-Porath and Cedar, 2000).
Our understanding of imprinting centres depends largely on studies of clinical
disorders in which imprinting of one of the above-mentioned clusters (15q and 1 lp)
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has been disturbed. Therefore, before discussing models that have been proposed to
explain the mechanism of operation of the IC, it is necessary to review in some detail
each of these two clusters, including the individual genes they contain and relevant
aspects of the pathology associated with them. This is done in the following sections.
1.1.8 THE CLUSTER OF IMPRINTED GENES IN 15qll-ql3
Much recent effort has gone into the identification and analysis of transcripts within
the large imprinted region of chromosome 15ql l-ql3 (see for example Lee and
Wevrick, 2000, Meguro et al., 2001). This predominantly paternally expressed
domain is bounded on the centromeric side by the marker D15S1035; all transcripts
centromeric to this are apparently biallelically expressed. On the telomeric side, the
paternally expressed domain is bounded by the gene UBE3A, with all transcripts
distal to this gene again being expressed from both alleles (Figure 1.1). UBE3A itself,
as discussed below, is maternally expressed in a tissue-specific pattern. As already
described, Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are both
associated with anomalies of the imprinting of this region.
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Figure 1.1. Gene map ofhuman chromosome 15ql 1 -ql 3 (not to scale). The map
indicates the direction of the centromere (cen) and telomere (tel), and identifies some
of the genes within this region for reference. These are shown as dark circles
(paternally expressed), grey circles (maternally expressed) or open squares
(nonimprinted). An imprinting control centre (IC) associated with the 5' end of the
bicistronic SNRPN-SNURF locus is indicated. The large arrow below this indicate
the regional imprinting control exerted from the IC. The small arrows show
overlapping sense and antisense transcription. The open block arrow indicates the
extent of the region frequently deleted in PWS and AS. The locations of the markers
D15S1035, D15S174 and D15S165, referred to in the text, are indicated. The dark
arrow indicates the critical region implicated in PWS and the grey block arrow
indicates the region implicated in AS (Modified from Ji et al., 1999, Lee and






















1.1.8.1 The Prader-Willi and Angelman syndromes
PWS (OMIM #176270) and AS (OMIM#105830) are distinct clinical entities that
were first described in 1956 and 1965 respectively (Prader et al., 1956, Angelman,
1965, Bower and Jeavons, 1967, Cassidy, 1997). It was only decades later that
cytogenetic and then also molecular evidence converged to link the two conditions.
PWS and AS are considered the classical manifestations of genomic imprinting in
man since they result from the absence of either maternal (AS) or paternal (PWS)
genomic contributions from 15q 1 l-ql3. This, in turn, may result from various
different mechanisms affecting one or more genes in this region (Ledbetter et al.,
1981, Smith et al., 1992, Chan et al., 1993, Sutcliffe et al., 1994, Smith et al., 1997,
Matsuura et al., 1997).
1.1.8.2 Prader-Willi syndrome
PWS has been intensively studied over a period ofmany years; it was the first
example of a microdeletion syndrome identified by high resolution chromosome
analysis, the first recognised human disorder of genomic imprinting, and also the
first disorder recognised as resulting from UPD (Butler et al., 1986, Cassidy, 1997).
PWS has an incidence of 1 in 10,000-15,000, occurring in both sexes and all races
(Cassidy, 1997, Christian et al., 1998). The clinical characteristics include infantile
hypotonia, hypogonadism, and later in childhood hypeiphagia and obesity. Patients
have a narrow bifrontal diameter, almond shaped palpebral fissures, narrow nasal
bridge, small narrow hands, short stature, developmental delay, and behavioural
problems. A third ofpatients also present hypopigmentation (Cassidy, 1997, Couper
and Couper, 2000).
Between 60 and 70% ofPWS cases are due to a ~4 Mb deletion of 15q 11 -ql 3 on the
paternally-derived chromosome. 28% of cases are due to maternal UPD. These two
common mechanisms are functionally equivalent in resulting in lack of a paternal
15q 1 l-ql3 contribution. A small but biologically very interesting group of patients
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(less than 2%) have structurally normal, biparentally-derived chromosome 15s, but
have an abnormality of the imprinting process which results in non expression of the
paternal genes within the PWS critical region (Cassidy, 1997).
1.1.8.3 Angelman syndrome
AS has an estimated incidence of 1 in 20,000. It is characterised by severe mental
retardation, absent speech, abnormal laughter and ataxic gait, seizures or abnormal
EEG, microcephaly, brachycephaly, and a characteristic facies with macrostomia and
prognathism (Williams et al., 1988, Meijers-Heijboer et al., 1992, Smith et al., 1997,
Fridman et al., 2000). Bower and Jeavons (1967) likened the easily provoked and
prolonged paroxysms of laughter and ataxic jerky movements to the movements of
puppets; hence this condition was for a while referred to as the "happy puppet"
syndrome (Magenis et al., 1988).
Like PWS, AS patients may be pathogenetically classified into one of the following






la ~4-Mb interstitial maternal
del(15qll-ql3)
65%-75% Abnormal Extremely low





Ha UPD (maternal deficiency)
with normal parental
chromosome
3%-5% Abnormal Extremely low
lib UPD with predisposing
parental translocation
<1% Abnormal Significant
Ilia Imprinting mutation with
deletion of IC
3%-5% Abnormal Significant
Mb Imprinting mutation without
detectable deletion of IC
3%-5% Abnormal Low
IV Point mutation in UBE3A 4%-6% Normal Significant
V AS phenotype with no
identifiable molecular
abnormality
10%-14% Normal Occurs rarely
Table 1.2. Classification ofAS according to underlying cause. The term "abnormal"
is used to indicate that only the paternal, unmethylated pattern is seen on analysis of
the SNRPN promoter region (as in Jiang et ah, 1999).
AS may result from deletions, UPD or imprinting mutations, but in addition in some
cases point mutations in the UBE3A gene (including truncating and missense
mutations) have been described as the only abnormality. Unlike PWS therefore
(which is generally considered a contiguous gene syndrome), AS appears to be a
single-gene disorder. There remains, however, a substantial number of patients with
an AS phenotype (>10%) in whom none of these molecular or cytogenetic alterations
can be identified. Some of these may be attributable to misdiagnosis or a phenocopy
(Matsuura et ah, 1997, Fang et ah, 1999).
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Although, as noted in Table 1.2, the recurrence risk for cytogenetic deletion cases of
AS is very low, at least one case ofmaternal germ-line mosaicism for the AS-
associated 15q deletion has been reported. In this AS family with recurrence of
del(15), the mother's chromosomes 15 were structurally normal, but the two patients
and their unaffected brother all shared an identical maternally-derived haplotype
distal to the deletion region, suggesting that they had indeed inherited the same
grandpaternal chromosome 15 from the mother (Kokkonen and Leisti, 2000).
1.1.8.4 The 15qll-ql3 chromosomal region
A 15ql l-ql3 deletion was first described in PWS patients in 1980 (Ledbetter et al.,
1980). This was also confirmed by Butler et al. (1986), who by analysing
chromosome 15 short arm and satellite region variants demonstrated that the del(15q)
was paternal in origin and also that the chromosomes of both parents were
structurally normal. Later studies by Nicholls et al. (1989) of two patients who did
not have cytogenetic deletions, demonstrated that in these cases the PWS was due to
a maternal uniparental heterodisomy, the first time that this situation had been
associated with a human genetic disease.
The cytogenetic and molecular histories of PWS and AS intersected when several
patients whose phenotype was compatible with AS were reported to have a deletion
also involving 15ql 1 -ql3 (Magenis et al., 1987 and 1988, Williams et al., 1988).
Molecular analysis indicated that in contrast to PWS patients, in these AS cases it
was always maternal markers that were absent (Knoll et al. 1989, Smith et al., 1992).
Magenis et al. (1990) further showed that the extents of the deleted regions in PWS
and AS were essentially the same, implying that differential expression of one or
more genes from the maternal and paternal homologues must underlie the different
phenotypes of the two conditions. A similar conclusion was reached from
observations on a rare example of a familial deletion, described by Greenstein
(1990). One individual in this family had PWS, while a cousin had AS. The father of
the child with PWS and the mother of the child with AS were brother and sister,
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consistent with the known parental origins of sporadic cases and strongly implying
that the deletions were identical in extent in both patients.
1.1.8.5 Genes identified in the 15qll-ql3 region
Several groups have exerted efforts towards gene identification in the PWS/AS
deletion region of 15q 11 -q 13, Genes and transcripts have been scrutinized to
differing extents to establish their imprinted or non-imprinted patterns of expression.
So far ~15 genes and more than 20 anonymous ESTs have been mapped to this
region. In this respect, it is worth considering that according to a notional genome-
wide average gene density, a region of this size might be expected to contain -100
genes (Figure 1.1) (Lee and Wevrick, 2000).
1.1.8.6 Genes within the PWS minimal region
Any gene considered to be a candidate for PWS should lie between the markers
D15S1035 and D15S174 (Figure 1.2). However, the PWS critical region is very
large, and single-gene mutations or kb-size deletions have not been identified (with
the exception of the IC mutations, see below). It therefore seems likely that PWS is a
contiguous gene syndrome (Mann and Bartolomei, 1999, Nicholls, 1999). The
examples below of individual genes that map to this region are discussed in a
centromeric to telomeric order:
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Figure 1.2. Partial gene map of human chromosome 15ql 1 -ql 3 (not to scale). A)
The directions of the centromere (cen) and telomere (tel) are indicated. The block
arrow identifies the markers referred to in the text that enclose the PWS region.
Some of the genes that map within this region are indicated for reference. B) The
genes that map to this region (and that are further discussed in the text) are indicated
as before (Figure 1.1): dark circles (paternally expressed), grey circles (maternally
expressed), open squares (nonimprinted). EST SGC32610 is represented as a grey
square as its expression was found to be biallelic in fibroblast cell lines and brain but
maternally biased in lymphoblastoid cell lines. (Modified from Ji et al., 1999, Lee





























i) The BCL8 gene is centromeric to the border of the critical region (it lies beyond
the D15S1035 marker limit; Figure 1.1). The BCL8 region is a recurrent site of
rearrangements in diffuse large-cell lymphomas (DLCL). This gene has not yet been
completely characterised but two transcripts have been identified, a more abundantly
expressed of 2.6 kb and a 4.5 kb transcript (Dyomin et al., 1997). RT-PCR analyses
have demonstrated that BCL8 is normally expressed in human testis and prostate and
frequently expressed in DLCL but interestingly, this gene is not normally expressed
in lymphoid tissues. BCL8 is thus the only gene known (so far) to be ectopically
activated in lymphomas, and is presumed to have a role in the pathogenesis of this
disease (Dyomin et al., 1997). The imprinted status ofBCL8 itself has not been
investigated. However, at least three ESTs (NIB1540, SHGC13938 and A00B45) that
map between BCL8 and D15S1035 and also one EST (SHGC15126) corresponding
to the poorly-characterised MYLE gene are all biallelically expressed in lymphoblast
cell lines, fibroblast cell lines and brain (see Figure 1.2). It therefore seems likely that
BCL8 is also non-imprinted (Lee and Wevrick, 2000).
ii) The EST SGC32610 is telomeric to MYLE and maps within the PWS region. It is
biallelically expressed in fibroblast cell lines and brain but is preferentially
maternally expressed in lymphoblastoid cell lines (Lee and Wevrick, 2000). This is
somewhat reminiscent of UBE3A (at the opposite end of the imprinted domain), for
which incomplete imprinting in brain has been shown (see below).
iii) Further telomeric to BCL8 is the intronless gene ZNF127 (Figures 1.1 and 1.2).
This encodes a protein with a RING C3HC4 zinc-finger (C, Cys; H, His) and multiple
C3H zinc-finger motifs. The RING zinc-finger domain was first identified in the
RING1 gene within the MHC region of chromosome 6p21.3 (Lovering et al., 1993).
The C3HC4 RING-fingermotif (Cys-X2-Cys-X(9_39)-Cys-X(i-3)-His-X(2-3)-Cys-X2-
Cys-X(4_4g)-Cys-X2-Cys, where X is any amino acid) has been identified in more than
a hundred different proteins with a diverse range of functions. The RING finger is
likely to function in protein-protein interactions and many RING proteins may
mediate formation ofmacromolecular complexes (Saurin et al., 1996, Jong et al.,
1999a and b).
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The C3H motif has the consensus Cys-X(i_2)-Tyr/Phe-X(2-5)-Gly-X(i_2)-Cys-X2-Gly-
X2-Cys-X-Tyr/Phe-X-His. (Jong et al., 1999 a and b). Although the exact function of
the C3H domain has not been elucidated, Carballo et al. (1998) showed that
tristetraprolin, the prototype C3H zinc finger protein, inhibited the production of
TNF-a by destabilizing its messenger RNA. This suggested that C3H proteins as a
class may be RNA-binding proteins.
Human and mouse ZNF127 constitute a separate subfamily ofRING-finger proteins
with both C-terminal RING-finger and C3H motifs. As ZNF127 has three C3H
motifs, it may mediate RNA binding as part of a ribonucleoprotein complex in
conjunction with the RING-finger (Jong et al., 1999 a and b).
Differential methylation ofZNF127 has been described; in brain its CpG island is
completely unmethylated on the expressed paternal allele, but methylated on the
maternal allele (Driscoll et al., 1992; the cDNA DN34, referred to in this paper, was
later shown to correspond to ZNF127, Jong et al., 1999b). The 3' end ofZNF127 is
located within an intron ofZNF127AS, an antisense transcript that is also paternally
expressed (Jong et al., 1999a and b).
iv) The intronless NDN gene is paternally expressed, and encodes the DNA-binding
protein necdin. MWis expressed in multiple tissues and in virtually all postmitotic
neurons from early neurogenesis until adult stages (Nakada et al., 1998, Jay et al.,
1997, Sutcliffe et al., 1997, Gerard et al., 1999). Necdin appears to act as a neuronal
growth suppressor that is functionally similar to the retinoblastoma tumour
suppressor protein (Rb) (although it is structurally dissimilar). Like Rb, necdin can
suppress cell proliferation by interacting with the transcription factor E2F1, which
promotes cell-cycle progression. Necdin has also been demonstrated to suppress the
growth ofRb-deficient osteosarcoma cells (SAOS-2). Thus, necdin might
complement Rb function in order to prevent postmitotic neurons from resuming cell
division (Taniura et al., 1998, Nakada et al., 1998).
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v) The MAGEL2 gene (or NDNL1) lies 41 kb distal to NDN. It encodes a 529 amino
acid protein with 51% sequence identity to necdin. MAGEL2 contains an additional
188 amino acids at the N-terminus compared with NDN and does not have a proline-
rich, acidic N-terminus, as necdin does. It is expressed only from the paternal allele
in brain. The murine orthologue Magel2 is also imprinted, with patemal-only
expression predominantly in late developmental stages; the RNA expression pattern
ofMagel2 in the developing nervous system overlaps with that ofNecdin (Lee et ah,
2000).
vi) The intronless gene C150RF2 (chromosome 15 open reading /rame 2) spans 7.5
kb. Its 3.5 kb open reading frame encodes a predicted 1156 amino acid protein.
Despite being flanked by two imprinted genes {MAGEL2 and SNRPN), it is
biallelically expressed in adult testis (the only tissue where it is expressed) and
therefore very probably does not contribute to the PWS phenotype (Farber et ah,
2000).
vii) The SNRPN gene is paternally expressed and encodes a small (240 aa) nuclear
spliceosomal ribonucleoprotein. There is a processed pseudogene, SNRPNP], on
human chromosome 6 (Leff et al., 1992, Ozcelik et al., 1992, Gray et ah, 1999).
There is some confusion in the literature over exon numbering within SNRPN. Eight
exons were originally described; when 2 new exons were later discovered they were
initially referred to as -1 or a and 0 or p, but have since been renumbered as exons 1
and 2. Also, several alternative 5' exons ofSNRPN have been identified. These are
part of a transcript known as BD, and are of particular relevance because they lie
within the imprinting centre (IC) that regulates this region (Dittrich et al., 1996). The
most recent data indicates that the genomic structure ofSNRPN is even more
complex; the identification of new exons at its 3' end brings the total number to date
to 20. These eight new 3' end exons do not appear to have any coding potential
(Wirth et al., 2001).
Using phylogenetic analysis ofSNRPNmRNA in different eutherian mammals, Gray
et al. (1999) identified a second highly conserved coding sequence within this gene,
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which they termed SNURF (SNRPN upstream reading/fame), that encodes a 71
amino acid protein. Thus it appears that SNRPN is a bicistronic gene.
By using RT-PCR and parent-specific DNA methylation analysis, Glenn et al. (1996)
demonstrated that SNRPN is imprinted. It is differentially methylated at the CpG
island associated with its exon 1 (originally-1/a), being methylated on the repressed
maternal allele; another CpG island identified in intron 7 was demonstrated to be
preferentially methylated on the expressed paternal allele (Kubota et al., 1997,
Cassidy, 1997). Methylation analysis of the SNRPN exon 1 (a) was also performed
by Beuten et al. (1996) and is now commonly used for the molecular diagnosis of
PWS.
Recent analyses of chromosomal translocations in PWS patients have identified a
new breakpoint translocation region that maps 70-80 kb distal to the SNURF-SNRPN
gene. These translocations disrupt some of the new 3' exons, but it has also been
hypothesised that they may disrupt the HBII-85 sequence (see following paragraphs)
or even affect an as yet unknown gene in this region (Wirth et al., 2001).
Meguro et al. (2001) carried out an extensive study of the allelic expression of 118
cDNA clones identified in the GeneMap database as lying within the PWS/AS region
delimited by the genetic markers D15S1035 and D15S165. They demonstrated the
presence of a number of transcripts that while lacking protein coding potential, were
expressed only from the paternal allele. Furthermore, within this region a large direct
repeat (DR) cluster was also identified. This contains box C, D' and D sequence
motifs characteristic of a particular class of snoRNAs (small nucleolar RNAs). There
are over 150 known snoRNAs, many ofwhich are believed to have specific roles in
the posttranscriptional modification of rRNA prior to its incorporation into the
assembling ribosome. The C/D box and H/ACA box snoRNAs are two families
characterized by specific sequence motifs, thought to have roles in ribose 2-0-
methylation and in pseudouridylation, respectively (Lowe and Eddy, 1999, De los
Santos et al., 2000).
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Three brain-specific C/D box snoRNAs and one H/ACA-box snoRNA were also
identified by Cavaille et al. (2000), in both human and mice. The three C/D box
snoRNA genes were mapped to the PWS region of human chromosome 15 and were
given the names HBII-13, HBII-52, HBII-85 (and MBII-13, MBII-52, MBII-85 for the
mouse orthologues). These snoRNAs were again paternally expressed, as judged
from their absence from brain tissue of a PWS patient. It has therefore been
considered that the DR cluster that encodes these various snoRNA transcripts may
contribute to the phenotype ofPWS (Meguro et al., 2001).
viii) PARI and PAR5 (for Prader-Willi/Angelman region) are two paternally
expressed non-coding transcripts identified in fetal brain cDNA libraries (Sutcliffe et
al. 1994). PARI and PAR5 are located within 300 kb telomeric to the SNRPN gene.
Between these two genes (among other ESTs) map the PWCR1 and IPW genes (see
below), which are also non-coding (De los Santos et al., 2000). Small deletions of a
region that includes SNRPN exon 1 (exon a) were found to result in loss of
expression not only ofSNRPN, but also ofPARI and PAR5, thus defining the
presence of a paternal imprinting control region (see below) (Sutcliffe et al., 1994).
ix) PWCR1 (for Prader-Willi chromosome region 1), is an intronless gene without an
open reading frame. The most abundant of its several alternative transcripts is a short
(140 nt) RNA which is well conserved between human and mice and represents a
member of the C/D box snoRNA family (see above). Like these other transcripts,
PWCR1 is not expressed in PWS patients with either the classical deletion or an IC
microdeletion, indicating that it requires the action of the IC regulatory element for
its expression (De los Santos et al., 2000).
x) The next gene in a telomeric direction is IPW (maps -250 kb distal to SNRPN).
This is widely expressed, only from the paternal allele, but again does not appear to
encode a protein (Glenn et al., 1996, Wevrick and Francke, 1997).
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1.1.8.7 Genes within the AS critical region
The AS region lies between the markers D15S174 and D15S165 (Figure 1.3). The
most centromeric gene identified within this interval is UBE3A.
Figure 1.3. Map of part ofhuman chromosome 15ql 1-ql 3 (not to scale) showing the
AS region. The map indicates the direction of the centromere (cen) and telomere (tel)
and identifies some of the genes within this region (discussed in the text). The mono-
or bi-allelic pattern of expression of the genes is indicated as before (Figures 1.1 and
1.2). The GABAa receptor genes are indicated as dark squares, as conflicting
evidence has identified them as biallelically and/or paternally expressed (see text).
The positions of duplicated sequences related to HERC2 in this region are indicated
by grey ovals. The open block arrow indicates the extent of the region frequently
deleted in AS. The locations of the markers D15S174 and D15S165, referred to in the
text, are indicated. The grey block arrow indicates the AS critical region (see text).
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i) UBE3A encodes the E6-AP ubiquitin-protein ligase (see below). Its 16 exons (six
ofwhich make up the 5'-UTR) span -120 kb. Two processed pseudogenes,
UBE3APJ and UBE3AP2, with 90-95% nucleotide sequence identity to UBE3A,
have been mapped to chromosomes 2 and 21 respectively. At least five alternatively
spliced mRNA forms of UBE3A have been identified (Kishino et al., 1997, Kishino
and Wagstaff, 1998).
E6-AP is a member of the ubiquitin-protein ligase family that is defined by the
presence of a carboxy terminal "hecf' (homologous to the E6-AP carboxyl terminus)
domain (Nakada et al., 1998). The ubiquitination process involves four different
classes of proteins that act together to target selected proteins for degradation (Jiang
et al., 1999).
UBE3A is biallelically expressed in fibroblasts and lymphoblasts. However, this gene
is imprinted in certain regions of the brain in both humans and mice, showing
maternal monoallelic expression (Albrecht et al., 1997, Rougeulle et al., 1997, Vu
and Hoffman, 1997). Chromosomal inversions, translocations and mutations
affecting UBE3A have all been described in AS patients that have a normal
methylation pattern at the SNRPN locus (Michaelis et al., 1995, Greger et al., 1997,
Kishino et al., 1997, Kishino and Wagstaff, 1998, Matsuura et al., 1997, Fang et al.,
1999).
Besides UBE3A, there are other transcripts that have been identified in close
proximity. These are an intronless transcript (transcribed in the same direction as
UBE3A) of 3.5 kb in length, and an antisense transcript with its 5' end 6.5 kb
upstream of the UBE3A stop codon, crossing the 3' end of UBE3A. The intronless
sense transcript has the same imprinting pattern as UBE3A, while in contrast the
antisense transcript is oppositely imprinted, with preferential expression from the
paternal allele in brain (Rougeulle et al., 1997).
As for Igf2r/Air, the presence of the antisense transcript poses questions regarding its
role in UBE3A regulation. For example, a transcript competition model proposes that
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in tissues such as brain, where the antisense transcript is monoallelically (paternally)
expressed, it prevents expression in cis of UBE3A, which can therefore only be
expressed from the antisense maternal chromosome. In other tissues, the antisense
transcript is not expressed and UBE3A can be transcribed from both alleles
(Rougeulle et ah, 1998). Unlike the Igf2r/Air locus, however, this model has not been
experimentally tested at this locus.
ii) The PAR2 gene, for Prader-Willi/Angelman region gene 2 (marker D15S225E), is
telomeric to UBE3A and has been described as not imprinted (Nakao et ah, 1994).
iii) The genes encoding the y-aminobutyric acid (GABA) type A receptor subunits,
p3 (GABRB3), a5 (GABRA5) and y3 (GABRG3) span 800 kb of the distal part of the
PWS-AS region. GABA, the principal inhibitory neurotransmitter in the central
nervous system, exerts its effects through these GABAa receptors. Conflicting
studies have described these genes as either imprinted (Meguro et ah, 1997) or not
imprinted (Gabriel et ah, 1998). In the mouse, Nicholls et ah (1993) had concluded
that Gabrb3 was non-imprinted. Meguro et ah (1997) analysed mouse A9 hybrid cell
lines containing a single normal human chromosome 15, either paternal or maternal.
Their findings indicated that all three GABAa receptor genes (in contrast to the
findings in the mouse) were expressed only from the paternal allele. However,
opposite results were obtained by Gabriel et ah (1998), who similarly used somatic
cell hybrids containing either a maternal or a paternal human chromosome. RT-PCR
analysis indicated that all three GABAa receptor genes were non-imprinted. These
conflicting results may in part be attributable to variability in the degree to which
somatic cell hybrids maintain the imprinting patterns of the donor human
chromosomes.
iv) Telomeric to the GABA receptor genes is the non-imprinted P gene, associated
with recessive tyrosinase-positive albinism (OCA2) (Spritz et ah, 1997). Its
heterozygous deletion is thought to underlie the mild hypopigmentation described in
patients with PWS and AS type la (Table 1.2) (Saitoh et ah, 1994, Cassidy, 1997,
Jiang et ah, 1999).
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v) Low-copy repeat elements have been identified at both ends of the PWS/AS
deletion interval, near to the deletion breakpoint hotspots on 15ql 1 -ql 3 (Figures 1.3
and 1.4, BP-2 and BP-3). These represent members of one gene family, with an
ancestral locus, HERC2 on the telomeric side of the interval, and several duplicated
copies. This repeat element (termed D15F37) is widely expressed, with a
predominant transcript of 6-7 kb and a minor one of 15 kb. The -15 kb transcript was
termed HERC2 (for Hect domain and RCC1 domain protein 2). It encodes a large
predicted protein of 4834 aa and 528 kDa (Ji et al., 1999), that may function as a
guanine nucleotide exchange factor and as an E3 ubiquitin ligase, potentially
involved in the intracellular vesicular transport and degradation pathway.
Evolutionary duplications ofHERC2 have lead to a family of both adjacent (on
chromosome 15ql3) and dispersed (15ql 1 and 16pl 1.2) copies. In the mouse, Herc2
mutations result in neuromuscular secretory vesicle and sperm acrosome defects and
juvenile lethality (Ji et al., 1999).
1.1.8.8 Molecular characteristics of the PWS/AS deletion on human 15qll-ql3
As already described, the -4 Mb PWS/AS deletion spans the region between
D15S1035 and D15S165 (Christian et al., 1995). Two breakpoint clusters have been
mapped centromeric to ZNF127 (Figure 1.4), while the telomeric breakpoint is distal
to the P gene (Mann and Bartolomei, 1999), within the //E7?C2-homologous repeat
cluster. A fourth translocation cluster region in the 3' region ofSNRPNwas
mentioned above.
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Figure 1.4. Map of the PWS/AS deletion region ofhuman chromosome 15ql 1 -ql 3
(not to scale). The map indicates the directions of centromere (cen) and telomere
(tel), and the allelic expression patterns of inidividual genes are colour-coded as
before (Figure 1.1). The open block arrow indicates the extent of the region
frequently deleted in the PWS and AS, delimited by the markers D15S1035 and
D15S165. The two proximal and one distal common deletion breakpoints regions
(BP-2 to BP-3) for PWS and AS deletions are indicated by zigzag lines, as is the
translocation breakpoint cluster 3' to SNRPN. The positions of duplicated sequences
related to HERC2 are indicated by grey ovals (Modified from Ji et ah, 1999, Lee and
Wevrick, 2000, De los Santos et ah, 2000, Nicholls, 2000).
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The 15ql 1 -ql 3 region is involved in an unusually high number and diversity of
recurring rearrangements. Besides the ~4 Mb PWS/AS deletion, over half of all
supernumerary marker chromosomes result from rearrangements at the proximal and
distal ends of 15ql 1 -q 13 (Christian et al., 1995). Other rearrangements involving this
region include duplications, triplications and balanced reciprocal translocations
(Christian et al., 1998). Considering the variety and frequency of these
rearrangements, 15ql 1 -ql3 can be regarded as a "hot spot" for chromosome
anomalies (Eichler, 1998).
Christian et al. (1995, 1998 and 1999) were able to identify four recurring
breakpoints in 15ql 1-ql 3 in PWS and AS patients, numbered 1 to 4 (BP1-4). An
analysis of 53 PWS and 33 AS deletion patients showed 44% of them to be deleted
for the molecularmarker D15S542 ("Class I" patients), while the remaining 56%
were not deleted for this marker ("Class II" patients). The centromeric breakage
point for Class I patients is referred to as BP1 and that for Class II as BP2 (Figure
1.4) (Christian et al., 1999).
BP3, at the telomeric end of the deletion, lies within the HERC2 repeat cluster; two
duplicated copies of a 400 kb genomic region are found in tandem at this point. The
last breakpoint region, BP4, has been located between markers D15S1031 and
D15S1010 and has been described in cases of inv/dup, duplication and triplication of
chromosome 15 (Christian et al., 1999).
1.1.8.9 Origin of UPD in PWS and AS
As mentioned above, UPD accounts for 25% ofPWS and 2-5% ofAS. The incidence
figures quoted above for the two disorders therefore imply frequencies ofmaternal
and paternal UPD15 as respectively 1/40,000-1/60,000 and 1 in 400,000 to
1/1,000,000 respectively (see also Robinson et al., 2000). The more than tenfold
difference between the frequency ofmatUPD and patUPD is attributed to the higher
rate of nondisjunction in female gametogenesis. Using recombination analysis with
microsatellites covering the entire chromosome 15, Fridman and Koiffrnann (2000)
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determined that heterodisomic PWS cases had originated byMI nondisjunction,
while the cases of isodisomic PWS UPD15 had originated by postzygotic
duplication. In five cases ofAS with paternal UPD15, four isodisomies were
detected. Three of these showed homozygosity for all markers, corresponding to a
mitotic error, while the remaining case was defined as originating from aMil ND
event. These results support the idea that most maternal UPD15 results from MI
errors, with rare cases beingMil or due to postzygotic errors, while on the other hand
most paternal UPD15 is postzygotic in origin.
In 24% of the cases ofmatUPD15 examined by Robinson et al. (2000), the patients
also showed an extremely skewed pattern ofX-chromosome inactivation. As only
those cases of trisomic zygote rescue with a relatively late origin of the diploid cell
line will result in skewed X inactivation, this probably indicates a post-zygotic loss
of the paternal chromosome in these cases.
1.1.8.10 The imprinting centre (IC) region of chromosome 15qll-ql3
In addition to the typical ~4 Mb PWS/AS deletion discussed above, much smaller
microdeletions (and other chromosomal rearrangements) upstream ofSNRPN have
been described in a group of patients that show evidence of abnormal imprinting in
15q 11 -q 13. Careful molecular analysis has gradually enabled the narrowing down of
the size of the shortest chromosomal region involved in these cases ofPWS and AS
(Woodage et al., 1994, Greger et al., 1994, Michaelis et al., 1995, Burke et al., 1996,
Buiting et al., 1999).
Sutcliffe et al. (1994) described deletions of 5 kb and 60 kb in a familial and a
sporadic case of PWS respectively. The deletions removed exon 1 ofSNRPN, which
is embedded in a differentially methylated CpG island. What was particularly
interesting, however, was that these mutations caused altered methylation and loss of
paternal gene expression over hundreds of kb. It was also noted that the 5 kb deletion
was benign when maternally inherited. Based on these observations, the authors
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proposed the presence of an imprinting control region or imprinting centre (IC) near
exon 1 ofSNRPN.
Further evidence for the existence and function of the IC region was described by
Buiting et al. (1995). These authors demonstrated that different inherited
microdeletions of the region were capable of causing both AS and PWS syndromes,
and that rather than two completely separate paternal and maternal IC elements, there
was a single cA-acting IC that regulated the chromatin structure, DNA methylation
and gene expression through the domain (Dittrich et al., 1996, Buiting et al., 1999).
Fine analysis, however, did enable the demonstration of adjacent, largely non-
overlapping minimal regions of the IC that were deleted specifically in AS or in
PWS cases (see below).
The disruption of the epigenetic program by the IC deletions means that while
chromosome 15 exhibits a normal biparental mode of inheritance, AS patients have
two chromosomes with a paternal identity (hypomethylation and biallelic expression
ofpaternally expressed genes) while conversely, PWS patients have two
chromosomes with a maternal identity (hypermethylation and silent paternal genes).
In a sense, therefore, these patients have functional UPD, despite the biparental
origin of their chromosomes (Horsthemke et al., 1997, Mann and Bartolomei, 1999).
The exact locations of the IC deletions in AS and PWS are different: AS deletions
involve the upstream BD exons, while in PWS the deletions map slightly further 3',
encompassing SNRPN exon 1 (exon a or-1) (Dittrich et al., 1996, Saitoh et al.,
1996). From analysis of two families with IC microdeletions, Ohta et al. (1999a)
demonstrated that the AS shortest region of deletion overlap (AS-SRO) was -35 kb
centromeric to exon 1 ofSNRPN. Buiting et al. (1999) similarly identified an AS
family with a 5 kb IC microdeletion (the smallest found so far in AS) that further
narrows down the AS-SRO to a 880 bp fragment containing two of the BD upstream
exons. The analysis of the BD exons' structure has also indicated that the elements of
the IC region have undergone multiple duplication events. Since the duplications
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include not only the exons but flanking DNA as well, they are probably the result of
chromosomal events such as unequal crossovers (Farber et al., 1999).
In the case ofPWS it is the distal part of the IC that is deleted. The critical region is
<4.3 kb spanning the SNRPN gene CpG island and exon 1, again as determined by
the shortest region of overlap ofmicrodeletions in PWS (PWS-SRO) (Dittrich et al.,
1996, Ohta et al., 1999b).
The function of the IC is as yet not completely understood, and several models have
been proposed to explain its action. In the model proposed by Dittrich et al. (1996),
the IC consists of an imprintor and an imprint switch initiation site. The imprintor
encodes the BD transcript; it is transcribed from the paternal chromosome only and
acts in cis on the switch initiation site (which may be the SNRPN promoter, exon 1 or
a site close by), possibly by introducing a local change in the chromatin structure. In
the XX germline, a trans-acting factor specific for female germline cells is involved
in completing the switch and/or initiating the bi-directional spreading of the maternal
imprint on the paternally derived chromosome which switches off the imprintor
activity.
In the absence of this maternal trans-acting factor (XY germline), the maternal
imprint on the maternally-derived chromosome is lost, starting from the switch
initiation site (spreading of the paternal imprint) (Dittrich et al., 1996, Ferguson-
Smith, 1996, Kelsey and Reik, 1997). The model implies that in a given AS family,
the grandfather is able to switch the imprint ofhis deletion-bearing maternal
chromosome, because the maternal-to-paternal switch does not involve the activity of
the BD exons. On the other hand, his daughter (the mother of the AS child) cannot
switch the epigenotype, because the paternal-to-maternal switch depends on BD
activity. Exon 1 (SNRPN) meanwhile, is required for establishing the maternal-to-
paternal switching (Dittrich et al., 1996, Ferguson-Smith, 1996).
The suggestion that the IC controls imprint switching in the male and female germ
line implies that IC microdeletions can transmit silently for multiple generations, but
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that when the sex of the transmitting individual changes, the mutation blocks the
appropriate resetting of the imprint specific for that individual germ-line. Thus, PWS
IC mutations block the normal matemal-to-patemal imprint switch in the male germ
line and AS IC mutations block the patemal-to-matemal imprint switch in the female
germ line (Ohta et al., 1999b).
In a recent description of a family with PWS in male and female first cousins, Ming
et al. (2000) demonstrated a submicroscopic deletion ofSNRPN. In this family, the
two cousins' fathers and two paternal aunts had the same deletion and were clinically
normal. Since the surviving paternal grandfather did not carry the deletion, it was
assumed to derive from the grandmother. Thus, an imprinting centre mutation can
yield a "grandmatrilineal" inheritance pattern, in which a woman carrying the
mutation (which affects imprinting when paternally transmitted) is at risk of having
affected grandchildren through her unaffected sons. PWS does not become evident as
long as the deletion is passed through the matrilineal line (Ming et al., 2000).
An alternative "two-step" model for imprint switching involves the erasure of the
imprints, which requires the SNRPN CpG island and occurs in both germlines,
followed by an active resetting. In this model, BD activity is involved specifically in
resetting the maternal epigenotype in the female germline, where it is expressed from
both "erased" chromosomes. In the absence ofBD transcription in the male germline,
a paternal imprint is acquired (Ferguson-Smith, 1996, Kelsey and Reik, 1997).
More recently, however, evidence has emerged that suggests that the PWS IC may
act not just to "switch" epigenotype to paternal in spermatogenesis, but to maintain
the imprint in somatic cells. Bielinska et al. (2000) described a PWS family in which
the father is mosaic for an IC deletion of ~200 kb spanning SNRPN on his paternal
chromosome. They found that the deletion chromosome had acquired a maternal
methylation imprint in his somatic cells. The findings were supported by a chimaeric
mouse model of the deletion, in which the chromosome with the paternal deletion
has also adopted a maternal methylation pattern in somatic tissues. These results
indicate that a paternal chromosome can postzygotically acquire a maternal imprint,
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and therefore that the PWS IC element is not only required for establishing the
paternal imprint in the paternal germ line but also for the postzygotic maintenance of
this imprint. In this PWS family, unlike that ofMing et al. (2000), the IC deletion
was inherited from the grandpaternal rather than the grandmaternal chromosome via
the father. This indicated for the first time that contrary to the prediction of the
"switch" models, the grandpaternal chromosome is not immune to rearrangements
that ultimately result in PWS (Mann and Bartolomei, 1999).
Some experiments have been performed to address the possible cw-regulatory
properties of the IC. In a transgenic Drosophila model, Lyko et al. (1997)
demonstrated that a fragment from the region around SNRPN exon 1 can function as
a parent-of-origin-independent transcriptional silencer. The DNA fragment used
comprised nt -203 to +538 (relative to nt 1 ofSNRPN exon 1) and the authors were
able to narrow down the silencer activity to a 215 bp sequence (nt -203 to +12) that
contained the SNRPN promoter. However, it is still unknown whether this result
reflects the presence of a transcriptional silencer that is also active in mammalian
cells.
Nuclear matrix binding assays have been used to demonstrate the presence ofmatrix
attachment regions (MARs) ar high density within the IC region of 15ql 1 -ql3
(Greally et al., 1999). MARs are regions ofDNA identified by their preferential
association with the nuclear matrix (the structural "scaffold" that remains after
treatments that deplete nuclei ofmost of their DNA) (Cockerill and Garrard, 1986).
MARs are frequently found in association with regulatory elements such as
enhancers and represors of transcription, origins ofDNA replication, and cA-acting
regulators of chromain structure and cytosine methylation (Rollini et al., 1999). In
the PWS/AS region, MARs could exert a chromatin-organizing effect that proceeds
differently on passage through the male and female germ line. The resulting allelic
differences in chromatin structure dependent gene regulation would be recognized as
genomic imprinting. According to this model, the heterochromatin-forming
propensity of the IC must be differently modulated by other factors during male and
female gametogenesis (Greally et al., 1999).
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1.1.8.11 Histone acetylation in 15qll-ql3
Chromatin immunoprecipitation revealed that the unmethylated CpG island of the
active, paternal allele ofSNURF-SNRPN was associated with acetylated histones,
whereas the methylated maternally derived, inactive allele was hypoacetylated.
When cells were treated with a DNA methyltransferase inhibitor, inducing
demethylation of the CpG island, gene expression from the maternal allele was
reactivated (Saitoh and Wada, 2000). These studies showed that SNURF-SNRPN is
associated with parent of origin specific histone acetylation which is confined to the
CpG island. The findings re-emphasize the intimate link between methylation and
histone acetylation status in the epigenetic control of gene expression. It was also
pointed out that since these experiments demonstrated that a gene that is silenced in
PWS can be reactivated by drug treatment, there may be future possibilities for
pharmacological therapy in disorders of genomic imprinting.
1.1.8.12 Asynchronous replication in 15qll-ql3
By FISH analysis, the normal human chromosome 15 homologues were
demonstrated to replicate asynchronously and to exhibit preferential association with
each other during late S phase. Knoll et al. (1994) observed asynchronous replication
in a high percentage of cells (25-40%) both from normal individuals and patients
with PWS and AS with chromosome 15 deletions. In contrast, asynchronous
replication was not found in PWS patients with maternal UPD. At least three
different replication patterns were discernible at the telomeric end of the PWS/AS
region: the paternal D15S63 allele showed early replication, while GABRA5 behaved
oppositely (maternal early). The P gene replicated asynchronously but this occurs
randomly with respect to its parental origin.
Further studies of a -650 kb region that includes SNRPNwere carried out by
Gunaratne et al. (1995). This domain replicates late in lymphocytes but
predominantly early in neuroblasts, where replication asynchrony was noted. A
familial PWS deletion that encompasses part of the 5' end ofSNRPN resulted in the
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loss of late replication of the domain in lymphocytes, when the deleted chromosome
15 is inherited paternally. Therefore, a potential allele-specific replication timing
control region colocalises with the ICR. Furthermore, this region seems to control the
replication of the paternal copy of the PWS domain in cis, and has no effect on the
replication of a paternal allele in trans or on the replication of the maternal copy in
cis or trans. This implies the existence of two different regions that control the
replication of the paternal and maternal alleles of the PWS region.
1.1.8.13 Nuclease hypersensitivity of the SNRPN transcription unit
A region of 150 kb including SNRPN was examined for nuclease hypersensitivity in
lymphoblastoid cell lines from PWS and AS individuals. This identified regions of
hypersensitivity that were preferentially or exclusively parental-origin-specific
(Schweizer et ah, 1999): exon 1 ofSNRPN, for example, is flanked by two
hypersensitive sites on the paternal allele, one (pHSl) just upstream of exon 1 and
the other (pHS2) ~1.7 kb downstream of exon 1 within SNRPN intron 1. Some other
hypersensitive regions were identified on the maternal allele, one of which coincides
with the AS minimal IC region and another ofwhich lies within SNRPN intron 1
immediately downstream of the paternal-specific hypersensitivity site. In general
terms, this study indicated a pattern whereby nuclease hypersensitivity of one allele
correlated with hypermethylation on the allele contributed by the other parent.
(Schweizer et ah, 1999).
1.1.8.14 The mouse model for PWS and AS
The first candidate mouse models for PWS and AS were described by Cattanach et
al. (1992 and 1997). Intercrosses between strains with chromosomal translocations
were used to derive progeny with UPD of the PWS/AS-homologous region of
chromosome 7. The maternal duplication (ie chromosomally comparable to PWS)
caused a murine imprinting defect that was expressed as an early postnatal lethality,
possibly resulting from impaired suckling activity. However, the paternal duplication
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was not associated with any detectable phenotypic effect which might correlate to
AS.
When targetted deletions within the region were made, an intragenic deletion within
Snrpn resulted in no phenotypic abnormality, suggesting that mutations ofSNRPN
alone might not suffice to produce PWS. However, mice with a larger deletion,
involving both Snrpn and the putative PWS-IC, lacked expression ofZfpl27, Ndn
and Ipw. Since these effects of the targetted IC mutation were similar to those of the
human IC mutations, the role of IC in controlling imprinting appears to be conserved
between humans and mice (Yang et ah, 1998).
Gerard et al. (1999) generated Ndn mutant mice, and demonstrated that a paternally-
inherited deletion allele resulted in post-natal cyanosis, dyspnoea, and lethality
(within 30 hours). The lethality associated with the paternal Ndn deletion appeared to
be due to a respiratory defect. It was therefore suggested that this is a relevant model
for the neonatal respiratory distress (resulting from muscular hypotonia) often
observed in humans with PWS. Necdin may thus be the first single gene within the
PWS deletion interval for which a loss of function mimics some phenotypic aspects
ofPWS.
A null mutation in Ube3a, the murine orthologue of the AS gene, has also been
produced by gene targetting. The maternally-deficient mice presented motor
dysfunction, inducible seizures, and a defect in contextual learning and hippocampal
long-term potentiation (LTP). LTP is an electrophysiological phenomenon whereby
stimulation ofpresynaptic axons increases the strength of connections to
postsynaptic neurons for days to weeks; it is regarded as a form of neuronal plasticity
and is considered the strongest candidate cellular mechanism for learning and
memory. This defect observed in the AS mouse model represented the first evidence
for a role of ubiquitination in mammalian LTP (Albrecht et al., 1997, Jiang YH et al.,
1998).
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1.1.9 THE CLUSTER OF IMPRINTED GENES IN llp!5.5
The second imprinted gene cluster that has been a major focus for study in both
human and mouse maps to human chromosome 1 lpl5.5. Genetic pathology in this
region is associated with Beckwith-Wiedemann syndrome (BWS). The region shows
conserved synteny with a cluster of imprinted genes on distal chromosome 7 in the
mouse (Hoovers et al., 1995, Yuan et ah, 1996, Zubair et ah, 1997, Ainscough et ah,
1998, Paulsen et al., 1998) (Figure 1.5).
Figure 1.5. Simplified map of genes within the imprinted cluster on human
chromosome 1 lp 15.5 (not to scale). Individual genes mapping to this region are
indicated by dark circles (paternally expressed), grey circles (maternally expressed)
or open rectangles (non-imprinted). The small arrows show overlapping and
antisense transcription. The two putative regional imprinting control centres are
marked as IC. The three loci that have been specifically implicated in the
pathogenesis of Beckwith-Wiedemann syndrome are indicated as BWS (modified
















































Figure1.5.Schematicdia ramoft elo ationsenew thinimpr t dcl s rhu chromosome1lpl5
1.1.9.1 The Beckwith-Wiedemann syndrome
This syndrome (OMIM #130650) was described independently by Beckwith in 1963
and Wiedemann in 1964. It has a frequency of 1 in 14,000 births and is characterised
by pre and postnatal overgrowth, macroglossia and anterior abdominal wall defects,
typically omphalocoel (the EMG triad) (Weng et al., 1995). Variable features of
BWS include organomegaly, transient hypoglycaemia, hemihypertrophy,
genitourinary abnormalities and in about 5% of affected children, embryonal tumours
(mainly Wilms' tumour but less frequently also adrenocortical carcinoma,
hepatoblastoma or rhabdomyosarcoma) (Mannens et al., 1994).
The pathogenesis ofBWS, like that of PWS/AS, is heterogeneous. About 15% of
cases are familial, these displaying a maternal inheritance pattern. Balanced
translocations involving 1 lp 15 are seen in 1-2 % ofBWS patients. Most of the
remaining cases are sporadic (20% of these being associated with segmental/mosaic
paternal UPD) (Weng et al., 1995). Inactivating mutations of the CDKN1C gene
(encoding p57KIP2) have been reported in 40% of the familial and 5% of sporadic
BWS cases, and loss of the maternal imprinting of IGF2 has been described in 30%
ofBWS patients (Reik and Maher, 1997, Hatada et al., 1996, Algar et al., 2000).
Several different translocation breakpoint cluster regions (BWSCR) have been
defined in patients with BWS. BWSCR1 comprises 5 breakpoints clustered
centromeric to IGF2 and HI9, that disrupt the gene KVLQT1. As discussed below,
these BWSCR 1 translocations have been postulated to cause BWS through indirect
effects on the expression of one or both of the genes CDKN1C and IGF2.
BWSCR2 and BWSCR3, however, map distantly to the BWS imprinted gene cluster,
lying respectively 5 Mb and 7 Mb proximal to BWSCR1 (Figure 1.6). BWSCR2 is
defined by the breakpoints in two patients, and has been associated specifically with
hemihypertrophy, a clinical finding not seen in patients with translocations involving
BWSCR 1 or BWSCR3 (Hoovers et al., 1995 Alders et al., 2000). The BWSCR2
translocations disrupt ZNF215, a tissue-specifically maternally expressed zinc finger
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gene, but the precise nature of the link between this remote translocation site and the
more telomeric BWS imprinted gene cluster remains unclear.
Figure 1.6. Locations of the BWS breakpoint regions on human chromosome 1 lpl5
(map not to scale). Four of the genes in the region are indicated by the coloured
rectangles as before; the directions of the centromere (cen) and telomere (tel) are also
indicated. The three breakpoint regions are indicated as BWSCR1, BWSCR2,
BWSCR3, the last two mapping 5 Mb and 7 Mb from BWSCR1 (modified from
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As in the PWS-AS region, imprinted and non-imprinted genes are interspersed
within the BWS region. Specific features that have contributed to our understanding
of imprinting are described below, taking the individual genes in a centromeric to
telomeric order.
i) The NAP2 gene (nucleosome assembly protein 2) encodes a highly acidic 375 aa
protein, homologous to the yeast nucleosome assembly protein (NAP1) (Hu et al.,
1996). NAP2 is biallelically expressed. It has therefore been considered as defining
the centromeric border of the distal BWS imprinted domain. However, the recent
finding of an imprinted gene at BWSCR2, 5 Mb farther centromeric (Alders et al.,
2000), suggests that this may underestimate the true extent of imprinting effects on
11 p 15.5.
ii) TSSC3 (or IPL, imprinted inplacenta and /iver) was the first apoptosis-related
gene demonstrated to be imprinted. It is maternally expressed in most tissues during
human development (exceptions being the heart, testis and kidney). In adult brain
and blood, TSSC3 is biallelically expressed; however, in most neuroblastoma,
medulloblastoma and glioblastoma tumours, it was found to be monoallelically
expressed (Qian, et al., 1997, Muller et al., 2000). Given that TSSC3 may have a
growth inhibitory effect, it has been argued that suppression of its expression, due to
retention or regaining of imprinting, is involved in the process of tumour
development (Muller et al., 2000).
iii) The ORCTL2 gene (organic cation transporter-/ike 2) is also referred to as IMPT1
and TSSC5. It has 2 transcripts, encoding predicted proteins of 253 and 424 amino
acids. Although this gene is imprinted, its imprinting has been described as "leaky",
meaning that the paternal allele is expressed at 20-30% the level of the preferentially
expressed maternal allele and that there is little or no allelic bias at all in fetal
fibroblast and lymphoblast cell lines. "Leaky" imprinting may reflect cellular
heterogeneity, with certain populations of cells having complete repression of one
allele and others showing biallelic expression (Cooper et al., 1998, Dao et al., 1998).
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iv) The CDKN1C gene (orp57KIP2) encodes a cyclin-dependent kinase inhibitor that
induces G1 cell cycle arrest and is homologous to p21CIP1/WAF1, a mediator of p53-
directed cell cycle arrest. CDKN1C has a transcribed polymorphic hexanucleotide
repeat within exon 1, that encodes a proline alanine repeat (PAPA). This gene is
preferentially (90-95%) expressed from the maternal allele, except in the brain,
where comparable expression ofboth alleles has been demonstrated (Hatada et al.,
1995, Matsuoka et al., 1995 and 1996, Zhang et al., 1997, Algar et al., 2000).
A null mutation ofCdknlc in the mouse causes umbilical abnormalities
(omphalocoel) and respiratory problems (Zhang et al., 1997). Mutations of CDKN1C
are also found in a proportion ofBWS patients, most commonly in familial cases
(Lam et al., 1999). The mutations in these cases are derived from unaffected carrier
mothers, suggesting that loss ofCDKN1C function results in BWS when the
expressed allele encodes an inactive product and the other allele is repressed by
genomic imprinting (Hatada et al., 1996).
v) Telomeric to CDKN1C is the KVLQT1 gene, that encodes a voltage-gated
potassium channel. This gene is maternally expressed in all human tissues except the
heart. KVLQT1 has 14 exons and spans a 300 kb region (Lee et al., 1997b, Mannens
and Wilde, 1997).
KVLQT1 mutations cause long QT syndrome (LQT type Romano Ward), a
dominantly inherited cardiac arrhythmia (Mannens and Wilde, 1997, Caspary et al.,
1999). Deletions and insertions within KVLQT1 have also been described in patients
with the Jervell and Lange-Nielsen cardioauditory syndrome (JLN), an autosomal
recessive condition characterised by congenital bilateral deafness associated with QT
prolongation on the electrocardiogram, ventricular arrythmias and high risk of
sudden death (Neyroud et al., 1997, Caspary et al., 1999, Mannens and Wilde, 1997).
The murine Kvlqtl gene is strongly expressed in heart, lung, gut, kidney and uterus.
While its expression is maternal in early development, the paternal allele becomes
increasingly active during development and juvenile animals show completely
60
biallelic expression. In humans, the lack ofparent-of-origin effect in the LQT and
JLN syndromes is due to the relative lack of imprinting in the heart, the main
affected tissue (Gould and Pfeiffer, 1998, Caspary et al., 1998). Interestingly,
although KVLQT1 is involved in chromosomal rearrangements that are found in a
small proportion ofBWS patients, so far no BWS patients with LQT or JLN
syndromes have been reported (Lee et al., 1997a).
vi) KVLQT1 has an antisense transcript named KVLQT1AS or LIT1 (long QT intronic
transcript 1) that is paternally expressed but which in many patients with BWS is
abnormally expressed from both the paternal and maternal alleles, (loss of
imprinting, LOI). LIT1 spans over 60 kb and is not translated (Lee et al., 1999,
Mitsuya et al., 1999, Smilinich et al., 1999).
In the study of Lee et al. (1999a), 58% ofBWS patients showed loss of maternal
allele-specific methylation of the CpG island upstream ofLIT1. The LOI ofLIT1
appeared not to be associated with LOI of IGF2, and LOI ofLIT1 was suggested to
be the most common genetic alteration in BWS. (Also, the fact that LIT1 and IGF2
are independently affected in BWS patients has lent support to the view that in this
region there are actually two imprinted domains (discussed in section 1.1.10.4) (Lee
et al., 1999a). It has been suggested that the unmethylated LIT1 CpG island acts as an
insulator between CDKN1C and its enhancers, so that LOI ofLIT1 would result in
suppression of CDKN1C. However, in mice lacking Dmntl, where presumably both
CpG islands are unmethylated, Cdknlc remains active (John et al., 1999).
Furthermore, some of the BWS patients with translocations within KVLQT1 have
been reported to show abnormal IGF2 expression. Thus, there may not be complete
independence between the regulation of the centromeric and telomeric regions of the
1 lpl5.5 cluster (Horike et al., 2000).
vii) Telomeric to KVLQT1 maps MTR1 (named for resemblance to MLS1, a gene
with homology to melastatin), also known as LTRPC5 (large transient receptor
potential-related channel 5). MTR1 has 24 exons and spans 18.5 kb. It is alternatively
spliced to encode two proteins of 872 and 1165 amino acids, both ofwhich have
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several predicted membrane-spanning domains. Transcripts have been identified in
several fetal and adult tissues and also inWilms' tumours and rhabdomyosarcomas.
By RT-PCR analysis of somatic cell hybrids, exclusive expression ofMTR1 in cell
lines carrying a paternal chromosome was demonstrated. However its murine
orthologue (Mtrl) is biallelically expressed (Enklaar et al., 2000, Prawitt et al.,
2000).
viii) The TSSC4 and TSSC6 genes were first identified on the so-called
subchromosomal transferable fragment or STF, a 2.5 Mb fragment that suppressed in
vitro growth of a rhabdomyosarcoma cell line. TSSC4 and TSSC6 code for 329 and
290 amino acid proteins respectively, with no close similarity to other known
proteins. However TSSC6 shows some weak similarity to TAPA1/CD81 (located only
60 kb centromeric from TSSC6, between TSSC4 and TSSC6) prompting the
suggestion that these genes may have arisen by duplication followed by sequence
divergence. TSSC4 and TSSC6 have a slight allelic expression preference in some
tissues, but are mostly biallelically expressed (Lee et al., 1999b) in humans. In the
mouse, there are some differences in expression, despite the conservation of the
overall gene content and organization of the region. Tssc4, for example, unlike its
human counterpart, is imprinted in mouse placenta (Paulsen et al. 2000).
ix) The TAPA1/CD81 gene (see above) encodes a 26 kD membrane protein with four
transmembrane domains, part of a signal transduction complex in T cells that
respond to activated complement and has a critical role in early T-cell development.
TAPA1 belongs to the TMSF group of genes, and inactivation of some TMSF
proteins has been shown to enable tumour progression. TAPA1 is paternally
expressed, but its mouse orthologue, although imprinted until e8.5, is biallelically
expressed after this date (Reid et al., 1997).
x) The ASCL2 gene (or HASH2) is maternally expressed only in the extravillus
trophoblast. It is not expressed in benign androgenetic hydatidiform moles. However,
expressio was detected in malignant moles, perhaps reflecting LOI in these tumours.
In mice, mutation of the maternal Mash2 orthologue is an embryonic lethal. This
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may indicate that HASH2, also, is needed for normal development. If so, embryonic
lethality ofpaternal UPD for 1 lp 15.5 could provide an explanation for the fact that
virtually all paternal UPD seen in BWS patients is mosaic (Alders et ah, 1997).
xi) The imprinting status of the next gene, TH (tyrosine hydroxylase) has not been
formally investigated. However, the recessive inheritance pattern of infantile
Parkinsonism (Segawa disease, OMIM #605407) that results from THmutations,
suggests that TH is biallelically expressed.
xii) The imprinting of INS has been a matter of considerable interest. Giddings et al.
(1994) studied the imprinting of Ins2, (the mouse homologous of INS) using single
strand conformational polymorphism analysis. They showed that the gene was
biallelically expressed in embryonic pancreas but that only the paternal allele was
expressed in the yolk sac. The finding that Ins2 was imprinted in mice supports
observations that imply that the human INS gene may also be imprinted. Specifc
alleles at a VNTR (variable number of tandem repeat) locus in the 5' region of INS
have been associated with an increased risk of insulin-dependent diabetes mellitus
(IDDM), and there is a parental-origin dependence to this association (Bennett et al.,
1997, Dunger et al., 1998). Conclusive evidence that INS is indeed also imprinted in
humans has been recently described by Moore et al. (2001), who demonstrated that
INS, like Ins2, is imprinted in the yolk sac.
xiii) The following two genes, IGF2 and H19, have been intensively studied and
used as a model for the regulation of genomic imprinting. They are therefore
described separately in the next section (1.1.10.3).
xiv) The LM23MRP gene encodes an L23-mitochondrial related protein, an essential
component of the large ribosomal subunit, which is predicted to contact and bind to
ribosomal RNA. The gene is within 40 kb ofH19, orientated "tail-to-tail", but is
biallelically expressed. It has been considered to constitute the telomeric border of
the imprinted 11 pi5.5 domain (Tsang et al., 1995).
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1.1.9.2 The IGF2 and H19 genes
The IGF2/Igf2 gene encodes a growth factor that seems to be involved mostly in
fetal growth, and was one of the earliest identified imprinted genes. Mice with a
targetted mutation disrupting Igf2 displayed a heterozygous dwarfism phenotype, but
only when the mutation was paternally inherited. The weights ofmice with the
mutation were -60% ofwild type (De Chiara et al., 1991). The inheritance pattern
results from paternal monoallelic expression of Igf2 during embryonic development
(Giannoukakis et al., 1993, Ohlsson et al., 1993). The human IGF2 gene is
transcribed from four tissue-specific promoters, with transcription from the P1
promoter (preferentially active in adult liver) being biallelic (Vu and Hoffman, 1994,
Vu et al., 2000).
H19 encodes a 2.5 kb RNA without open reading frame, and although its biological
role is not entirely clear, it has been considered to have tumour suppressor activity
(Zhang et al., 1993, Chen et al., 2000b). H19 is transcribed only from the maternal
allele and is very abundant in the developing mouse embryo, but after birth this gene
is repressed in most tissues (Pachnis et al., 1988, Bartolomei et al., 1991, Zhang and
Tycko, 1992).
Igf2 and H19 lie - 90 kb apart, are reciprocally imprinted (as is also the case in
humans) and have therefore been extensively studied in an effort to understand their
regulatory interdependence (Thorvaldsen and Bartolomei, 2000). Regulatory regions
important for the expression ofboth genes have been identified; these comprise
differentially methylated regions (DMR) and a number of tissue-specific enhancers
downstream ofH19 (Sasaki et al., 2000).
Three DMRs have been found in Igf2, two of which (DMR0 and DMR1) are located
5' of the promoter PI and one (DMR2) near the last exon (exon 6 in mice). In H19,
there is a DMR -2 kb upstream from the transcription start site, which is methylated
in sperm and unmethylated in oocytes (Sasaki et al., 2000, Vu et al., 2000).
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Leighton et al. (1995) identified a region essential for maintaining the regulation of
both H19 and Igf2. In this study, the regulation of the expression of Igf2 and Ins was
disrupted by a deletion spanning H19 itself and 10 kb of the 5' flanking sequence,
suggesting a function of this H19 region to imprint Ig/2. By producing mice
harbouring a 1.6 kb deletion (including the DMR) it was demonstrated that H19 was
activated and Igf2 expression was reduced when the deletion was paternally inherited
and that conversely H19 expression was reduced and Igf2 was activated upon
maternal inheritance of the deletion.
It was deduced from such studies that the H19 DMR (that spans ~2 kb and is 2 kb 5'
ofHI9) is required for the reciprocal imprinting of the two genes and also (to judge
from the timing of its differential methylation) that it serves as the allelic mark
distinguishing paternal and maternal alleles. This region has also been shown to act
as a transcriptional silencer in Drosophila (Lyko et al., 1997, Ripoche et al., 1997,
Thorvaldsen et al., 1998). In addition, by conditional deletion transgenic
experiments, Srivastava et al. (2000) demonstrated that the presence of the H19
DMR on the maternal chromosome is continually needed at different stages of
development in mice in order to keep Igf2 silenced.
Endoderm and muscle-specific enhancers downstream ofH19 are also involved in
the regulation of Igf2/H19 imprinting. By deleting the endoderm enhancers, Leighton
et al. (1995) observed that neither H19 nor Igf2 was expressed on the chromosome
with the deletion, indicating that both genes utilise the same enhancers, albeit on
different parental chromosomes. It was also observed that when an extra set of
enhancers was inserted midway between Igf2 and H19, the normally silent maternal
Igf2 allele was activated in endodermal tissues without changing the level ofH19
expression, indicating that the endoderm enhancers in their correct location are
essential for the imprinted expression of both Igf2 and H19. At least five enhancer
regions have been identified, and interestingly, they resemble a large cluster of
tissue-specific enhancers at the locus control region (LCR) of the P globin gene
cluster (Webber et al., 1998, Li Q et al., 1999, Sasaki et al., 2000).
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Such observations led to the enhancer competition model, which was based on the
similar patterns of expression of Igf2 and H19 in many endoderm and mesoderm
derived tissues, implying the sharing of tissue-specific enhancers. The enhancers
would preferentially activate H19 on the maternal chromosome (perhaps due to
proximity or to high affinity), leaving the maternal Ig/2 allele silent or only weakly
expressed. On the paternal chromosome, the enhancers cannot interact with H19
because the 5' region ofH19 is heavily methylated and assumes a closed chromatin
structure; thus the enhancers would engage with Igf2 (Bartolomei and Tilghman,
1997, Sasaki et al., 2000).
This model suggests that H19 transcription on the maternal chromosome is required
to maintain the silence of the maternal Igf2 allele. To test this prediction, Schmidt et
al. (1999) examined a transgenic model in which the H19 promoter and structural
gene had been deleted. However, the absence of transcription from the H19 promoter
had no effect on the imprinting of Igf2 in liver, and only a small effect in skeletal
muscle. This led to a modified version of the enhancer-competition theory, in which
it was proposed that Igf2 imprinting is determined by a methylation-regulated
chromatin boundary at the H19 DMR. One experiment suggesting such a property
for the H19 DMR consisted ofmoving the DMR to a position downstream of the
H19 gene, between the endodermal and skeletal muscle enhancer elements. The
DMR was thus positioned between between the H19 promoter and the muscle
enhancers. On maternal inheritance, activation ofH19 in skeletal muscle but not in
liver was blocked, consistent with the presence of insulator activity being exerted by
the ectopic H19 DMR (Kaffer et al., 2000).
Two maternal-specific nuclease hypersensitive regions, HS1 and HS2, related to the
DMR upstream ofH19, constituted good candidate sites for the binding of proteins
involved in the structure of the putative chromatin boundary (Hark and Tilghman,
1998, Ben-Porath and Cedar, 2000). Boundary elements are generally defined as ex¬
acting DNA sequences that delineate specialised gene expression domains in
chromatin. Thus when placed at either side of a gene and its regulatory elements,
they insulate that transcription unit from the regulatory elements of neighbouring
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genes (Sasaki et al., 2000). Analysis of the H19 HS1 and HS2 revealed that they
overlap with several short CG-rich repetitive elements that are recognition sites for
the zinc finger protein CTCF (Kanduri et ah, 2000, Pfeifer, 2000, Thorvaldesen and
Bartolomei, 2000). CTCF (CCCT-binding factor) is a transcription factor that plays a
role in insulator activity at the chicken P globin locus (Bell and Felsenfeld, 2000). Its
activity is sensitive to the methylation state of the DNA target site; zinc-fingers
proteins such as CTCF prefer to interact with the major groove ofDNA and
presumably the projection of the methyl group attached to cytosine prevents the zinc
finger from recognising key bases within the recognition sequence (Hark et al., 2000,
Bell and Felsenfeld, 2000, Wolffe, 2000).
The model currently proposed to mediate the reciprocal imprinting of Igf2 and H19 is
that the maternal chromosome represents the default or unimprinted state. CTCF
binds to the insulator element between the two genes, and the insulator-CTCF
complex blocks the Igf2 gene from the enhancer that is positioned 3 'ofH19.
Consequently, only the H19 gene is active. When the DMR and the H19 gene are
methylated, as on the paternal chromosome, CTCF fails to bind to the insulator and
then the 3' enhancer can activate the Igf2 promoter (Wolffe, 2000) (Figure 1.7).
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Figure 1.7. Regulated insulator activity at the Igf2-H19 locus.
A) The Igf2 and H19 genes are about 90 kb apart (not to scale). The small arrows
indicate the start site and direction of transcription of each gene. The positions of
the insulator (at the imprinting control region) and the enhancer are indicated.
There is in fact more than one tissue-specific downstream enhancer region.
B) On the maternal unmethylated locus, CTCF can bind to the insulator and prevent
the 3' enhancer from activating the Igf2 promoter. The enhancer can still
efficiently activate the unmethylated H19 promoter.
C) On the paternal methylated locus, CTCF can no longer bind to the insulator
because the DNA is methylated (Me) and insulator activity is therefore lost. In
addition, methylation of the H19 gene sequence represses transcription directly.
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1.1.9.3 The two domain hypothesis in Beckwith-Wiedemann syndrome
As described above, structural or regulatory alterations of several different genes
have been implicated in the pathogenesis ofBWS. The patterns of abnormality have
led to the suggestion that there are two distinguishable imprinted domains within the
1 lpl 5 BWS locus. One of these involves the antisense transcript LIT1, and the
second is related to IGF2 (Horike et ah, 2000). Despite their proximity and their joint
involvement in BWS, there is so far little direct evidence for a mechanistic link
between the imprinting of the two domains. For example, their timing and direction
of imprinting in the germline differ; the H19 paternal allele is active until late in
spermatogenesis, while the CDKN1C maternal allele is silent and is activated by
passage through the female germline late in oogenesis (John et al., 1999).
Mouse models have been used to investigate the role that each of the two imprinted
domains may have in the development ofBWS. A mouse double mutant for both
Cdknlc and Igf2 exhibits aspects ofBWS that are not seen in other models involving
each gene independently, such as macroglossia and a marked placentomegaly
(Eggenschwiler et al., 1997).
The fact that BWS can apparently result from either biallelic expression of IGF2 or
CDKN1C mutations, as well as the corresponding overlapping phenotypes in mice,
strongly suggest that these genes may act in a common growth control pathway.
Grandjean et al. (2000) demonstrated that Cdknlc expression is down-regulated in
mice with high serum levels of Igf2, suggesting that the effects of increased IGF2 in
BWS may be mediated in part through a decrease in CDKN1C expression.
Interestingly, this effect was not observed in the placenta, where there is evidence
suggesting that Ig/2 acts through a different (and currently unidentified) receptor.
Similarly, to investigate the mechanism by which mutations of the putative
centromeric imprinting centre result in BWS, Horike et al. (2000) analysed human
chromosomes carrying a targeted deletion of the LIT1 CpG island in somatic cell
hybrids. This deletion abolished LIT1 expression on a paternal chromosome, and this
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was accompanied by activation of the normally silent paternal allele ofmultiple
imprinted genes in the centromeric BWS domain (including KVLQT1 and CDKN1C).
However, the deletion had no effect on the regulation ofH19. These studies suggest
that LIT1 has a role in the BWS region that includes silencing of CDKN1C, thus
reinforcing the idea that LIT1 is an imprinting control element.
1.1.10 OTHER IMPRINTED LOCI IN HUMANS
Besides the two intensively-studied clusters of imprinted genes on chromosomes 11
and 15, other regions of the genome deserve attention because they illustrate specific
points relevant to the regulation of imprinting. Two of these regions are on
chromosome 6, and two on chromosome 7.
1.1.10.1 Imprinted genes on chromosome 6
The 6q24 chromosomal region has been associated with the rare disorder transient
neonatal diabetes mellitus (TNMD). This rare disorder is characterised by
intrauterine growth retardation, dehydration and failure to thrive. The diabetes results
from a congenital lack of insulin secretion, and although recovery occurs by 18
months of age ~40% of patients relapse and develop permanent type 2 diabetes later
in life (Temple et al., 2000, Gardner et al., 2000).
Two imprinted genes have recently been described in 6q24. These are ZAC1 and
HYMAl. ZAC1 is paternally expressed, and encodes a zinc finger protein, which
promotes apoptosis and cell cycle arrest. It is also a transcriptional regulator of the
type 1 receptor for the pituitary adenylate cyclase activating peptide (PACAPi-R), an
intra-islet regulator of insulin secretion. ZAC1 is thus a strong functional candidate
for being involved in TNDM, and abnormal methylation of the CpG island
associated with it has been demonstrated in some TNDM patients (Gardner et al.,
2000, Kamiya et al., 2000). TNDM, therefore, may be added to the short list of
human diseases (also including PWS, AS, BWS, and PHP-lb, discussed later) that
result from abnormal control of imprinting. HYMAl (hydatiform mole associated
transcript) is located 70 kb upstream of the coding region ofZAC1, and associated
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with the same differentiallymethylated CpG island that represents part of the ZAC1
transcription unit (Arima et al., 2000). It is a non-coding transcript that like ZAC1, is
paternally expressed, and may be considered part of the same transcription unit. The
extent of the 6q24 imprinted domain is presently unknown.
IGF2R (or M6PR) maps in humans to chromosome 6q26, and codes for the insulin¬
like growth factor type 2 receptor, for which the ligand is IGF2 (Barlow et al., 1991,
Bartolomei et al., 1997). IGF2R is involved in targeting of lysosomal enzymes from
the Golgi apparatus to the lysosomes, as well as in the intemalisation and
degradation of IGF2 (O'Dell and Day, 1998, Jirtle, 1999). The corresponding Igf2r
gene is imprinted in the mouse, being expressed from the maternal allele except in
CNS where is biallelically expressed (Vu and Floffrnan, 1994). Human IGF2R has
been reported not to be imprinted, in that it is biallelically expressed (Treacy et al.,
1996). However, the intragenic DMR2 (see below) does show maternal allele-
specific methylation in humans (Smrzka et al., 1995). In fact, it has been suggested
by others that there is tissue-specific monoallelic expression of IGF2R, and that this
may also be a polymorphic trait (Xu et al., 1993, Treacy et al., 1996). Loss of
heterozygosity (LOH) or abnormal allelic expression of IGF2R has been detected in
some human cancers (Kong et al., 2000).
The murine Igf2r gene has two DMRs: DMR1, located at the promoter, and DMR2,
an intronic CpG island. Detailed experimental analysis has defined DMR2 as a 113
bp box that includes an 8 bp de novo methylation signal (DNS) at its 3' end and a 6
bp allele-discriminating signal (ADS) that prevents the paternal allele from
undergoing de novo methylation (Stoger et al., 1993, Birger et al, 1999). As
previously mentioned, this intragenic DMR is the promoter for an antisense RNA
transcribed from the paternal allele. The antisense RNA (named Air for antisense
Igf2rRNA ) terminates more than -100 kb distant, within the flanking non-imprinted
gene MasI gene (Smrzka et al., 1995, Wutz et al., 1997, Lyle et al., 2000). Despite
the functional evidence (see section 1.1.8.6) thatAir represses Igf2r transcription in
cis on the paternal allele, there may be dissociation between Air and the regulation of
Ig/2r in some tissues. Thus, Air is derived only from the paternal allele in CNS,
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where it is unmethylated while the methylated maternal allele is silent (Hu et al.,
1999), even though Igf2r is biallelically expressed in this tissue.
1.1.10.2 Silver-Russell syndrome and imprinting on human chromosome 7
The Silver-Russell syndrome (SRS) is characterised by pre and postnatal growth
failure and dysmorphic features. Though it may be etiologically heterogeneous, in
7% of SRS cases maternal UPD7 has been demonstrated, suggesting that at least one
gene on this chromosome is imprinted (Preece et al., 1997, Bernard et al., 1999).
De novo duplication of the maternal chromosome 7p 11.2-p 13 has also been reported
in SRS patients. This suggests that the intrauterine growth retardation seen in
maternal UPD7 may result from an increased dose of a paternally imprinted gene on
chromosome 7 rather than the absence of a paternal growth-promoting gene
(Devriendt, 2000, Monk et al., 2000). The duplicated region contains the genes for
growth factor receptor-binding protein 10 (GRB10) and insulin like growth factor-
binding proteins 1 and 3. Paternal UPD of this region in mouse causes prenatal
overgrowth, and in human lymphocytes the GRB10 genomic interval has been shown
to replicate asynchronously (Monk et al., 2000)
Yoshihashi et al. (2000) found that GRB10 was monoallelically expressed in human
fetal brain and was transcribed from the maternal allele in somatic cell hybrids. In
two of 58 SRS patients, they found a maternally-derived P95S substitution. They
suggested that these findings indicated that these maternally transmitted mutant
alleles contributed to the SRS phenotype. However, it now appears that GRB10
imprinting is very complex. Blagitko et al. (2000) demonstrated expression from
both the paternal and maternal allele, in a highly tissue- and isoform-specific fashion.
In human fetal brain, GRB10 was paternally expressed, in contrast to the mouse in
which it is maternally expressed. This may represent the first example of a gene that
is oppositely imprinted in human and mouse. The role of GRB10 in SRS remains
uncertain.
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There are also imprinted genes on human chromosome 7q. MEST (PEG1) is the
orthologue ofMest/Pegl, the first imprinted gene mapped to mouse chromosome 6
(Kaneko-Ishino et al., 1995), and is expressed only from the paternal allele. The
disruption ofMest by gene targeting in embryonic stem cells showed that the
mutation was silent on passage through the female germ line. On paternal
transmission, the mutant allele caused embryonic growth retardation and abnormal
maternal behaviour (Lefebvre et al., 1998). Another gene in 7q32, COPG2,
(coatomer protein complex subunit y2) has been described as imprinted (Blagitko et
al., 1999) but this finding is now in doubt because of overlap between transcripts
derived from COPG2 and MEST (Yamasaki et al., 2000).
1.1.11. IMPRINTED REGIONS IN MOUSE
Some clusters of imprinted genes have been identified through studies in the mouse,
with subsequent extrapolation to humans. One example is the region ofmouse
chromosome 7 that contains Peg3 (human PEG3 is on 19ql3.4). Peg3 was identified
during a subtractive cDNA screen between parthenogenetic and biparental mouse
embryos (Kuroiwa et al., 1996), it encodes a paternally expressed zinc-finger protein.
Human PEG3 has also recently been shown to be paternally expressed (Murphy et
al., 2001). Targetted mutation ofPeg3 results in a phenotype characterised by growth
retardation and altered maternal behaviour that results in death of the offspring. This
alteration has been attributed to deficient neuronal connectivity (Li L. et al., 1999,
2000).
Another paternally-expressed gene in the same region ofmouse chromosome 7 is
Ocat (ossification centre-associated transcript). Its exon 1 is only 200 bp upstream of
Peg3, and Ocat is transcribed away from Peg3 (Szeto et al., 2000). Zim2 is a further
zinc finger gene, located 25 kb downstream ofPeg3. However, the Peg3 and Zim2
transcripts share identical 5 'ends, composed of 7 small exons. Alternative splicing
events connect these 7 exons either with the remaining 2 exons ofPeg3 or with the
remaining 4 exons ofZim2. The two genes share identical transcription start sites and
probably therefore also share upstream regulatory elements (Kim et al., 2000).
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Another cluster of two oppositely imprinted genes, Delta-like (Dlkl) and Gtl2 has
been described on mouse chromosome 12. The two genes are 120 kb apart and are
transcribed in the same orientation. The paternal-specific expression ofDlkland
maternal-specific expression of Gtl2 appear to be closely coordinated in a fashion
similar to that of the Igf2/H19 pair (Schmidt et al., 2000). This reciprocally imprinted
expression pattern is again conserved in the the DLK1 and GTL2 human orthologues
on chromosome 14q32 (Wylie et ah, 2000).
1.1.12 X- CHROMOSOME INACTIVATION
As described above, imprinted genes often share several general characteristics; they
tend to be located in clusters, to be regulated by a cA-acting imprinting centre, and to
be associated with antisense transcripts. These properties also feature in the process
ofX inactivation, which is an interesting model for investigating similarities between
the two inactivation mechanisms.
X inactivation is a mechanism for equalising the sex chromosome gene dosage in
males and females (Latham, 1996). It is believed to require several different steps,
namely: counting the number ofX chromosomes in a cell (n), randomly choosing (n-
1) X chromosomes to be inactivated per diploid genome, and initiating inactivation
of these chromosomes (Panning and Jaenisch, 1998, Pereira and Vasques, 2000).
There is normally an equal probability that either X chromosome will be inactivated
in a given cell (Chandra and Brown, 1975, Penny et al., 1996). In marsupials,
however, the maternal X is preferentially active and the paternal X is inactive
(Sharman, 1971).
X inactivation starts at the X-inactivation centre (Xic/XIC), defined as the minimum
cA-acting region required for an X chromosome to be inactivated. In humans XIC
maps to Xql3 (Brown et al., 1991). Two genes have been identified at Xic: Xist (for
X-inactive specific transcript) and Tsix, a gene antisense to Xist (Penny et al., 1996,
Lee and Lu, 1999). Xist is expressed exclusively from the inactive X chromosome. It
spans ~40 kb and encodes a ~15 kb non-coding RNA transcript, which is located in
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the nucleus and is required in cis to propagate X inactivation. Human X:autosome
translocations containing XIC reveal spreading of this inactivation effect onto the
autosomal segment (Clemson et ah, 1996, Penny et al., 1996).
As for autosomal imprinted genes, methylation also participates in the regulation of
Xic. In male somatic tissues Xist is hypermethylated at multiple CpGs at its 5' and 3'
ends as well as some sites within the gene. In females, methylation ofXist is
incomplete but consistent with methylation of one allele (the active X) per cell
(Belmont, 1996).
The 5' regions ofmany genes are methylated on the inactive X chromosome (Xi) and
unmethylated on the active chromosome (Xa). Meanwhile, the 5' regions of genes
that escape X inactivation remain unmethylated on both alleles (Tinker and Brown,
1998). Several (though not all) of the latter are clustered in and around the pseudo-
autosomal region and in Xpl 1, suggesting that X inactivation, like imprinting, is a
regional phenomenon, whereby entire blocks of genes are coordinately regulated
(Brown et al., 1997).
In the process of inactivation, the Xi acquires particular features that differentiate it
from Xa: Xi is late replicating, highly methylated on CpG islands and rich in
hypoacetylated histone H4, all markers of gene inactivity (Hansen et al., 1996,
Pereira and Vasques, 2000). The silent XIST gene on Xa also replicates before the
expressed allele on Xi, supporting the view that replication timing is determined by
the large, multi-replicon domain in which a gene is located, and not necessarily by its
expression state (Gartler et al., 1999).
As for some imprinted genes, an antisense transcript has been identified at theXist
locus. Tsix overlaps the 3' end ofXist and is transcribed in the reverse orientation.
Initially biallelically expressed, it becomes monoallelically expressed at the onset of
X inactivation, marking only the future Xa (Lee and Lu, 1999). During
differentiation, loss of Tsix transcription seems to correlate with the stabilisation of
Xist RNA on the Xi. Thus, the level ofXist RNA before differentiation may be
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controlled by Tsix through an antisense RNA-mediated mechanism (Pereira and
Vasques, 2000), as also suggested for some imprinted autosomal genes. Upon
differentiation, Tsix is repressed on the future Xi, leading to stabilisation of the allelic
Xist RNA. At the end of differentiation Tsix is off in both Xs, but Xist is expressed
only from Xi. Based on these results it has been proposed that the initiating element
for X inactivation is a repressor of Tsix (repTsix) that is expressed during
differentiation and X inactivation. This repressor starts the cascade of events leading
to X inactivation by associating with the Tsix promoter in all but one X chromosome
per diploid cell (Pereira and Vasques, 2000).
1.1.13 EPIGENETIC CHANGES IN CANCER
Disturbances of genomic imprinting have been implicated in the development of
cancer. Also, some of the syndromes caused by abnormalities of imprinting confer a
risk of particular tumour types. The Rnudson "two hit" model for recessive
oncogenesis has been modified to take account of the effects of imprinting.
Classically, the two "hits" required for loss of tumour suppressor gene function are
observed as deletions (manifesting, if acquired, as loss of heterozygosity, LOH) or
point mutations (Jones and Laird, 1999, McBurney, 1999, Tycko, 2000). In the case
of dominantly-transmitted cancer-predisposing syndromes, one of the "hits" is
inherited. However, for an imprinted gene, the normal epigenetic silencing of one
allele can be considered as another kind of first "hit". The second "hit" could occur
through LOH or epigenetically, silencing the tumour suppressor gene through DNA
methylation and histone acetylation (Feinberg, 1993, Jones and Laird, 1999, Tycko,
2000).
Loss of imprinting (LOI) of growth promoting genes is also involved in cancer. This
refers to the failure of the cell to maintain normal monoallelic expression (Feinberg,
1999). LOI may thus result in increased expression of an imprinted proto-oncogene,
Furthermore, mutational inactivation of an IC has the potential to alter the regulation
ofmultiple tumour suppressor genes or proto-oncogenes (Jirtle et al., 1999).
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LOI at the IGF2 locus has already been referred to in Beckwith-Wiedemann
syndrome. Biallelic expression of IGF2 has also been detected in 70% ofWilms'
tumours, in 40% of colorectal cancers (compared to 13% of samples of normal
colon; Ogawa et al.1993, Feinberg, 1999) and in 30% ofbreast cancers (Wu et ah,
1997). LOI ofboth IGF2 and H19 has been identified in cervical and in ovarian
cancer (Chen et ah, 2000b). In contrast, IGF2 imprinting status has generally been
maintained in infant leukaemias and neuroblastomas (Hattori et ah, 2000). LOI of
IGF2/HI9 is further discussed below.
In neuroblastomas, deletions in distal lp36 are preferentially maternal in origin,
indicating that this region may contain an imprinted tumour suppressor gene (Caron
et ah, 1993). One candidate gene mapping to this region is TP73 (OMIM *601990).
TP73 is maternally expressed and encodes a protein (p73) very similar to p53.
Occasional LOH of TP73 has been observed in various tumours, but so far no
convincing evidence for somatic mutations of the gene has been accumulated. Thus
p73 may be much less important than its homologue p53 in respect of tumour
suppressor activity. However, a role for TP73 in the pathogenesis of neuroblastoma
has not been totally excluded; it could contribute to this process through a gene-
dosage effect or secondary to transcriptional silencing of the remaining allele (Hu et
ah, 2000, Judson et ah, 2000).
Epigenetic silencing of an imprinted tumour suppressor gene could involve histone
deacetylation and/or DNA methylation. Deregulation of histone acetyltransferase
(HAT) and deacetylase (HDAC) activity is certainly frequent in human cancer
(Pedone et al, 1999). Inhibition ofHATs or inappropriate activation ofHDACs could
therefore be part of the mechanism causing loss of imprinting in human cancer.
Abnormalities in methylation have been studied more intensively, however. The von
Hippel-Lindau gene (VHL) is an example of a tumour suppressor that may be
silenced by methylation. Germline VHL mutations predispose to renal cell
carcinomas and hemangioblastomas, while somatic mutations have been found in
sporadic renal cell carcinomas. Also, in -20% of the latter, the VHL promoter is
hypermethylated (Tycko, 2000). This therefore appears to be a frequent alternative to
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LOH as a route to the somatic "second hit" . Other tumour suppressor genes that can
be inactivated by hypermethylation include hMLHl (colonic, gastric and endometrial
cancer) andpl6/INK4A (involved in multiple types of cancer) (Tycko, 2000).
Abnormalities in tumour DNA methylation are also reflected in the activity of the
methyltransferase enzymes. RNA and protein levels ofDNMT3A, DNMT1 and
DNMT3B are elevated in several tumours (Robertson et ah, 1999, Tycko, 2000).
Whether this can be causally related to tumour suppressor hypermethylation, though,
is unclear. In a study of colon carcinoma cells in which exons 3, 4 and 5 ofDNMT1
were disrupted, it was found that DNMT activity was only decreased by -20%,
implying that other methylases may take over this activity (Rhee et al., 2000).
As mentioned, abnormalities in the imprinting ofH19 and IGF2 have been
frequently described inWilms' tumour (WT) and other tumours. The biallelic
silencing ofH19 in WT is accompanied by abnormal H19 methylation in tumour and
surrounding normal kidney. This suggested that an epigenetic error affecting the
DMR ofH19 occurred early in embryogenesis (Frevel et al., 1999). Silencing ofH19
accompanies LOI of IGF2 inWilms' tumours, suggesting alterations of these genes'
coordinated epigenetic regulation as the mechanism underlying the participation of
this locus in tumorigenesis (Steenman et al., 1994).
LOH or UPD at an imprinted locus may result in the deletion of the only functional
copy of an imprinted tumour suppressor gene (Jirtle et al., 1999). Alternatively,
epigenetic changes may be capable of inactivating the expressed allele of an
imprinted tumour suppressor gene. H19 is one example of an imprinted gene that has
been suggested to have tumour suppressor activity. Dao et al. (1999) demonstrated
that in several childhood tumours the normal monoallelic methylation ofHI9 and its
upstream sequences has often been converted to an abnormal pattern ofbiallelic
hypermethylation. As a result of this change both alleles resembled the imprinted
paternal allele ofH19.
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Abnormal imprinting of genes in 1 lpl 5.5 has also been seen in a large proportion
(51%) of hepatocarcinomas (Schwienbacher et al., 2000b). Loss of the normal
maternal-specific methylation at the putative BWS IC2 was associated with silencing
of the maternal allele of CDKN1C and IGF2 in these tumours. The authors refer to
this phenomenon as "gain of imprinting". From studies such as these, it is certainly
clear that imprinted regions are susceptible to epigenetic alterations in their
expression patterns during tumorigenesis, and that this susceptibilitymay result in
the common involvement of imprinted regions in cancer.
The idea that epigenetic changes at imprinted loci can be involved in tumorigenesis
has been extended further, to incorporate polymorphic variation in imprinting control
as a cancer risk factor. As described above, imprinting ofM6P/IGF2R in humans
seems to be a polymorphic trait, with most individuals having biallelic expression.
Given the evidence that IGF2R can act as a classical tumour suppressor gene, with
LOH and "second-hit" point mutations in liver tumours (de Souza et al. 1995), Jirtle
et al. (1999) have suggested that individuals who have an imprinted M6P/IGF2R
gene may have an increased susceptibility to tumour development because they
already have an epigenetic "first hit".
The Wilms' tumour gene WT1 has also been intensively studied with respect to
imprinting and cancer development. WT arises from an abnormal development of
embryonal kidney cells. The abnormal regulation of 1 lpl5.5 genes in WT has been
alluded to above. A proportion ofWT, though, results from mutations of the WT1
gene, which is also required for normal kidney development (Ramani and Cowell,
1996). WT1 has been found to be imprinted in 40% of preterm human placentas, and
since its imprinted status does not correlate with gestational age, WT1 imprinting is a
polymorphic trait (Nishiwaki et al. 1997). In fibroblasts and lymphocytes, too,
polymorphic WT1 imprinting has been seen, though here the paternal rather than the
maternal allele is expressed (Mitsuya et al. 1997). This finding, for a known tumour
suppressor gene, again suggests, as for IGF2R, the possibility that such a
polymorphic trait could influence both tissue- and individual-dependent
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susceptibilities to cancer and possibly also the response to medication (Bunzel et al,
1998, Jirtleetal., 1999).
At the WT1 locus, an antisense promoter (WT1-AS) corresponding to a DMR located
in intron 1 has been suggested to be involved in control ofWT1 expression. WT1-AS
does not have an ORF and is monoallelically expressed in normal kidney, but is
biallelically expressed (and its DMR hypomethylated) in Wilms' tumours (Malik et
al., 2000). The WT1-AS DMR has therefore been suggested to be a primary site of
epigenetic disturbance in the pathogenesis ofWilms' tumour.
1.1.14 THE EPIGENETIC MARK
One of the most important features of genomic imprinting is its reprogramming,
which occurs upon each passage through the germline in successive generations.
How exactly this occurs relates intimately to the question: how are the parental
alleles of imprinted genes distinguished or "marked"? Some aspects of this process
have been touched upon in the discussion of the molecular basis for PWS and AS.
Although the mechanism of imprint establishment is still poorly understood, there is
a minimal set of criteria that this process should comply with. These are (Bartolomei
and Tilghman, 1997, Ueda et al., 2000):
i) The imprint mark must be established in the gametes, since this is the
time when the alleles are in separate compartments and can be
differentially modified.
ii) The imprint mark must be stably maintained after fertilisation, in all
tissues in which the imprint is recognised.
iii) The modification must be capable of being erased and reset during the
production of germ cells, so that the correct sex-specific imprint is
transmitted to the progeny.
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Considering these criteria, two models have been proposed for the way in which the
imprint is set during successive generations. One model proposes that the imprint
mark of the same-sex chromosome is simply maintained during gametogenesis,
whereas the imprint of the opposite sex is reversed. The second model proposes that
existing epigenetic modifications are first erased from both parental chromosomes in
both germ lines, and that the imprints are then established in a sex specific fashion at
a later stage (Constancia et al., 1998).
Since, as described above, it is well established that methylation plays an important
role in genomic imprinting, part at least of the differential methylation present in
imprinted genes has been considered as the strongest candidate for the imprinting
mark. In mouse germ cells, global demethylation occurs by E12.5-E13.5, when all
imprinted sequences are demethylated in both sexes. This is followed by a
remethylation wave at El5.5, only certain sequences (CpG sequences) retaining
methylation differences between the oocyte and sperm genomes (Razin and Shemer,
1995). The global demethylation occurring at early stages of germ cell development
also includes imprinted genes, but it has been demonstrated that HI9 and Ig/2 are not
completely demethylated, and that slightly higher levels ofmethylation are present in
male compared to female primordial germ cells (PGCs). However, it has also been
shown that Igf2 and H19 (and also Igf2r and Snrpn) are biallelically expressed in
both germlines, beginning by El 1.5. This suggests that their imprints are indeed
largely erased. Interestingly, one region that escapes the global demethylation wave
seems to be the 5' end ofXist, as it has been shown that it remains methylated in both
sexes at this stage (Villar et al., 1995, Szabo and Mann 1995, Razin and Shemer,
1995, Ben-Porath and Cedar, 2000, Ueda et al., 2000).
After imprint erasure, the second step in this process is the re-establishment of
imprinting. This was studied by Chaillet et al. (1991) using a transgene locus. It was
found that the differential methylation patterns of this imprinted transgene were
erased in the PGCs and that distinctive patterns emerged afterwards, during germ cell
maturation.
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In the female mouse, the oocytes in dictyote stage arrest (from E13.5) are apparently
not methylated until after birth, when methylation occurs during oocyte growth. This
process coincides with the presence ofhigh levels ofDnmtl in the nucleus of the
growing oocyte (Constancia et ah, 1998).
After fertilization, the remodelling ofmethylation occurs at sites flanking the core
DMR from very early stages, ultimately producing the allelic methylation state of
somatic tissues. In one sense, at their CpG islands the two alleles must withstand
opposing modifying processes, in that methylation on one allele must be protected
from the general demethylation occurring over the rest of the genome and also the
hypomethylated state of the other allele must resist the subsequent global
remethylation wave. Transcription factors (such as Spl) seem to participate in the
protection ofCpG islands from de novo methylation. Transcription may thus have a
role in keeping CpG islands in their hypomethylated state, presumably by preventing
their de novo methylation or by inducing demethylation (Razin and Shemer 1995,
Constancia et al., 1998).
Finally, the states of demethylation and remethylation must depend at least partly on
the activity of the different methyltransferase enzymes. Ramsahoye et al. (2000) have
proposed that restoration ofDNA methylation after blastocyst implantation depends
on the de novo activity ofDnmt3 and its expression in early development indicates
that it is the major enzyme responsible for re-establishing the methylation patterns. In
early postimplantation development Dnmtl supports the methylation carried out by
Dnmt3 by completing the methylation of those CpG sites that have been
hemimethylated by Dnmt3 and by maintaining methylation patterns through
replication. When Dnmt3 is down-regulated in later development, no further de novo
methylation occurs. The CpG specificity ofmethylation in the soma reflects the
specific maintenance methyltransferase activity ofDnmtl (Ramsahoye et al., 2000).
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1.1.15 EVOLUTION OF GENOMIC IMPRINTING
One of the most intriguing questions regarding genomic imprinting is "why is this
mechanism necessary at all?" Imprinting must confer some evolutionary advantage,
to counteract the potentially deleterious consequences of the fact that by silencing
one allele of certain genes, mammals have discarded the advantages of diploidy in
exchange for a state ofhaplosufficiency (Preece and Moore, 2000).
The three most current hypotheses concerning the evolution of genomic imprinting
suggest that this process may have: i) evolved as an extension of the host defence
mechanism ofprokaryotes, or ii) evolved as a mechanism to protect female mammals
from malignant trophoblast disease or finally iii) originated to control fetal growth
and also natural selection (Hall, 1990, Preece and Moore, 2000).
i) The host defence hypothesis was suggested by Barlow (1993), based on the
knowledge that in bacterial restriction systems, methylases modify the specific
recognition sites on the bacterial DNA, thus protecting the host genome from
cleavage by restriction endonucleases. Foreign (eg bacteriophage) DNA is not
protected and can therefore be digested. By analogy, in mammals the DNA
methyltransferases may have evolved to prevent expression of invading viral
genomes. If so, genomic imprinting may be a result of the evolution ofDNA
methyltransferases from an agent for host defence towards a mechanism that
regulates gene expression. Nonetheless, this theory does not offer an immediate
explanation for why mammals in particular use this machinery to silence a subset of
their own genes (Bartolomei and Tilghman, 1997).
The other two hypotheses both concern two circumstances pertaining to mammalian
reproduction. One is that mothers have to tolerate the invasive characteristics of a
tissue which is half "foreign" and the second is that they must be able to restrict the
growth potential of their offspring in order not to sacrifice maternal well-being
(and/or the well-being of other subsequent litters) (Hall, 1990).
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ii) Varmuza and Mann (1994) proposed that genomic imprinting evolved as a
mechanism to protect female mammals from malignant trophoblast disease. These
authors considered that as in no other group of animals does the embryo invade its
parent tissue so intimately, female mammals gain protection from malignant
trophoblast disease by the inactivation in their oocytes of those genes necessary for
trophoblast development. (As mentioned elsewhere, paternal genes are known to be
required for trophoblast development.) However, this theory does not explain why
there is silencing of some paternal genes (Bartolomei and Tilghman, 1997).
iii) A third theory (and one that has gathered more experimental support) was
proposed by Moore and Haig (1991). It suggests that imprinting evolved as result of
the conflicting "interests" ofmaternal and paternal genes regarding their offspring.
Each parent has different interest in relation to the growth of the offspring
(particularly in a polygamous species). The male's interest is in getting the female to
invest as much nutritional resources as possible in his offspring. Paternally derived
genes would thus foster large offspring, while maternally derived genes would
evolve in such a way as to moderate growth, in order to safeguard the mother and her
future reproductive potential. As it seems that monogamy is comparatively rare in
animals, it has been suggested that imprinting emerged as an evolutionary
consequence ofpatterns of reproduction in placental mammals (Haig and Graham,
1991, Barlow, 1995, Bartolomei and Tilghman, 1997, Pennisi, 1998, Pagel, 1999).
In the context of the relationship between mother and offspring in mammalian
development, it may be noted that disruption of the maternally imprinted gene
Pegl/Mestl resulted in general retardation of embryonic growth, but in the particular
case of adult females, was also associated with poor maternal care. This suggests that
imprinted genes may extend their influence on growth regulation into the adult stage,
thereby affecting the care of the next generation (Lefebvre et a., 1998, Nicholls,
2000).
Insights into the validity of the parental conflict theory for evolution of genomic
imprinting may also be had from comparative studies, of for example the cis-
85
regulatory mechanisms in humans and other species, e.g. marsupials and
monotremes. Monotremes (that include the platypus and spiny anteater) have been
considered as the earliest mammalian lineage, preceding the later divergence of
marsupials and eutherian mammals. There are two theories regarding the evolution
of these groups, under one ofwhich monotremes and marsupials belong to a shared
clade, while the other suggests an early split ofmonotremes from the marsupial-
eutherian clade (John and Surani, 2000).
TheM6P/IGF2R gene is maternally expressed in the South American opossum (a
marsupial), as it is in eutherian mammals, although it lacks the intron 2 DMR
postulated to be involved in imprint control. M6P/IGF2R genes are not imprinted in
monotremes, in either platypus or echidna (Killian et al., 2000). It is suggested that
these results indicate that invasive placentation and gestational fetal growth are not
required for imprinted genes to evolve. Unless there was convergent evolution of
M6P/IGF2R, these results also support the view that the lack of genomic imprinting
in monotremes reflects the fact that these species represent the earliest mammalian
forms, and that genomic imprinting originated later in the marsupial and eutherian
linages (Killian et al., 2000).
However if the view of a shared monotreme-marsupial clade prevails, then it must be
considered that genomic imprinting in eutherians and marsupials may have evolved
independently, unless there was a subsequent loss of this form of gene regulation in
monotremes (John and Surani, 2000, Killian et al., 2000).
Considering once again the parental conflict theory, it has been suggested that
imprinting would not evolve in monogamous species, because the parents will have a
common interest in all their offspring. However, in the monogamous mice P.
polionotus and other species, H19, Igf2r and Igf2 are imprinted. This situation could
be explicable if even limited partner exchange were sufficient to induce conflict, but
it should also be considered that the evolutionary distance between the different
species investigated is not great enough for a loss of imprinting to have occurred
(Pennisi, 1998, Tilghman, 1999).
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It has been demonstrated that genomic imprinting also occurs in plants, as in the case
of the gene MEDEA (MEA) in Arabidopsis. MEA was the first gene relevant to seed
development demonstrated to be imprinted. It is maternally expressed in the embryo
sac; however given that Arabidopsis self-pollinates, all the offspring of a given plant
have the same father, and so the parental conflict should be relaxed. By way of
explanation, it has been suggested that imprinting in Arabidopsis is an evolutionary
relic inherited from outbred ancestors, and is in the process ofbreaking down, with
slight differences among races (Mora-Garcia and Goodrich, 2000). It is also of
interest that imprinting is not observed in birds; in these species once the egg is laid
the resources are fixed, and can consequently no longer be altered by the action of
paternal genes (Devriendt, 2000).
Although there is evidence that supports all three hypotheses regarding the evolution
of genomic imprinting, none of them is an entirely satisfactory explanation for this
phenomenon. It may be that all of them reflect different parts of the role and the
importance that this mechanism has regarding gene regulation and evolution.
The experimental work described in the remainder of this thesis relates to efforts to
investigate the imprinting of an imprinted region not discussed above, the GNAS1
region of human chromosome 20, and to determine the extent of this imprinted





CHAPTER 2. MATERIAL AND METHODS
2.1 MATERIALS
2.1.1 Chemicals and reagents
Chemicals for general use were supplied either by Sigma (Sigma-Aldrich Company
Ltd.) or BDH (Merck, Ltd.) and were ofmolecular biology grade. Bacterial media
were supplied by Difco U.K. Ltd.
2.1.2 Radiochemicals
The radiolabelled nucleotides [a32P] dCTP at a specific activity of 3000 Ci/mmol
and [y P] ATP at a specific activity of 1415 Ci/mmol were both supplied by
Amersham Life Science. The four Redivue™ 33P-labelled dideoxynucleotide
triphosphate terminators were also supplied by Amersham Life Science.
2.1.3 Vectors and markers
The 1 kb ladder DNA marker and other DNA molecular markers used were from
Gibco BRL Life Technologies. The vectors used for the construction of subclone
libraries were obtained as follows: the pUC18 vector was obtained from Stratagene,
the pCRII vector from Invitrogen and the TVEC vector from Promega. The
Epicurian Coli ® JM109 competent cells were purchased from Stratagene.
2.1.4 ENZYMES
Restriction enzymes and T4 DNA ligase were supplied either by Gibco or by New
England Biolabs. Taq DNA polymerase was supplied at a concentration of 5U/pl by
Gibco and Promega. ThermoSequenase™ DNA polymerase was supplied in the
ThermoSequenase radiolabeled terminator cycle sequencing kit and in the
89
ThermoSequenase™ dye terminator cycle sequencing pre-mix kit, both from
USB/Amersham Life Science.
2.1.5 SOLUTIONS AND BUFFERS
Solutions and buffers were prepared using distilled and deionised water and were
stored at room temperature (between 15°C and 25°C ). Sterilisation of the solutions
and buffers was performed by autoclaving at 121 °C for 15 minutes. The components
of general solutions and buffers are described in appendices 2A and 2B.
2.1.6 ELECTROPHORESIS AND DNA TRANSFER MATERIALS
Agarose gels were prepared using standard grade agarose from Sigma Chemical
Company Ltd. The 19:1 acrylamide:bisacrylamide mix used for preparing
sequencing gels was supplied as a 40% solution by BDH Chemicals. Hybond-N+
membranes were supplied by Amersham Life Science.
2.1.7. HUMAN GENOMIC DNA
The normal human genomic DNA used in various places during these studies was
obtained from 5 non-related female subjects. This panel of normal DNAs was used,
among other things, for the identification of expressed polymorphisms in the 3' utr
regions of the CTSZ and CGI-107 genes (Chapters 5 and 6).
2.1.7.1 Parthenogenetic DNA
Human genomic DNA ofparthenogenetic origin was obtained from a
lymphoblastoid cell line established from the parthenogenetic chimaera F.D (Strain
et ah, 1995). The leucocytes of this patient had been shown to be 100 %
parthenogenetic in origin.
This parthenogenetic DNA was used for various purposes, based on the central idea
that the differentially methylated regions (DMRs) associated with imprinted genes
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could be identified or highlighted by comparing the methylation patterns of normal
and parthenogenetic DNA. Analysis by Southern blotting for known imprinted loci
(SNRPN, on chromosome 15 and IGF2R on chromosome 6) had confirmed that F.D.
lymphoblastoid cell DNA lacked paternal-specific methylation patterns, suggesting
that screening for methylation differences between F.D. and normal DNA might be
used to identify unknown imprinted human genes.
Such a screen for regions displaying differential allelic methylation (DMRs) was
carried out in collaboration with the laboratory ofDr. Y. Hayashizaki (Tsukuba,
Japan). This screen used restriction landmark genomic scanning for methylation
differences (RLGS-M), a technique developed in the Hayashizaki laboratory (Hatada
et al., 1991, Hayashizaki et ah, 1994, Kamiya et ah, 2000). Using the RLGS-M
technique, two spots named NV149 and A20 were identified as candidate imprinted
loci. These were excised from the gel, and cloned and sequenced. NV149 proved to
map upstream of the ZAC gene and allowed the demonstration that ZAC is a
paternally expressed imprinted gene and most likely the gene that is dysregulated in
transient neonatal diabetes mellitus (Kamiya et ah, 2000). The other spot, A20,
proved to contain a new exon of the GNAS1 gene (Chapter 3).
2.1.7.2 Collection of paired fetal and maternal DNAs
In order to analyse allelic expression of the genes described in this thesis, a collection
of paired first-trimester fetal and maternal DNAs was first used, to identify fetuses
heterozygous for an expressed sequence polymorphism. Thereafter, reverse
transcription of informative fetal RNAs from several tissues was performed. This
collection of samples has been described before (Campbell et ah, 1994) and includes
fetal tissues between 6 to 12 weeks gestation, together with a maternal blood sample.
Maternal and fetal DNAs were extracted from leucocytes and fetal tissues
respectively. From fetal tissues, RNA had also been extracted, and using this
material, fetal cDNA was prepared. This was done by reverse transcription of total
RNA from fetal tissues (see below), and the cDNA mix was then used directly for
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PCR amplification. Some of the cDNA samples used in these experiments had been
already prepared by Dr. Bruce Hayward for use in previous analyses. 1 pi of cDNA
was used for each PCR amplification.
2.2 METHODS
2.2.1 DNA ISOLATION
2.2.1.1 Isolation of plasmid DNA
A protocol modified by R. Treisman from the original method by Birnboim and
Doly, 1979, and Ish-Horowicz and Burke, 1981, was used for isolation ofplasmid
DNA. A single colony was used to inoculate 10 ml of LB-broth, containing the
appropriate antibiotic. The culture was incubated overnight at 37°C, using vigorous
shaking (225 rpm). The bacteria were pelleted by centrifugation at 4000 rpm for 10
min, and resuspended in Solution I (500 pi) (Appendix 2A). 1 ml of Solution II was
added and mixed, followed by incubation at room temperature for 5 to 10 min. Ice
cold Solution III (750 pi) was added and the mix was shaken vigorously. The lysate
was spun down at 4000 rpm for 10 minutes and the supernatant removed into fresh
tubes and phenol/chloroform extracted as described below (section 2.2.1.5).
After the final extraction, the aqueous phase was transferred into fresh tubes and the
DNA was precipitated by adding 2 vol of ice-cold absolute ethanol. The tubes were
centrifuged at 4000 rpm for 10 min. The supernatant was discarded and the DNA
pellet washed with 70% ethanol and allowed to air dry. The pellet was resuspended
in 200 pi TE containing DNAse-free RNAse (at 20pg/ml), and stored at -20°C.
The quality ofDNA obtained by this method was adequate for sequencing using the
33P cycle sequencing method and for PCR analysis. A better quality ofDNA for
fluorescent cycle sequencing was obtained when the S.N.A.P.™ kit (a .simple nucleic
acid prep) kit by Invitrogen was used. The DNA obtained with this kit was used in
-3-3
both P and ABI automatic sequencing.
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2.2.1.2 Isolation of plasmid DNA with the S.N.A.P.™ kit
The S.N.A.P.™ kit was used mainly to obtain plasmid DNA of good quality for
sequencing by the ThermoSequenase™ dye terminator cycle sequencing method.
The kit components were resuspension buffer, lysis buffer, precipitation buffer,
binding buffer, wash buffer and final wash buffer.
A single colony was used to inoculate 3 ml of LB-broth, containing 20 pg/ml
ampicillin, which was incubated with vigorous shaking (225 rpm) at 37°C overnight.
The bacteria were pelleted in a microcentrifuge at 14000g for 5 minutes, and
resuspended in 150 pi of resuspension buffer by gently pipetting up and down. 150
pi of lysis buffer was added and mixed gently by inverting the tube 5-6 times. After
3 minutes at room temperature, 150 pi of ice-cold precipitation salt was added and
the tube was inverted 6-8 times to ensure thorough mixing. The mixture was
centrifuged at 14000g for 5 minutes, after which the supernatant was pipetted into a
sterile microcentrifuge tube and the pellet was discarded. 600 pi ofbinding buffer
was then added and after mixing by inversion, the solution was pipetted onto the
S.N.A.P. ™ miniprep column, which was then placed into a 2 ml collection tube.
The plasmid DNA was bound to the column by centrifuging the solution through it
for 30 s. The column was then washed with 500 pi of wash buffer, followed by 900
pi of final wash buffer. The column was then dried by brief centrifugation and finally
the plasmid DNA eluted in 60 pi ofTE or dffrO.
Alternatively, when a larger amount ofhigh quality DNA from a specific plasmid
was needed, Qiagen Maxi kits were generally used, according to the suppliers'
instructions.
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2.2.1.3 DNA isolation from PI artificial chromosome (PAC) clones
PAC DNA was isolated by the rapid alkaline lysis miniprep method, a modification
of a standard Qiagen Tip method that uses no organic extractions or columns (as
suggested by the UK HGMP Resource Centre and as adapted for Pieter de Jong's
laboratory). PAC clones of interest were received from the HGMP Resource Centre
on LB-agar slopes containing kanamycin. To obtain single colonies, they were
restreaked onto the same agar type, and incubated at 37°C overnight.
A single isolated bacterial colony was used to inoculate 2 ml LB-broth supplemented
with 25pg/ml kanamycin in a 12-15 ml snap-cap polypropylene tube. This culture
was incubated at 37°C overnight (up to 16 h) with vigorous shaking (225 rpm). The
cells were pelleted by centrifugation at 3000 rpm for 10 min. The supernatant was
discarded and the pellet was resuspended in 0.3 ml ofPI solution (see Appendix
2A). 0.3 ml of P2 solution was then added and the tube was gently shaken. After 5
min at room temperature, the appearance of the suspension changed from very turbid
to almost translucent. 0.3 ml of P3 solution was slowly added to each tube and gently
shaken during addition. A thick white precipitate of protein and E. coli DNA was
formed.
After at least 5 min on ice, the tube was centrifuged at 10000 rpm for 10 min at 4°C,
and returned to ice. The supernatant was transferred to a 1.5 ml Eppendorf tube that
contained 0.8 ml ice-cold isopropanol. The sample was mixed by inverting the tube a
few times and placed again on ice for at least 5 min before centrifuging in a cold
microcentrifuge for 15 min. The supernatant was removed and 0.5 ml of 70% ethanol
was added; the tube was inverted several times to wash the DNA pellets. This
procedure was performed twice, after which the supernatant was removed and the
pellet was allowed to dry at room temperature (15-25°C) before being resuspended in
40pl TE.
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2.2.1.4 DNA isolation from PI artificial chromosome (PAC) clones; modified
method
Although the quality of the PAC DNA obtained with the above method was adequate
for sequencing using 33P terminators, it was found that the quality and quantity of
PAC DNA obtained could be improved by using a modified version of the alkaline
lysis method.
A single colony was used to inoculate 5ml of LB containing kanamycin (25pg/ml),
which was incubated at 37°C for 4-7 hrs with vigorous shaking (225 rpm). This
culture was used to inoculate 250ml LB for overnight culture at 37°C with vigorous
shaking (225 rpm). The bacteria were pelleted by centrifugation at 6000 rpm for 20
min and resuspended in 5 ml of solution Pl. 5 ml of solution P2 was then added and
mixed (this was done in Corex™ tubes). The mix was left at room temperature for 10
min, 5 ml of solution P3 was added, and the tube was placed on ice for 10 min.
The cell debris was removed by centrifugation at 12000 rpm for 20 min at 4°C. The
supernatant was filtered through cheesecloth into clean Corex™ tubes and ice cold
isopropanol (0.6 vol.) was added. After mixing well, the mixture was centrifuged at
room temperature at 12000 rpm for 20 min. The supernatant was poured off and the
pellet was washed with 70% ethanol and allowed to air dry, before being
resuspended inl.5 ml TE (pH8). 1.5 ml ice cold 5M LiCl was added and the mixture
was centrifuged at 12000 rpm for 15 min at 4°C. The supernatant was transferred to
fresh Corex™ tubes and an equal volume of isopropanol was added. Aftermixing
the mixture was centrifuged at 12000 rpm for 20 min and the supernatant was
discarded. The pellet was washed with 70% ethanol.
After air drying the pellet was resuspended in 250pl TE (pH8) containing Rnase
(20pg/ml) and left at room temperature for 30 min. To this solution was added 250pl
1.6M NaCl containing 13% (w/v) polyethylene glycol. This was mixed well and the
PAC DNA was recovered by centrifugation at 12000 rpm for 15 min at 4°C. The
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supernatant was removed by aspiration and the pellet was resuspended in 200pl of
TE (pH8.0).
2.2.1.5 Measurement ofDNA concentration
The concentration ofDNA was determined by measuring the absorbance of the
solution at 260 nm (A260), using an appropriate water or TE blank as reference. For
most purposes, lOpl of sample was diluted in 1 ml ofwater or TE before measuring.
The original DNA concentration was then calculated according to the formula
[DNA] = Dilution factor x A260 x 50 pg/ml
2.2.1.6 Phenol/chloroform extraction of DNA
An equal volume ofphenol/chloroform/isoamyl alcohol (25:24:1) was added to the
DNA solution of interest. After mixing well, the mixture was microcentrifuged for 5
min. The aqueous phase was removed and the procedure was repeated. The second
aqueous phase was then transferred to a clean tube and an equal volume of
chloroform was added. After microcentrifuging again for 5 min, the aqueous phase
was transferred to a new tube and ethanol precipitated.
2.2.1.7 Ethanol precipitation of DNA
The volume of a given DNA sample was measured and the salt concentration
adjusted by adding 1/10 volume of sodium acetate (3M; pH 5.2). Aftermixing well,
2 volumes of ice-cold ethanol were added. When small amounts (generally < 1 pg)
ofDNA were precipitated, 10 pg of tRNA was added to increase recovery from the
dilute DNA solutions. The DNA was placed on ice for 30 min, and then pelleted by
centrifugation at 12000g for 15 min. The supernatant was discarded and the pellet
was washed twice with 70% ethanol, spinning briefly. The pellet was then allowed to
air dry (vacuum drying was also sometimes used) and finally resuspended in the
appropriate volume ofTE or water.
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2.2.1.8 First strand cDNA synthesis
To synthesize the cDNA used in the RT-PCR experiments described in Chapters 3, 5
and 6, the preferred reverse transcriptase was Superscript II (Gibco-BRL). The RT
reaction was set up as follows: 5 pi of 3 pM primer (oligo(dT)RACE), 3 pi ofRNA
and 10 pi of dFEO, were combined in an Eppendorf tube on ice, covered with
mineral oil, incubated at 85°C for 3 minutes to denature RNA secondary structure
and returned to ice for 2 minutes. 6 pi of 5 X RT II Buffer, 3 pi 0.1 M DTT, 1.5 pi
20 mM each dNTP, 0.5 pi RNA guard™ and 1 pi of Superscript RT II were added.
The RNase inhibitor RNA guard ™ was derived from human placenta and was
purchased from Amersham Pharmacia at a concentration of 29700 units/ml. The RT
reaction was then incubated at 42°C for 60 minutes, 50°C for 15 minutes and 95°C
for 15 minutes, and stored at -20°C. For each experiment, 2 pi of this RT reaction
were used in a 50 pi final volume PCR, as described in the following section.
2.2.2 THE POLYMERASE CHAIN REACTION
PCR reactions were carried out in a Hybaid Omnigene™ Thermal Cycler or in a
Perkin Elmer Thermal Cycler TCI. The reactions were carried out in either 0.5 ml
tubes or 96 well microtitre plates. The Gilson pipettes, tips, tubes and reagents used
were sterile and kept separately from those used in other experiments. To avoid the
possibility of extraneous DNA contamination in the PCRs, all the reactions were set
up in a separate room, specially designated for this activity.
The PCRs were carried out in lx PCR buffer (see Appendix 2A for different recipes
used), with 200pM deoxynucleoside triphosphate (dNTPs), 10-20 pmol primers, 1U
Taq polymerase, and template DNA (0.1 pg genomic DNA, 0.1-1 ng plasmid DNA)
in a final volume of 50pl. In order to prevent evaporation and subsequent alteration
of the buffering conditions, the PCRs were overlaid with mineral oil (Sigma).
Depending on the characteristics of the template, an initial denaturation step at 94°C
for 5 min was used followed by the addition of Taq polymerase. The PCR cycling
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conditions used were in general, 94°C for lmin, the appropriate primer annealing
temperature for 1 min and primer extension at 72°C for 1 min (if the product was <
500 bp) or 3 min (if the product was > 500 bp). The overall number of cycles for the
reactions was dependent on the type ofDNA template; in general 25-30 cycles were
used when working with plasmid DNA and 35-40 cycles when working with human
genomic DNA and PAC DNA.
Some of the subclone libraries containing DNA fragments derived from the PAC
DNAs under study were analysed by colony PCR. The subclone glycerol stocks were
kept in microtitre plates and 1 pi of the stock was used directly in the PCR reaction.
Alternatively, when the clone of interest was streaked on LB agar plates, a small
amount of the colony was taken using an autoclaved pipette tip and transferred to the
wall of the PCR tube (in sufficient amount to be visualised) below the liquid surface.
2.2.2.1 Oligonucleotides
The oligonucleotide PCR primers described were generally designed by selecting a
sequence of about 20 nucleotides with the aid of one of two computer programs,
either "Oligo 4.0" (used formost of the primers) or "Primer 3". The Oligo 4.0 primer
analysis software by Wojciech Rychlik takes into consideration among other
parameters that the two primers are of approximately equal predicted Tm and that
their 3' ends are not complementary.
The Primer 3 software was developed at the Whitehead Institute in 1998 by Steve
Rozen and Helen Skaletsky. This program predicts the best pair of primers to
amplify a given target within the desired sequence, taking into account parameters
such as primer Tm, pair complementarity and primer size.
Custom-synthesized oligonucleotides were purchased from Sigma-Genosys Ltd.,
Oswel DNA Services, or MWG-Biotech GmBH. They were supplied as lyophilised
products from a synthesis scale of 0.03 pmol. The sequences of oligonucleotides
used in the work described in this thesis are listed in the corresponding chapters.
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2.2.3 RESTRICTION ENZYME DIGESTION OF DNA
Restriction endonuclease digestions were performed under the buffer and
temperature conditions recommended by the suppliers for each enzyme. In general
terms, depending on the amount ofDNA used, reactions were carried out in final
volumes of 20, 50 or 100 pi (made up with sterile water) and incubated for 5-16 hr.
Typically 1 pg ofplasmid and PAC DNA was digested, while in the case of genomic
DNA 10 pg was used. If required for further manipulation of the digested DNA, the
sample was then phenol/chloroform extracted and ethanol precipitated.
2.2.4 AGAROSE GEL ELECTROPHORESIS
DNA was usually size fractionated and visualised by agarose gel electrophoresis.
Gels were prepared at concentrations ranging from 0.8 to 3% agarose
(weight/volume) in the appropriate volume of 0.5 x TBE buffer or 1 x TAE (see
Appendix 2A). In general terms, higher percentage gels were used to visualise low
molecular weight DNA, and low percentage gels were used to visualise high
molecular weight DNA. Ethidium bromide was added to a final concentration of 0.5
pg/ml to molten agarose before each gel was poured. Before electrophoresis, DNA
samples were combined with one-tenth volume loading buffer (see Appendix 2A).
The samples were then electrophoresed alongside an appropriate size marker at 50-
150 volts until the dye marker had run a sufficient distance. The DNA was visualised
by viewing under ultraviolet (UV) transillumination at 260-270 nm and
photographed using an electronic imager (Fujifilm thermal imaging system FTI-500,
ImageMaster®VDS, Pharmacia Biotech). Where fragments were to be purified from
the gel for further manipulation, a 360 nm hand-held UV lamp was used to visualise
the DNA, in order to minimise photolytic damage to the DNA.
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2.2.5 ALKALI BLOTTING
The genomic DNA (~10 jag) or PAC DNA (-1 (ag) of interest was digested with the
desired restriction enzyme(s) in a final volume of 50 jal. The digests were separated
by electrophoresis on a 0.8% TAE agarose gel and transferred to a positively charged
nylon membrane (Hybond N+). Prior to transfer the gels were depurinated in 0.25 M
HC1 for 15 minutes and then blotted using 0.4 M NaOH as transfer buffer. The
transfer apparatus consisted of a transfer buffer reservoir, a blotting platform with
3MM filter paper wicks, and paper towels above the gel. Gels were placed on the
blotting platform on top of three layers of 3MM filter paper and surrounded with
cling film. The gel was then sequentially overlaid with the Hybond N+ membrane,
three further layers of 3MM paper and a 5-10 cm stack of absorbent paper towels.
Pressure was applied using a rigid glass or perspex plate with a weight of~ 200 g.
The transfer was allowed to proceed for at least 16 h, after which the membrane was
rinsed in 2 x SSC and air-dried. The DNA was fixed to the membrane by baking at
80°C and/or by cross-linking (using a Stratalinker® UV crosslinker).
2.2.6 PREPARATION OF SUBCLONE LIBRARIES
Subclone libraries were prepared from several PAC DNA clones. The plasmid
vectors used were pUC18, pCRII and TVEC. Typically, 1 pg ofPAC DNA was
digested with 50 U of enzyme in a final volume of 100 pi for 3 hours at 37°C. The
digested DNA was phenol/chloroform extracted, and ethanol precipitated with 10 pg
of carrier tRNA. The pellet was resuspended in 10 pi of dH20 at a nominal
concentration of -100 ng/pl.
The vectors used for the preparation of the subclone libraries were digested with the
corresponding restriction enzyme and the phosphate groups were removed by
treatment with shrimp alkaline phosphatase to prevent religation of the vector to
itself.
100
200 ng of insert DNA were ligated to 40 ng of vector overnight at room temperature,
using 1U ofT4 DNA ligase in a 20 pi final volume containing T4 DNA ligase buffer
(included in the T4 ligase kit). The ligation reaction was then ethanol precipitated
and the final pellet was resuspended in 4 pi of dH20.
2.2.7 PREPARATION OF ELECTROCOMPETENT E. coli
The host cells used were E. coli strain JM109 purchased from Stratagene. A culture
of JM109 was grown for 16 h at 37°C in 10 mis of LB-broth. This culture was used
to inoculate 1 1 of sterile LB-broth, which was incubated at 37°C with vigorous
shaking, until the apparent optical density (Aeoo) reached 0.5-1. The culture was
chilled on ice for 30 min and then pelleted by centrifugation at 4000 g for 15 min.
The supernatant was removed and the bacterial pellet was resuspended in 1 1 of ice-
cold sterile dE^O. The cells were pelleted and washed again in 20 ml of ice-cold
10% glycerol. The cells were then frozen in 45 pi aliquots and stored at -70°C.
2.2.8 TRANSFORMATION OF COMPETENT E. coli
For transformation ofE. coli by electroporation, 1 pi of the precipitated, resuspended
ligation reaction was used. This was added to the 45 pi bacterial aliquot and left on
ice for at least 5 min. The cells were placed in a chilled 0.2 ml electroporation
cuvette and then pulsed using a GenePulser™ apparatus (BioRad), set at 25 pF, 2.50
kV, with the external pulse controller at 200Q.. The cuvette was removed from the
apparatus and 1 ml of LB-broth (without ampicillin) was immediately mixed with the
cells, which were then cultured at 37°C for 1 h to allow pre-expression of the
antibiotic resistance. Thereafter, 200 pi of this culture were plated onto LB-agar
plates (see Appendix 2B) containing appropriate antibiotic selection and cultured at
37°C for 16 h.
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The subclone colonies obtained from these transformations were picked into 200 pi
of LB-broth and ampicillin in 96 well plates. These were incubated overnight and
then glycerol added to 10% final concentration for storage at -70°C until required.
2.2.9 PREPARATION OF THE HYBRIDISATION MEMBRANES USED FOR
SUBCLONE LIBRARY SCREENING
To allow several rounds of future screening by hybridisation, the subclone libraries
were replicated onto hybridisation membranes. Cultures were transferred to nylon
membranes laid on LB-ampicillin plates using a 96-prong "hedgehog" plating
device. They were allowed to grow for 12-16 hours before lysis and fixing of the
DNA. These cultures were performed in 22x22 cm plastic plates with lids, which
were prepared by washing with detergent, rinsing twice with dHaO, drying, washing
with 70% ethanol, drying again and sterilisation by exposure to UV light for 20 min.
250 ml ofmolten LB-agar-ampicillin was poured into each plastic plate and allowed
to set, and the plates finally exposed again to UV light as above before use.
Each prong of the stainless steel "hedgehog" plating device corresponds to one well
of the 96-well plates used to store glycerol stocks, and also has a notch at its end that
by capillary action retains a few pi of the thawed culture. Care was taken to avoid
contamination of the glycerol stocks when more than one plate was being
transferred; prior to dipping into the wells, the spikes were rinsed three times in
dHiO and then sterilised twice with 70% ethanol and a Bunsen burner. After
sampling the glycerol stock plate, the cultures were immediately stamped out onto a
20 x 20 cm hybridisation membrane twice, side by side, to create a master and a
duplicate grid.
After the culture period, the membranes were first submerged in 10% SDS for 5 min,
then in denaturing solution (see Appendix 2A) for 5 min and then in neutralising
solution for 15 min. They were allowed to dry on 3MM filter paper, and the DNA
was then fixed to the membrane by baking at 80°C for two hours. Finally, prior to
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hybridisation the membranes were washed in 2 x SSC to remove any remaining
bacterial debris.
2.1.10 HYBRIDISATION SCREENING OF THE SUBCLONE LIBRARIES
Probes for hybridisation were generated by a modification of the random priming
method (Feinberg and Vogelstein, 1984) using the T7 QuickPrime™ kit (Amersham
Pharmacia Biotech) with [a32P] dCTP (3000Ci/mmol) as the radionucleotide. The
DNA fragment for labelling (25-50 ng) was isolated on a low-melting-point agarose
gel. The band was excised from the gel with a minimum of excess agarose and
placed in a pre-weighed microcentrifuge tube that was then weighed again. 3 ml of
distilled water per gram of gel slice was added and the tube was heated at 65°C for 2
minutes to melt the agarose. The sample was mixed to homogeneity and 25 pi
aliquots were prepared. Prior to labelling, each aliquot was heated in a water bath at
95°C for 7 minutes.To a clean microcentrifuge tube was added the denatured DNA,
reagent mix (a buffered aqueous solution containing dATP, dGTP, dTTP and random
9mer oligodeoxyribonucleotides), 3 pi of [a32P] dCTP (30pCi) and 4 U ofT7 DNA
polymerase. The components were mixed gently and then centrifuged briefly and
incubated at 37°C for 15 minutes. The labelled DNA was denatured by heating at
95°C for 2 minutes, then cooled immediately on ice and added to the hybridisation
bottle.
For hybridisation, the membranes were rolled between nylon nets, and applied to the
inner surface of cylindrical hybridisation bottles. 20 ml of prehybridisation mix (see
Appendix 2A) was added to the hybridisation bottle, which was rotated at 65°C for 1
h. Afterwards, the prehybridisation mix was replaced by 10 ml of prewarmed
hybridisation mix containing labelled probe as above and the hybridisation was
allowed to continue overnight.
For the 5' end labelling of oligonucleotides with y32P-ATP, the labelling reactions
consisted of 30 ng ofprimer per sample, 1 pi of 10 x PNK buffer, 3 pi ofy32P-ATP,
5U ofT4 polynucleotide kinase (PNK) and dH20 to 10 pi. The reaction was
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incubated at 37°C for 40 min and then added directly to the hybridisation bottle. The
hybridisation in this case was allowed to proceed overnight at 48°C. The
hybridisationmix used was the Quick oligo hybridisation mix (see Appendix 2A).
2.1.11 POST-HYBRIDISATION WASHING AND RADIOACTIVE SIGNAL
DETECTION
After hybridisation, non-specifically bound random-primed DNA probe was
removed by washing the membranes twice in 2 x SSC/0.1% SDS for 20 min at 65°C
and once in 1 x SSC/1% SDS for 20 min at 65°C. Afterwards, the membranes were
sealed in a plastic bag or cling film and exposed to X-ray film in light-proof cassettes
with intensifying screens for between 16 h (overnight) and several days. When
oligonucleotide probes and the Quick oligo hybridisationmix were used, the
membranes were washed only at a stringency of 4 x SSC/0.1% SDS at 48°C for 4x 5
min. If needed for subsequent hybridisation experiments, the membranes were
washed for longer periods of time as before or at greater stringency, and then
exposed to autoradiographic film as before to ensure complete removal of probe.
2.1.12 DNA SEQUENCING
DNA sequencing was carried out using one of two commercially available protocols:
the ThermoSequenase™ radiolabelled terminator cycle sequencing kit or the
ThermoSequenase™ dye terminator cycle sequencing kit (both Amersham USB).
ThermoSequenase™ is a Taq polymerase derivative that has been modified by site-
directed mutagenesis to increase its substrate affinity for dideoxynucleoside
triphosphates, thus greatly improving its characteristics for sequencing (Tabor and
Richardson, 1995).
Plasmid DNA was used directly in cycle sequencing without further manipulation
after extraction. PCR products, however, were first treated with exonuclease I and
shrimp alkaline phosphatase (SAP). The exonuclease I was used to remove residual
single-stranded primers. The shrimp alkaline phosphatase removes the remaining
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dNTPs from the PCR mixture, which would otherwise interfere with the sequencing
reaction. Typically, reactions were performed using 5 pi of PCR product, lpl (10U)
of exonuclease I and 1 pi (2U) of SAP, for 15 min at 37°C, after which the enzymes
were heat inactivated at 80°C for 15 min.
2.1.13 Manual (radioactive) sequencing
The present methods for DNA sequencing are modifications of the original Sanger
end-terminator sequencing techniques (Sanger, 1977). They are based on the
principle that a 2',3'-dideoxynucleotide (supplied as either ddGTP, ddATP, ddTTP
or ddCTP) can be incorporated into the end of a growing DNA chain by forming a
phosphodiester bond between its 5' carbon atom and the 3' carbon of the previously
incorporated nucleotide. However, its 3' carbon atom cannot participate in further
phosphodiester bonding due to the lack of a -OH group, resulting in a base-specific
termination of chain synthesis (hence the name "chain termination").
The termination mixes were prepared for each [a33P] labelled ddNTP (A, C, G, T)
according to the supplier's specifications, each containing 0.25pi of each
radiolabelled ddNTP. A DNA-primer premix was then prepared, consisting of 1 pi of
the nucleotide master mix (containing either dGTP or, when required to eliminate
compression artefacts occurring in G/C-rich sequences, dITP ), 3.2 pmol primer, lpl
of reaction buffer (see Appendix 2A), 25-250 fmol template DNA, 1 pi of
ThermoSequenase polymerase, and water to a final volume of 10 pi.
This premix was distributed between the four termination mixes. 40 to 45 cycles of
95°C for 30 s, 55°C 30 s, 72°C 1 min were then performed, after which 4 pi of
formamide stop solution was added to each reaction. The samples were denatured for
5 min at 80°C and 2.5 pi of each was loaded immediately onto a glycerol-tolerant 6%
polyacrylamide sequencing gel (see Appendix 2A). The gels (0.4 mm x 38cm x
50cm) were prepared in Biorad sequencing gel rigs. The gel solution came from a
950 ml stock to be made up to the equivalent of 1 litre with 20X glycerol tolerant
buffer; the other components were 8M urea, 6% acrylamide/N, N'-methylene
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bisacrylamide (19:1; Acrylogel 5, BDH-Merck) and dH20. To 95 ml of this stock
were added 5 ml of 20X glycerol tolerant buffer and the gel was polymerised by
adding 150 pi of 25% ammonium persulphate and 100 pi of TEMED immediately
before pouring. Polymerisation was allowed to proceed for a minimum of 1 hour,
after which electrophoresis was performed using IX glycerol tolerant buffer at 90 W
for 2-6 hours, depending on length of read required. The sequencing reactions were
always loaded in the order A, C, G, T.
After electrophoresis the gel was transferred onto 3MM filter paper, covered with
cling-film and dried under vacuum at 80°C for ~1 hour. The ding-film was then
removed and the gel exposed to autoradiographic film in light-proof cassettes for a
minimum of 16 h.
2.1.14 ThermoSequenase™ dye terminator cycle sequencing
This method allows all four termination reactions to be performed in a single tube,
since each ddNTP is labelled with a different fluorochrome. Reactions were set up in
0.5 ml PCR tubes, using 4 pi of the terminator ready reaction mix, 100-250 ng
double stranded DNA, 6 pM primer, and water to 10 pi. The mix was overlaid with
mineral oil and 25 cycles consisting of 96°C for 30 s, 45°C for 15 s and 60°C for 4
min were performed in a Perkin Elmer TCI themal cycler. The sequencing products
were then ethanol precipitated to remove the bulk of unincorporated fluorescent
ddNTPs. The pellet was dried at 90°C for 1 min and resuspended in the formamide
loading buffer (see Appendix 2A). The samples were denatured at 95°C for 3 to 5
min and kept on ice until loaded onto the sequencing gel.
The sequencing reactions were electrophoresed on an ABI Prism™ 377 DNA
sequencer, and the output analysed using the ABI software. This system was used in
preference to 33P especially when working with plasmid templates, mainly because it
was possible to handle a large number of samples simultaneously. However, for
some applications, such as direct sequencing ofPAC templates, radiolabelled
terminator sequencing was clearly superior in quality.
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Various primers, including custom synthesized ones, were used for sequencing as
described in the text. For initial characterization of clones, appropriate vector-
specific primers were usually used, these being the M13F and M13R primers in the
case of the plasmid subclone libraries and the T7 and SP6 primers for the direct
sequencing of the ends ofPAC clones (see Appendix 2D).
The sequences obtained were generally compared to database sequences using the
BLAST program hosted at NCBI (for URL see Chapter 7, bioinformatics) and
frequently also the NIX interface for simultaneous multiple sequence analysis
programs, hosted at the UK HGMP-RC. BLAST (Altschul et al., 1990) stands for
Basic Local Alignment Search Tool and is a set of search programs designed to
explore all of the available sequence databases for matches using any combination of
either protein or DNA sequences. BLAST uses an algorithm which is able to detect
close relationships among sequences which share only isolated regions of similarity.
NIX is a tool used for rapid identification of interesting regions in genomic or
transcribed nucleic acid sequences. NIX displays a graphical representation of the
ouputs ofmany programs (including BLAST for example) and allows viewing of
these results side by side, making it easy to spot features identified by more than one
program. URLs for all the bioinformatics facilities used in this work are listed in the
references chapter.
2.1.15 PULSED-FIELD ELECTROPHORESIS
In order to determine the sizes ofPAC clones, 1 pg ofDNA was digested with at
least two rare-cutting enzymes (Noll and Xhol for example). The digest was analysed
on a 1% agarose/TBE gel run without ethidium bromide and using two molecular
markers, 1 kb ladder (Gibco BRL) and a MidRange PFG Marker 1 (New England
BioLabs). Electrophoresis conditions were 200 volts, pulse time 4 s, temperature
14°C, run duration 16 h. After electrophoresis, the gel was stained with ethidium






10% w/v APS in dH20; aliquots were stored at
-20°C and defrosted only once
Acrylamide 30% stock (19:1), 28.5 % acrylamide, 1.5%
N,N'-methylene bisacrylamide.
Denaturing solution 0.5 M NaOH, 1.5MNaCl
Denhardt's solution 0.1% Ficoll 400, 0.1% polyvinyl pyrrolidone,
0.1% bovine serum albumin (BSA).
Depurination solution 250 mM HC1
DNA loading dye 0.25% bromophenol blue, 15% Ficoll 400
Ethidium bromide 10 mg/ml in dH20
First strand RT II buffer 5 x 250 mM Tris-HCl (pH 8.3), 375 mM KC1, 15
mM MgCl2
Glycerol tolerant buffer 20 x
stock (per 10 litres)
Tris-HCl 2160 g, taurine 720 g, EDTA
(disodium salt) 40 g, dH20 to 10 litres
Hybridisation mix 5 x Denhardt's, 5 x SSC, 0.1 % SDS, 0.1%
sodium pyrophosphate, 20% dextran sulphate
IPTG 1 OmM working solution in water
Loading buffer (sequencing) 98% deionised formamide, 10 mM EDTA (pH
8.0), crystal violet 0.01%
Neutralising solution 1.5 M NaCl, 0.5 M Tris HC1, pH 8
6% polyacrylamide sequencing
gel
95 ml of acrylamide/urea, 100 pi TEMED 150
pi of ammonium persulphate, 5 mis of 20 x
glycerol tolerant buffer
PCR Buffer I (lOx stock) 500 mM KC1, 250 mM TAPS, 125 mM KOH,
15 mM MgCl2.
PCR Buffer II (lOx stock) 500 mM KC1, 250 mM Tricine, 125 mM
KOH, 15 mM MgCl2
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PCR Buffer III (lOx stock) 100 mM Tris-HCl, 500 mM KC1, 125 mM
KOH, 15 mM MgCl2
PCR Buffer IV (lOx stock) 500 mM KC1, 250 mM TAPS, 125 mM KOH,
15 mM MgCl2, 1% Triton X-100
PCR Buffer V (lOx stock) 500 mM KC1, 250 mM Tricine, 125 mM
KOH, 15 mM MgCl2,1% Triton X-100
PCR Buffer VI (lOx stock) 100 mM Tris-HCl, 500 mM KC1, 125 mM
KOH, 15 mM MgCl2,l% Triton X-100





PNK 10 x buffer 50 mM Tris-HCl (pH 8.0), 10 mM MgCly 5
mM DTT
Prehybridisation mix 5 x Denhardt's, 5 x SSC, 0.1% SDS, 0.1%
sodium pyrophosphate
Quick oligo hybridisation mix 0.5 g BSA, 0.5 g Ficoll 400, 1 g SDS, 1 g




200 mM Tris-HCl pH 9.5, 65 mM MgCl2
10% SDS 10% w/v sodium dodecyl sulphate. Warm to
dissolve, pH to 7.2 with HC1
Solution PI (filter sterilized, 4°) 15 mM Tris-HCl (pH 8), 10 mM EDTA, 100
pg/ml Rnase A
Solution P2 (filter sterilized, room
temp.)
0.2 M NaOH, 1% SDS
Solution P3 (autoclaved, 4°C) 3 M potassium acetate, pH 5.5
Solution I (autoclaved and stored
at 4°C)
50 mM glucose, 25 mM Tris-HCl (pH 8.0), 10
mM EDTA (pH 8.0)
Solution II 0.2 M NaOH (freshly diluted from a 10 M
stock), 1% SDS
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Solution III 5 M potassium acetate 60 ml, glacial acetic
acid 11.5 ml, dH20 28.5 ml
20 x SSC 3 M NaCl, 0.1 M trisodium citrate, pH to 7
TAE 50 x STOCK (per litre) 242 g Tris base, 57.1 ml glacial acetic acid,
100 ml 0.5MEDTA (pH 8.0)
TBE 5x STOCK (per litre) 54 g Tris base, 27.5 g boric acid, 20 ml 0.5 M
EDTA, pH 8.0
TE lOx stock 10 mM Tris-HCl, 1 mM EDTA, pH 8.0
TEMED N,N,N',N'-tetramethyl-1,2-diaminoethane,
100% stock
X-GAL 20 mg/ml in dimethylformamide
33P sequencing stop solution 95% formamide, 20 mM EDTA, 0.05%
bromophenol blue, 0.05% xylene cyanol FF
APPENDIX B: Growth Media
Luria-Bertani (LB medium) 10 g/1 Bacto-tryptone, 5 g/1 Bacto-yeast
extract, 5 g/1 NaCl,
Luria-Bertani-agar As before plus 15 g/1 Bacto-agar (16 g/1 in the
case of the 20 x 20 cm plates).
APPENDIX C: Antibiotics
Ampicillin 50 mg/ml stock solution in dH20, 20 pg/ml
working concentration





M13F GTT TTC CCA GTC ACG ACG TTG TA
M13R AGC GGA TAA CAA TTT CAC ACA GGG
T7 CGC TAA TAC GAC TCA CTA TAG GG
SP6 GTC GAC ATT TAG GTG ACA CTA TA
dT Race GAG CTC GAG TCG ACA TCG A(T17)
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CHAPTER 3
GNAS1, AN IMPRINTED GENE IN DISTAL HUMAN
CHROMOSOME 20q13
CHAPTER 3. GNAS1, AN IMPRINTED GENE IN HUMAN CHROMOSOME
20ql3
3.1 INTRODUCTION
The human GNAS1 gene maps to chromosome 20ql3 (Levine et ah, 1991). It codes
for the a-subunit (Ga) of the heterotrimeric stimulatory G protein, Gs, that activates
adenylyl cyclase. Inactivating mutations of GNAS1 cause the autosomal dominant
syndrome pseudohypoparathyroidism type la (PHP-la) (Levine et al., 1980, 1986).
Pseudohypoparathyroidism (PHP) is a term applied to a heterogeneous group of
disorders whose common feature is end-organ resistance to parathyroid hormone
(Albright et al., 1942, Patten et al., 1990). In contrast, activating mutations of
GNAS1, which occur only in mosaic state, cause the McCune-Albright syndrome and
have also been found in a number of endocrine neoplasms, notably pituitary
somatotroph adenomas (Landis et al., 1989, Cohen and Howell, 1999).
A peculiar pattern of inheritance has been observed in families suffering from PHP-
la. Within one given kindred, individuals carrying the same inactivating mutation of
GNAS1 may have a different clinical presentation: some individuals display PHP-la,
while others have no hormone resistance but do have the characteristic skeletal
phenotype associated with PHP-la (Albright hereditary osteodystrophy).
Manifestation of the full PHP-la phenotype seems to depend upon maternal
transmission of the causative mutation (Davies and Hughes, 1993).
These differences in clinical presentation were considered to be the result of genetic
factors that might interact with the GNAS1 mutations and determine the presentation
of the endocrine disturbance. The maternal inheritance pattern led to the suggestion
that genomic imprinting might play a role. However, at the start of this study, the
evidence for imprinting was conflicting. On the one hand, an RT-PCR based analysis
had shown that in a large number of different human fetal tissues GNAS1 was
biallelically expressed (Campbell et al., 1994). On the other hand, in situ
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hybridization to tissues ofmice with uniparental disomy for the chromosomal region
including the homologous gene Gnas indicated a predominantly paternal origin of
glomerular Gnas transcripts. This result was also opposite to the pattern of
imprinting predicted from PHP-la families (Williamson et al., 1996).
This chapter describes more recent studies ofhuman GNAS1, in which it was
demonstrated that this gene is after all imprinted, as predicted from the anomalous
inheritance ofPHP-la, and that its allele-specific regulation is highly complex.
3.1.1 PARATHYROID HORMONE
In mammals parathyroid hormone (PTH) is the most important regulator of calcium
ion homeostasis. The peptide hormone is synthesised as a precursor protein,
preproPTH, containing a pre "leader" sequence of 25 amino acids and a pro-
sequence of 6 amino acids, which are both cleaved during the synthesis and secretion
process to yield the mature form of 84 amino acids (Spiegel and Weinstein, 1995,
Mannstadt et al., 1999).
PTH is produced by the parathyroid glands and its synthesis and secretion are largely
regulated by the extracellular concentration of calcium. In response to low blood
calcium levels, PTH is secreted into the circulation and then acts primarily in kidney
and bone. In kidney, PTH directly stimulates the tubular reabsorption of calcium.
Elevations in serum phosphate concentration depress serum calcium by reducing
bone resorption and by decreasing synthesis of l,25-(OH)2 vitamin D (Spiegel and
Weinstein, 1995, Mannstadt et al., 1999).
A PTH-related peptide known as PTHrP, was initially isolated from human
carcinomas and is responsible for the hypercalcemia associated with various
malignances. Unlike PTH, however, PTHrP does not circulate in appreciable
amounts in normal subjects but is instead, widely expressed in fetal and adult tissues,
where it is thought to regulate cell differentiation, cell proliferation, and
organogenesis as a paracrine or autocrine soluble factor. It also plays a major role in
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chondrocyte maturation and endochondral bone formation (Amling et ah, 1997,
Mannstadt et ah, 1999). It also has been demonstrated that PTHrP is able to increase
the expression of Bcl-2, a protein that controls programmed cell death in several cell
types (Amling et ah, 1997).
Human PTHrP mRNAs encode three different protein isoforms containing 139, 141,
and 173 amino acids. The first 13 amino acids ofPTHrP and PTH display a high
degree ofhomology (eight are identical). This similarity decreases markedly in the
14-34 region, where only three amino acids are identical, and beyond residue 34
there is no recognizable similarity (Wysolmerski and Broadus, 1994). For both PTH
and PTHrP, the 15-34 region functions as the principal PTH 1R binding domain.
PTHrP binds to the same receptor as PTH, and the biological responses achieved by
either ligand through this common receptor are largely indistinguishable, at least
regarding mineral ion homeostasis. These actions ofPTH (and PTHrP) are mediated
through the type 1 receptor or PTH1R; this is a G protein-coupled receptor of the
seven transmembrane domain family (Mannstadt et al., 1999).
3.1.2 CELL SIGNALLING UNITS COMPRISING THREE PROTEIN
MODULES
A huge number of biochemical functions carried out within eukaryotic cells are
regulated by diverse external chemical and physical stimulating factors. These
include, for example, a wide range of structurally diverse hormones (catecholamines,
gonadotropins, parathyroid hormones, etc.), odorants and light. The control of the
various intracellular biochemical functions is achieved by modulating the activities
of a small number of signalling units. The individual external effectors do not
actually enter the cell, but instead bind to receptors at the cell surface and initiate a
"cascade" of intracellular events leading ultimately to a cellular response. During
evolution, the repertoire of cell surface receptors has been expanded and adapted to
achieve the necessary diversity to respond to so many different external stimuli
(Neer, 1995, Sprang, 1997, Berman and Gilman, 1998).
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The most important class of signalling units in animal cells are three-protein
modules, each consisting of a receptor, an effector and a linking unit. The receptor
functions as a signal recognition element; the effectors are signal generators, changes
ofwhose activity cause variation in ionic composition or in second messenger levels
(such as cAMP or inositol phosphate) that in turn mediate downstream cellular
responses. The activities of these receptor and effector units are linked and
coordinated (among other elements) by members of the GTPase superfamily (G
proteins) (Berman and Gilman, 1998).
3.1.2.1 G Protein coupled receptors (GPCRs)
Nearly 2000 members of the superfamily ofG protein-coupled receptors (GPCRs)
have been reported to date. They are classified into over 100 subfamilies according
to their sequence homology, ligand structure and receptor function. All GPCRs have
a common structural motif containing 7 membrane-spanning regions with their N-
terminal end and three interhelical loops to the extracellular side of the membrane,
while the C-terminal end and three more loops are cytosolic. N-terminal segments
(consisting of 7-595 amino acids), loops (5-230 amino acids), and C-terminal
segments (12-359 amino acids) vary in size, an indication of their diverse structure
and function (Spiegel, 1996, Ji, et al., 1998, Lodish et al., 2000).
The receptors' intracytoplasmic loops transmit signals from receptor to G protein.
Mutational studies have located the essential signal-transmitting information of these
loops within short (6-16 residue) amino acid sequences near the junctions with the
transmembrane helices (Bourne, 1997). There is evidence that the GPCRs are
dynamic proteins that exists in equilibrium between two allosterically different
conformations, an inactive (R) or active form (R*) (Bond et al., 1995, Bourne, 1997).
Agonists have selective affinity for R*, so that agonist binding shifts the equilibrium
in favour of R*. When one such receptor ((^-adrenoceptor) was highly
overexpressed in myocardium of a transgenic mouse, sufficient R* was present to
allow maximal signalling response in the absence of agonist (Bond et al., 1995).
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3.1.2.2 The superfamily of regulatory GTP hydrolases (G proteins)
The main characteristic of the members of the GTPase protein superfamily is their
use of the hydrolysis ofGTP to control diverse cellular processes. These proteins can
act as "molecular switches": they are turned "on" when bound to GTP and turned
"off' when bound to GDP (Schwindinger and Levine, 1997).
Within the GTPase superfamily are the heterotrimeric G proteins and the group of
"small" monomelic Ras and Ras-like proteins. These two groups are regulated in
very different ways: both classes contain regions that promote the activity of specific
effector proteins by direct protein-protein interactions. However, heterotrimeric G
proteins are coupled directly to activate receptors, whereas Ras is linked only
indirectly via other proteins (Bourne et al., 1990, Koelle, 1997, Schwindinger and
Levine, 1997, Lodish et ah, 2000).
The group ofmonomelic proteins includes the*Ras, Rho, Rab, Arf, Sari and Ran
families. The Ras family regulates gene expression through the MAP kinase cascade;
the Rho family regulates reorganization of the actin cytoskeleton. Rab, Arf and Sari
families regulate intracellular vesicle trafficking and the Ran family regulates nuclear
transport (Sprang, 1997, Sasaki andTakai, 1998).
3.1.2.2.1 Heterotrimeric Gproteins structure
All the heterotrimeric G proteins share a common structure consisting of an a-
subunit (Ga-subunit) and a tightly coupled fly-subunit dimer (GPy-subunit) (Lodish
et al., 2000). The heterotrimeric G proteins were originally classified on the basis of
their Ga-subunit characteristics; however the growing number of different Gf3 and
Gy-subunits suggests that heterotrimeric G proteins should more properly be defined
on the basis of their combination ofGa, G|3 and Gy-subunits (Rahmatullah et al.,
1995).
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3.1.2.2.1.1 The Ga subunit ofheterotrimeric G proteins
The Ga-subunit protein has several biochemical activities: it binds guanine
nucleotides, has intrinsic GTPase activity and couples receptor with effector
molecules. Ga-subunits demonstrate the greatest diversity; they are unique to each
heterotrimeric G protein and are thought to confer functional specificity to it,
allowing discrimination among multiple receptors and effectors. 16 genes encoding
Ga-subunit proteins have been reported in mammals; they encode 20 different types
of subunits, some of them coding for more than one protein via alternative splicing
(Miric et al., 1993, Neer, 1995, Schwindinger and Levine, 1997, Farfel et ah, 1999,
Lodish et ah, 2000).
The Ga-subunits consist of two domains: a GTPase domain that contains the guanine
nucleotide-binding pocket as well as sites for binding receptors, effectors and the
GPy-subunit and an a-helical domain that contributes to the effector-binding site
(Masters et ah, 1988, Neer, 1995).
3.1.2.2.1.2 Classification of the a subunits ofG proteins
Based on the degree of amino acid identity of their a-subunits, G proteins have been
divided into 4 subfamilies: Gs (two genes identified), G, (eight genes), Gq (four
genes) and G12 (two genes) (Berman and Gilman, 1998). The proteins belonging to
each of these groups are shown in Table 3.1.
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family g-protein mw effector distribution
Gs sa 45kD Adenylyl cyclase (+) Ubiquitous
52kD Ca2+ channel
olf a 45kD Adenylyl cyclase (+) Olfactory epithelia
Sensory neurons
Gi jla 41kD Adenylyl cyclase (-)
Ca2+ and K+ channels
Widespread
brain
i2a 40kD Adenylyl cyclase (-)
Ca2+ and K+ channels
Widespread
f3a 40kD Adenylyl cyclase (-)
Ca2+ and K+ channels
Neuroendocrine
0 a 39kD Ca2+ channel (N-type) Nervous, neuroendocrine
tissue
2 a - Adenylyl cyclase (-)
tla - cGMP PDE Rod
,2 a - cGMP PDE Cone
Gustducin - - Taste buds
Gq q a 42kD PLCp Ubiquitous
na 43kD PLCP Ubiquitous
14a Spleen, lung, kidney, testis,
haematopoietic tissue
15a - - Elaematopoietic cell types
g12 12a - pla2 Ubiquitous
13a Na+/H+ exchanger Ubiquitous
Table 3.1. Classification of the G a-subunit proteins. MW: molecular weight; PLC =
phospholipase C; PLA2 = phospholipase A2; PDE = phosphodiesterase (modified
from Schwindinger and Levine, 1997).
119
Different types of receptors are linked to different G proteins, for example (3i- and
P2- adrenergic receptors are coupled to different Gs proteins that activate adenylyl
cyclase. In contrast, ai and a2-adrenergic receptors are coupled to Gq and G;,
respectively. Gj inhibits adenylyl cyclase and Gq stimulates phospholipase C to
generate second messengers (Schwindinger and Levine, 1997, Lodish et al., 2000).
Gza has been purified from bovine brain and shows a slow rate of guanine nucleotide
exchange when compared to Gsaand other G,a proteins (Simon et al., 1991). The
G0a protein is the most abundant G protein in neurons, but is otherwise expressed
only in endocrine cells and heart. The effects that the disruption ofG0a occasioned
in transgenic mice demonstrated that this protein plays a major role in motor control,
motor behaviour and in pain perception (Jiang M et al., 1998).
The genes encoding Gjia, Gj2a, G^a and G0a and Ga-subunits of the transducin rod
and cone receptors all have similar structures with conserved positions of splice
junctions. Several Ga proteins are expressed ubiquitously, but this is not the case, for
example, for the Gq group members: G^a is expressed only in bone marrow cells,
some early myeloid cells and in progenitor B cells; G15OC is also primarily expressed
in hematopoietic cell types (Wilkie et al., 1991).
The G^a subfamily has only two members, G^a and G^a that participate in cell
transformation and embryonic development. G^a participates in the regulation of
cell movement in response to specific ligands, as well as in developmental
angiogenesis. An activated form ofG^a induces cytoskeletal changes by way of
Rho (Offermanns et al., 1997). The activities ofmembers of the Rho family are
regulated by guanine nucleotide exchange factors (GEFs). pi 15, a GEF specific for
Rho, has an NH2-terminal region with similarity to the conserved domain of the
family of regulators ofG protein signalling (RGS). Members of the RGS family can
stimulate the GTPase activity of the a subunit of some G proteins. It has been
demonstrated that pi 15 has specific activity as a GTPase activating protein toward
the a subunits ofG^a and G^a, but not toward other G proteins. This GEF may act
120
as an intermediary in the regulation of Rho proteins by Gi2(x and G^a. It may define
a subset ofRGS proteins that have GAP activities but also couple RhoGEF activity
to G proteins a subunits (Kozasa et al., 1998).
Ga-subunits have a role also in the regulation of the structure of the Golgi apparatus.
The Golgi apparatus is involved in intracellular trafficking, and its structure can be
affected by transport inhibitors such as nordihydroguaiaretic acid (NDGA) that cause
Golgi disassembly. By over-expressing different Ga-subunits, Yamaguchi et al.
(2000) demonstrated that at least in the case of the constitutively active form ofGza
and Gi2a, such overexpression suppresses NDGA-mediated Golgi disassembly,
indicating that these G proteins have a function in protecting the Golgi structure.
3.1.2.2.1.3 The G0y-subunit ofheterotrimeric G proteins
Gp and Gy-subunits form a structural dimer that acts as a single entity. Gp and Gy
chains are polypeptides of 35 000 and 8 000 D respectively (OMIM 2000). So far 6
genes that code for GP-subunits and 12 genes that code for Gy-subunits have been
identified (Miric et ah, 1993, Schwindinger and Levine, 1997, Farfel et al., 1999,
Lodish et ah, 2000).
The GPy-subunit can facilitate Ga-subunit-receptor interaction, modulate effector
activity or mediate receptor desensitivity (Lodish et ah, 2000). The GPy complex can
also interact directly or indirectly with different effectors (Kleuss et ah, 1992).
Despite their close relatedness, the different types of GP-subunit proteins cannot
form dimers with all kinds of different Gy-subunit. For example, GPi can associate
with Gyi or G/2, whereas GP2 can associate with G/2 but not with Gyi, and GP3 is
unable to associate with either Gyi or Gy2 (Clapham and Neer, 1993).
The five known mammalian P subunits are between 53% and 90% identical to each
other. In contrast, the six y subunits are much more different from each other than are
the p subunits or the a subunits (Neer, 1995). The analysis carried out by
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Rahmatullah and Robishaw (1994) and Rahmatullah et al. (1995) showed that
selective interaction ofparticular Ga and Gy-subunits provides the mechanistic basis
for the assembly of specific Ga, G|3 and Gy-subunits combinations. This association
is dependent on prenylation of the Gy-subunit.
3.1.2.2.2 Ga-subunit crystallographic studies
The conformation of the Ga-subunit of the activated form ofGsa was determined at
2.5 A resolution (Sunahara et al., 1997). Gsa (as is apparently also the case with
other Ga-subunits) consists of two domains: a Ras-like domain common to all
members of the GTPase superfamily (encoding the structural elements for guanine
nucleotide binding), joined through two linker polypeptides to an a-helical domain
unique to the family of heterotrimeric G proteins.
At the core of every G protein is the guanine nucleotide-binding domain, consisting
of 200 residues with a central six-stranded P-sheet and five a-helices. Five of the six
P-sheets (Pi-p6) are parallel and one (P2) is antiparallel to the others. The five a-
helices (ai-as) surround the P-sheets.
The helical domain has an entirely a-helical secondary structure with one long
central helix (aA) surrounded by five short helices (aB-aF). It is linked to the GTPase
domain by two extended strands, linker 1 and linker 2. Between these two domains
lies a deep cleft within which the nucleotide is tightly bounded.
GTP is the organizing centre for three switch elements (switch I, II and III) that
undergo substantial conformational rearrangements on GTP hydrolysis. Apparently
the structure and orientation of the switch elements are essentially identical in Gsa,
G;a and Gta (Sunahara et al., 1997). As described for Gta switch I (Ser173-Thr183)
encompasses linker 2 and extends partially into the P strand. Switch II (Phe195-
Thr215) begins near the C-terminus of P3, extends through a2 and includes the 0.2 and
P4 loop. Switch III (Asp227-Arg238) spans the P4-a3 loop and occurs within a sequence
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segment that is the second of 4 sequence inserts (11-14) that are not present in the Ras
sequence used for comparison (Lambright et ah, 1994, Sprang, 1997). Switch I and II
(at least in Gta) are analogous to switch regions in Ras but switch III is unique to the
heterotrimeric family ofG proteins. The movement of switches I and II upon GTP
binding is in direct response to the presence of the y-phosphate group. Switch III,
however, has no direct contact with the bound guanine nucleotide. Upon activation,
switches II and III move towards each other and form multiple interactions.
The analysis ofmutations found in some PHP-la patients involving Arg258 and Gly259
residues (in Gsa), suggests that switch III is involved in both the activating
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mechanism and in maintaining the basal state of this protein. Arg mutations have a
direct result of decreased GDP binding due to loss of contacts between Arg258 side
chain and residues within the helical domain. Gly259 interacts with conserved
domains in switch II, a region that is important in maintaining the active state
(Warner et al., 1998 and 1999).
3.1.2.3 The (effector) adenylyl cyclase enzyme
The third element of the signalling unit that interacts with Gsa is the effector
adenylyl cyclase, whose activity is regulated by the activity of the Ga-subunit. The
adenylyl cyclase enzyme catalyses the conversion of intracellular ATP to cAMP. At
least 8 different forms of adenylyl cyclase (I-VIII) have been described. They have
molecular weights of ~120 000 (range of 1080-1248 amino acid residues). The
enzyme structure crosses the plasma membrane 12 times in 2 cassettes of 6
"transmembrane-spanning domains". The overall amino acid sequence similarity
among the different isoforms of adenylyl cyclase is ~50% (Cooper et al., 1995,
Taussig and Gilman, 1995). Most of the adenylyl cyclases are subject to multiple
forms of regulation and besides the Ga-subunits they can also be stimulated or
inhibited by, for example, protein kinase C, Ca2+ and GPy-subunits (Cooper et al.,
1995).
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3.1.3 MECHANISM OF ACTION OF THE G PROTEINS
As has been mentioned, the G proteins are turned "on" when bound to GTP and
turned "off' when bound to GDP. In the basal state, in the absence of hormonal
simulation, the protein is bound to GDP. Hormonal activation of the cell-surface
receptor then activates the release ofGDP; the subsequent binding to GTP over GDP
is favoured by the higher concentrations ofGTP in the cell. The intrinsic GTPase
activity of these GTP-binding proteins hydrolyses the bound GTP to GDP and Pi,
thus converting the active form back to the inactive form (Lodish et al., 2000).
Binding ofmany hormones and neurotransmitters to specific receptors stimulates
activity of adenylyl cyclase and results in the production of the intracellular second
messenger cAMP. The latter mediates the ultimate physiological effects of these
agonists, through a phosphorylation cascade that is initiated by activation of protein
kinase A. The mechanism of action of stimulatory G proteins can thus be
summarized as (Figure 3.1):
1. Binding ofhormone produces conformational change in the receptor.
2. The receptor binds to Gsa.
3. Binding to receptor induces a conformational change in Gsa. GDP bound to
Gsa is replaced by GTP and the a subunit dissociates from GPy-subunits
4. Gsa binds to adenylyl cyclase, activating synthesis of cAMP
5. Hydrolysis ofGTP to GDP causes Gsa to dissociate from adenylyl cyclase
and bind once again to GPy (Figure 3.1 modified from Lodish et al., 2000).
Figure 3.1. Mechanism of action of the G proteins. The steps are numbered 1 to
5 as explained in the text.
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3.1.4 FACTORS MODIFYING G PROTEIN ACTIVITY
There are various factors that may modify the mechanism of action ofG proteins.
For example, it has been proposed that the G(3y-subunit can play a role in
communicating the activating signal from the receptor to the nucleotide-binding site,
allowing the receptor to have effects on the a subunit that are not mediated by direct
contact (Iiri et al., 1994 and 1998).
The rate of hydrolysis ofGTP can also be modified, for example by substitution of
the alanine residue at position 366 of the Ga-subunit. It has been observed that when
this residue is mutated there is a spontaneous release ofGDP at a rate 80 times faster
than in the wild-type subunit (Iiri et ah, 1994 and 1998).
Proteins that regulate the slow intrinsic rate ofGTP hydrolysis by Ga-subunits are
called GTPase-activating proteins or GAPs. One of the GAP members is the family
known as regulators ofG protein signalling or RGS proteins. Nineteen genes that
code for these proteins have been described in mammals. RGS proteins are
recognizable in sequence by the presence of a conserved 120 amino acid core region,
which is flanked by variable arms, making up a protein of some 25kD overall
(Berman and Gilman, 1998).
The RGS proteins are negative regulators ofG protein signalling that act at the level
of the dissociated Ga-subunit. Their activity appears to be influenced by
palmitoylation of the Ga-subunit, as this modification decreases its affinity for
certain RGS proteins (Berman and Gilman, 1998). Activation of Gs by the (3-
adrenergic receptor is accompanied by an increase in the turnover of palmitate on the
Gsa subunit (Mumby, 1997). Although the RGS proteins had no effect on the time
course of nucleotide binding, they did potently stimulate (by at least 40-fold) the rate
ofGTP hydrolysis by several G proteins (Koelle, 1997) (Figure 3.2), indicating that








cyclase, phospholipase A2, ion
channel.
> Effector
Figure 3.2. GTPase cycle for heterotrimeric G proteins. The position in the cycle of
the RGS proteins is shown. The places in the cycle where Pertussis toxin (PTX) and
Cholera toxin (CTX) can exert their action are indicated. P;, phosphate (modified
from Koelle, 1997 and Hadley, 2000).
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Changes in the regulation ofGTPases that have an important pathological
repercussion are those caused by pertussis toxin (PTX) and cholera toxin (CTX).
Pertussis toxin (secreted by Bordetella pertussis) ADP-ribosylates a cysteine residue
located in the C-terminal tails of the Ga-subunit of the G;a family. This has the
effect ofblocking the catalysis ofGTP exchange by the activated receptor, leaving
the Ga-subunit unable to interact with a receptor or to exchange GDP for GTP, and
locking both GPy and Ga-subunits in their inactive states (Clapham and Neer, 1993,
Hadley, 2000) (Figure 3.2).
The cholera toxin (produced by the bacterium Vibrio cholerae) is an hexameric
protein containing 1 a subunit and 5 P subunits. The a subunit is an enzyme that
penetrates the plasma membrane and enters the cytosol, where it catalyses the
covalent addition of the ADP-ribose moiety from intracellular NAD+ to Gsa at the
arginine reside at position 201. ADP-ribosylated Gsa-GTP can activate adenylyl
cyclase normally but cannot hydrolyse the bound GTP to GDP; thus Gsa remains in
the active state, continuously activating adenylyl cyclase (Spiegel et al., 1985, Farfel
et al., 1999, Lodish et al., 2000, Hadley, 2000) (Figure 3.2). These two agents have
been useful to characterise the mechanism of action of specific heterotrimeric G
proteins depending upon how they are affected by treatment with one or other toxin.
3.1.5 THE GNAS1 GENE
Bray et al. (1986) described four species ofGsa cDNA in humans; they were named
Gsa-1 to 4. One of the clones described in their study (Gsa-1) had an open reading
frame of 1152 nt and coded for a protein of 394 amino acid residues. Its sequence
was 95% homologous to the bovine Gsa sequence used for comparison. The four
human Gsa sequences differed from each other in a region that corresponded to
amino acid residues 71-87 of the bovine Gsa gene.
As mentioned, Gsa-1 closely resembles bovine Gsa; Gsa-2 differs from Gsa-1 in
codon 86 (Gly) and the presence of three additional nucleotide residues (AGT) that
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code for Ser87. Gsa-3 has the codon GAT for Asp71 instead ofGAG for Glu71 and
lacks codons for amino acid residues 72-86 of Gsa-1. Gsa-4 has a GAC rather than a
GAT codon for Asp71, lacks codons for amino acid residues 72-86 and contains an
AGT codon for Ser72.
An alternative splicing scheme was proposed to explain how these four classes of
mRNA were derived from the same gene (later verified by Kozasa et al. (1988)). The
relative abundance of the different types ofGsa mRNAs (as assessed in human basal
ganglia) were 33%, 11%, 23% and 3% for Gsa-1 to 4 respectively. The Gsa-1,2 and
Gsa-3,4 isoforms correspond to the 52 kD and 45 kD forms ofGsa protein.
The genomic structure of the gene that codes for Gsa, GNAS1 was reported by
Kozasa et al. (1988). The genomic structure described was composed of 13 exons
and 12 introns, spanning a region of -20 kb. All the splice junctions conformed to
the GT-AG rule. The information obtained provided an explanation for the basis for
the alternative splicing that generates four isoforms ofGsa mRNA.
Isoform Gsa-3 lacks a stretch of 45 nt present in Gsa-1, which coincides with exon 3.
Therefore Gsa-1 and Gsa-3 are derived from the alternative splicing (by "exon
skipping") of exon 3. Gsa-2 has three nucleotides additional to Gsa-1, inserted at the
3' end of exon 3. Gsa-4 also has these three nucleotides additional to Gsa-3, in this
case between exons 2 and 4. These four types ofGsa mRNA are thus generated from
a single gene by alternative use of exon 3 and/or two alternative splice acceptor sites
of intron 3. These are only three nucleotides apart; at the 3' end of intron 3 is the
unusual splice junction sequence CTGCAG, which can be spliced in either of the
patterns CTG\CAG or CTGCAGV In the former case, use of the non-consensus CTG
instead of the consensus CAG results in the insertion of a single Ser codon in the
Gsa-2 and Gsa-4 mRNAs (Kozasa et al., 1988, Schwindinger and Levine, 1997).
The GC content of the 5' region (including and upstream of exon 1) is very high,
85%. An SI nuclease mapping analysis showed multiple transcriptional initiation
sites. Comparing this original description of the GNAS1 genomic structure to the
organisation of the human G,a gene revealed common features. The two genes have
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three identical exon junctions: the exon 1-2, 6-7 and 9-10 junctions ofGsa
correspond precisely to the junctions ofG,a exons 1-2, 4-5 and 5-6 respectively. This
suggests that Ga subunits of signal transducing proteins evolved from a common
ancestral gene (Kozasa et al., 1988).
The mapping ofGNAS1 to human chromosome 20 was first performed by using a
cDNA probe to screen a mouse/human somatic cell hybrid panel. The gene was later
located to 20ql3.2-ql3.3 by in situ hybridization (Sparkes et al.,1987, Levine et al.,
1991).
Subsequent reports demonstrated that the genomic structure originally reported for
GNAS1 was only partial, as additional exons were identified. A Gsa mRNA that uses
a different promoter and leading exon that lies -2.5 kb 5' of the original exon 1
(exon A), does not contribute an in-frame ATG. Its mRNA is therefore either not
translated, or less likely, encodes an N-terminally truncated form ofGsa by use of a
non-consensus downstream start codon (Ishikawa et al., 1990, Swaroop et al., 1991).
Another cluster of novel GNASJ exons was defined much farther upstream, during
the studies described in this chapter. This work was initiated by the results of a
project undertaken by our group in collaboration with the laboratory ofY.
Hayashizaki. A screen for novel imprinted loci was carried out by restriction
landmark genomic scanning for methylation differences (RLGS-M) between normal
and parthenogenetic human DNA. One differentially methylated spot, designated
A20, was identified, subsequent analysis ofwhich showed it to contain an exon that
was part of the GNAS1 gene. Further analysis of the upstream genomic region
identified other exons besides A20 and showed that the GNAS1 genomic structure is
much more complex and spans a bigger chromosomal region that originally thought
(see Discussion).
One transcript identified in these studies encodes a larger Gsa isoform named XLas
(extra-large Gsa-related protein). In this mRNA, a single large novel upstream exon
is spliced to exons 2-13 ofGsa. This yields a long open reading frame continuous
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with that of exons 2-13, encoding a protein with a large novel N-terminal domain in
place of the exon 1-encoded N terminus ofGsa. XLas was originally identified in the
rat while searching for proteins that undergo ADP-ribosylation by cholera toxin in
vivo. The strategy used was to incubate PC 12 cells in the absence or presence of
cholera toxin and then subject a postnuclear supernatant prepared from these cells to
"back-ribosylation" in vitro using cholera toxin and 32P-labelled NAD. A protein that
had become ADP-ribosylated by cholera toxin in vivo will thus show a reduced
incorporation of P ADP-ribose in the subsequent in vitro reaction. A protein with
apparent Mr of 94 kD, referred to as XLas (for extra large as) was identified.
The original description ofXLas (Kehlenbach et al., 1994) was of a cDNA (2956 nt)
containing an open reading frame of 2538 nt, beginning with an ATG at nt 46-48 and
encoding an 846 amino acid residue 92 kD protein. However, later analyses indicated
that the translation ofXLas probably actually starts at nt 439-441, resulting in a 715
amino acid residue 78 kD protein (this protein migrates anomalously on SDS-PAGE,
with an apparent mobility of 94kD, which was the reason for the original erroneous
assignment of the upstream ATG as the start codon). The XLas protein consists of
two portions: an N-terminal portion (referred as the "XL portion" of 367 amino
acids) and a C terminal portion (the "as portion") that is identical to amino acid
residues 47-394 of Gsa. The XL portion replaces the portion ofGsa encoded by exon
1. The XL portion of rat XLas appears to contain several structurally distinct
regions; an acidic polar N-terminal domain followed by a very alanine rich domain
containing a tetrapeptide repeat based on EPAA repeats, a proline-rich hinge, a
cysteine-rich domain and finally a domain with homology to exon 1 as in Gsa
(Kehlenbach et al., 1994 and 1995).
The predicted human protein has a tripeptide repeat motif, which is again rich in
proline, alanine, and an acidic amino-acid (aspartate rather than glutamate) (Hayward
et al., 1998a). XLas is localized in the plasma membrane, and like Gsa, can bind G
protein (3y subunits and activate adenylate cyclase (Klemke et al., 2000, Pasolli, et
al., 2000). However, a transmembrane receptor able to activate XLas has not been
identified.
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3.1.5.1 Gnas gene in mouse
From the studies carried out by Cattanach and Kirk (1985), using chromosomal
translocations in mice to generate offspring with segmental uniparental disomy
(UPD), it was demonstrated that for many chromosomal regions, proper development
in mammals requires both maternal and paternal contributions indicating the
presence of imprinted genes. In these studies, the distal part ofmouse chromosome 2
(a region of conserved synteny corresponding to human 20q) was recognised as
being imprinted. Because two different phenotypes resulted from maternal and
paternal UPD, the presence ofboth maternally and paternally imprinted genes in this
region was initially suspected. Later analyses have shown that within this region of
mouse chromosome 2 two different regions subject to genomic imprinting can be
identified. Molecular analyses have confirmed the conclusions of these classical
mouse genetics studies, since imprinted genes have been identified in both regions by
applying cDNA subtractive hybridisation and differential screening methods
(Kagitani et al., 1997, Kikyo et al., 1997, Williamson et al., 1998a).
Ashley et al. (1987) mapped the Gnas gene in the mouse to chromosome 2, which,
by the argument of homology of synteny, suggested an assignment of human GNAS1
to human chromosome 20 (confirmed by Sparkes et al., 1987). The mouse gene was
later mapped to a 20 centimorgan region between breakpoints T2Wa and T28H on
distal chromosome 2, a region of conserved synteny to human 20ql3-14 (Williamson
et al., 1996).
The finding that Gnas was located in an imprinted chromosomal region prompted
studies to determine if this gene was indeed under this form of regulation. The
knowledge that the Gsa protein (encoded by the human homologue GNAS1) was
deficient in patients suffering from PHP-la, whose full clinical presentation seemed
to depend on maternal inheritance of the mutation, seemed to indicate that the human
gene, too, might be imprinted.
132
A study ofGnas expression by in situ hybridization to tissues ofmice carrying
maternal duplication/paternal deficiency for distal Chr2 (MatDp2) and its reciprocal
(PatDp2) was carried out byWilliamson et al. (1996). Unexpectedly, however, they
described imprinting in mice in a manner opposite to that predicted by observations
in AHO. The RNA in situ hybridisation revealed high levels of Gnas mRNA in
glomeruli of PatDp2 embryos at late gestation and much lower levels in glomeruli of
MatDp2 embryos. This implied that the maternal, rather than the paternal, Gnas
allele is silenced in renal glomeruli.
Different conclusions were reached by Yu et al. (1998), who generated mice with a
null Gnas allele resulting from disruption of exon 2. This demonstrated, firstly, that
homozygous Gs deficiency is embryonically lethal. Maternal (Gnasm'lp+) and paternal
(Gnasm+/p~) heterozygotes for the null allele were shown to have distinct phenotypes,
suggesting both maternal and paternal imprinting. Resistance to parathyroid hormone
was present in Gnas m-/p+ but not in Gnas m+/p- mice, suggesting monoallelic Gsa
expression in the PTH target tissues (proximal renal cortex). In confirmation of this,
in renal cortex (and in adipose tissue) Gsa protein and mRNA levels were much
lower in m-/p+ than in m+/p- mice. These findings support the conclusion that Gnas
is imprinted in mice and suggest that similar imprinting in human GNAS1 may
explain the variable phenotypes observed in PHP-la.
The uniparental disomy phenotypes described by Cattanach and Kirk (1985) were
studied in utero by Williamson et al. (1998b). They generated mice and embryos
with maternal duplication/paternal deficiency (MatDp.dist2) and the reciprocal
(PatDp.dist2) of chromosome 2. They examined the uterine contents at several stages
and carried out weight comparisons between Pat and MatDp.dist2 mice and their
normal sibs. The weights were measured directly (wet weight) and also after 72
hours in a freeze-dryer (dry weight).
The PatDp.dist2 mice had an increase in wet weight compared to normal mice, but
this had diminished by birth and the placental weight was slightly diminished in the
second half of gestation. It was also noted that at 16.5 dpc, PatDp.dist2 embryos
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were severely oedematous and that the newborns had an increased length of the long
bones. On the other hand, the wet weight ratios of MatDp.dist2 embryos decreased
during the second half of the gestation, but placental weight was normal. The dry
weight analysis indicated that (at 16.5 dpc) there was no difference in either
PatDp.dist2 or MatDp.dist2 compared with normal, so the previous differences
observed were due to fluid retention. The histological analysis of several internal
organs revealed no overt abnormalities in both types ofmice.
3.1.6 MUTATIONS OF G PROTEINS
When the ability of a G protein to switch to the "on" state is altered, this change may
result in an increase or a decrease in the downstream signal. If the signal is increased
it results in the defective protein releasing GDP and binding GTP more rapidly than
normal; conversely a decreased signal results when the protein releases GDP more
slowly or binds GTP less avidly (Farfel et ah, 1999).
A defect of G protein-coupled signal transduction could result from quantitative
and/or qualitative changes in GPCRs and G proteins. Such changes can result from
mutations in the genes that code for both kinds of structure; the phenotypic result
will depend upon the biological activities and range of expression of the abnormal
gene. Factors relating to the mutation itself include whether it occurred in the germ
line or was somatic and also the precise nature of the mutation, resulting in a gain or
loss-of function of the protein involved (Spiegel, 1996).
3.1.6.1 Gain-of-function mutations in G proteins
Gain-of-function mutations lead to inappropriate activation of a G protein.
Constitutive activation will result in effector signalling despite the lack of normal
upstream signals from a hormone-activated GPCR. Such mutations act in one of two
ways: they can either accelerate the release ofGDP and cause receptor-independent
G protein activation, or block the GTPase reaction that terminates G protein
activation. The effects of the mutation are likely to be dominant, causing disease in
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heterozygous individuals, and may mimic the effects of hypersecretion of the
hormone normally activating the involved GPCR or G protein. However, the
circulating concentration of the hormone will actually be suppressed, reflecting
autonomous hyperfunction of the target gland (Spiegel, 1996, Cohen and Howell,
1999) and physiological feedback inhibition of hormone secretion.
At the receptor level, gain-of-function mutations have been identified, for example in
the receptors for LH and TSH. In the former case they have been found in the
germline in cases of familial male precocious puberty, and in the case of the TSH
receptor, somatically acquired gain-of-fimction mutations have been described in
hyperfunctioning thyroid adenomas (Spiegel, 1996).
3.1.6.2 Loss-of-function mutations in G proteins
Loss-of-function mutations can operate at various levels, ranging from blocking
normal mRNA and/or protein synthesis, to preventing the synthesized protein from
reaching its normal subcellular location, to impairing biochemical function despite
synthesis and normal targeting of the protein. Loss of function mutations in G
proteins may block receptor coupling or activation by GTP (Spiegel, 1996,
Schwindinger and Levine, 1997). Some loss-of-function mutations behave
dominantly and cause clinical disease in heterozygotes. Loss-of-function of a given
GPCR or of the G protein to which it is coupled will cause hormone resistance, with
a clinical phenotype that will resemble that resulting from deficiency of the hormone
itself. However, it is likely to be associated (conversely to the gain-of-function
mutation effect) with a high circulating concentration of the corresponding hormone
agonist (Spiegel, 1996).
3.1.6.3 Clinical conditions caused by mutations in the Ga-subunit
Several conditions caused by mutations in different members of the four groups of G
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Caused by defective signal termination - signal excessive.









Adenomas of the adrenal
and ovary










Caused by absent or inactive Cia - signal deficient.
Pseudohypo¬
parathyroidism type la




Type lb Gsa The sole defect is decreased response to
parathyroid hormone
Germ-line mutation
Night blindness G,a Point mutation Gly38Asp, mechanism is
not known.
Germ-line mutation
Caused by abnormal signal initiation - signal inadequate or excessive.
Pertussis G;a ADP-ribosylation of a cysteine blocks






Gsa Point mutation Arg385His blocks
activation by receptor and decreases
signal. Point mutation Arg23 lHis impairs





Gsa Point mutation Ala366Ser accelerates
GDP release, enhances signal at 34°C
(testis) but destabilizes and inactivates
Gsa at 37° (pseudohypoparathyroidism
type la)
Germ-line mutation.
Table 3.2. Clinical conditions associated with Ga-subunit mutations (modified from
Farfel et al., 1999).
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As can be seen in Table 3.2, the clinical and physiological consequences of the
different mutations in a-subunits are wide and several of them have been
characterised in detail. Among them is one form of dominantly inherited congenital
night blindness ("Nougaref' type) that is caused by a missense mutation in the gene
encoding the Ga-subunit of rod transducin, the G protein that couples rhodopsin to
cGMP-phosphodiesterase in the phototransduction cascade. The mutation, identified
in exon 2, corresponded to the change Gly38Asp. Gly38 is a highly conserved residue
among heterotrimeric G proteins (Gza is the only known G protein without a glycine
at this position). The missense mutation altering the homologous residue Glyl2Val
was the first oncogenic mutation discovered in p2 lras, and it may interfere with the
hydrogen bonds to the phosphate groups of GTP/GDP (Dryja et al., 1996).
Before discussing Gsa mutations that have been implicated in single gene disorders it
is also worth noting that an association study of GNAS1 has also been carried out to
assess its possible role in essential hypertension (Jia et al., 1999). By using the Fokl
polymorphism in exon 5, the authors demonstrated a significant difference in
frequency of the Fokl alleles between 268 white hypertensive individuals and a
matched group of 231 control subjects. These results suggested that the GNAS1 locus
might carry a functional variant that influences blood pressure variation and response
to P-blockade in essential hypertension, perhaps causing increased cAMP-mediated
cardiac contractility (Jia et al., 1999).
Gsa is not the only G protein subunit that has been associated with essential
hypertension. A polymorphism (C825T) in exon 10 of the gene encoding the GP3-
subunit of heterotrimeric G proteins was identified in some patients with essential
hypertension (Siffert et al., 1998). The polymorphism does not affect the amino-acid
sequence of Gp3, but in individuals carrying the T allele it was associated with the
occurrence of a splice variant (GNB3-S) in which nucleotides 498-620 of exon 9 are
deleted, causing the in-frame loss of 41 amino acids and one of the so-called WD
repeat domains of the Gp subunit. This alternative splicing results from the activation
of a cryptic splice acceptor site, and the resulting Gp3-s protein appears to be a
biologically active variant.
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Genotype analysis of 427 normotensive and 426 hypertensive subjects suggested a
significant association of the mutated allele with essential hypertension. Although the
presence ofG03 in cultured cells correlates well with increased Gj-dependent
hormone responses, the underlying molecular mechanism is not known yet (Iiri and
Bourne, 1998, Siffert et al., 1998, Farfel, 1999).
3.1.7 MUTATIONS IDENTIFIED IN GNAS1
Both gain and loss-of-function mutations have been described in the GNAS1 gene.
As has been explained before, the mutations can result in two different effects.
Mutations in GNAS1 that impair the ability ofGsa to hydrolyse GTP lead to
constitutive activation of adenylyl cyclase and result in hyperfunction and
autonomous growth of endocrine tissues. By contrast, mutations in GNAS1 that lead
to decreased expression or function ofGsa are associated with generalised resistance
to hormones that act by stimulating adenylyl cyclase (Schwindinger and Levine,
1997, Cohen and Howell, 1999).
3.1.7.1 Gain-of-function mutations ofGNAS1
Gain-of-function mutations of GNAS1 have been identified in McCune-Albright
syndrome (MAS) (OMIM#l74800), polyostotic and monostotic fibrous dysplasia
and in certain endocrine tumours, notably pituitary somatotroph adenomas.
3.1.7.1.1 McCune-Albrisht (MAS) syndrome
McCune-Albright syndrome (OMIM #174800) is a sporadic condition, characterised
by the clinical triad of polyostotic fibrous dysplasia, cafe-au-lait pigmented skin
lesions and endocrine dysfunction. The latter can be manifested as precocious
puberty, autonomous thyroid nodules, growth hormone excess and
hyperprolactinemia. The patients develop single ormultiple skeletal lesions that can
138
cause fracture, deformity and nerve entrapment (Albright et al., 1937, Wilson and
Foster, 1992).
From the observation that MAS occurs sporadically, and from the variable, patchy
distribution of the lesions, the suggestion was made early on that the disorder was
caused by somatic mosaicism, for a mutation that would be lethal in non-mosaic
state. Somatic mosaicism takes place when a mutation occurs postzygotically in a
somatic rather than in a germ cell. One would postulate that all cells that descend
from the mutated cell will manifest MAS related characteristics, while cells
descended from non-mutated cells will develop into normal tissues, thus explaining
the variability in tissue distribution. However, although the hypothesis that MAS
results from somatic mosaicism for a mutation has been verified, recent molecular
and cellular analyses suggest that the bone lesions ofMAS are not in fact clonal, but
contain a mixture ofmutated and normal cells (Bianco et al., 1998).
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Activating mutations ofArg have been found in a mosaic distribution in tissues
from subjects with MAS. The mutation at codon 201, within exon 8 of GNAS1, is
usually a C to T change resulting in Arg (CGT) to Cys (TGT). However, other
mutations involving the same residue, Arg (CGT) to His (CAT) and Arg (CGT) to
Gly (GGT) have also been described (Weinstein et al., 1991, Schwindinger and
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Levine, 1997). Arg mutations have also been described in patients with polyostotic
fibrous dysplasia (a phenotypic variant ofMAS) (Spiegel, 1996, Riminucci et al.,
1999).
3.1.7.1.2 Oncogenic associations ofGNAS1 (the gsp oncogene)
Vallar et al. (1987) described an altered Gsa protein in human growth hormone-
secreting pituitary adenomas. These tumours were characterised by high secretory
activity and intracellular cAMP levels. When cell membranes from these tumours
were stimulated by growth hormone-releasing hormone, GTP or by fluoride, no
effect upon adenylyl cyclase was observed. This finding indicated that the alteration
ofGsa could be the direct cause of the high secretory activity of the tumours in
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which it occurs. It represented the first description of an altered G protein in human
disease.
The first oncogenic Ga-subunit mutants were found in the Gsa gene ofpituitary
tumours from patients with acromegaly. A role for Gsa in tumorigenesis was
suggested by Landis et al. (1989), who established that the molecular basis for the
previously demonstrated constitutive activation of adenylyl cyclase was a mutation
in GNAS1 that resulted in replacement of either Arg201 or Gin227. Both of these
residues are located in the GTP-binding site and are important for GTPase activity.
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Mutations ofGsa at Arg inhibit the GTPase activity and result in a constitutively
active state, with ligand-independent stimulation of adenylyl cyclase (Spada et al.,
1990). Gin227 in Gsa is analogous to the cognate amino acid Gin61 that is frequently
replaced in the activated oncogene p21ras; point mutations in the latter gene that
inhibit GTPase activity are present in a variety of human tumours (Landis et al.,
1989).
201 227 • • • • •As the Arg and Gin mutations share some transforming characteristics with
p21ras, activated GNAS1 has been referred to as the gsp oncogene (for G stimulatory
protein). 40% of human pituitary somatotroph tumours have gsp mutations. The
proteins encoded by gsp have the same defects in signal termination that occur in
cholera: the inability to hydrolyse GTP and the persistent stimulation of adenylyl
cyclase (Schwindinger and Levine, 1997, Farfel et al., 1999). The resulting marked
elevation of intracellular cAMP results in the dominant character of the mutation
(Clementi et al., 1990). Somatotroph tumours resulting from gsp mutations have
different biological characteristics from those which are gs/'-negative (Landis et al.,
1989). They show greater sensitivity to inhibitory agents (somatostatin and its
therapeutic analogue octreotide, and also dopamine). This sensitivity to inhibition
may partly explain the low rate of tumour growth (Clementi et al., 1990, Spada et al.,
1990).
Similar findings ofmutations involving Arg and Gin have been reported in toxic
thyroid adenomas, adrenocortical adenomas and parathyroid tumours (Yoshimoto et
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al., 1993, Boothroyd et al., 1995). Thyroid-specific expression in transgenic mice of
201Gsa with the Arg to His mutation provided direct confirmation that the mutant
form ofGsa has an oncogenic activity, supporting the model that deregulation of
cAMP level alters growth control (at least in thyroid epithelium) (Michiels et al.,
1994).
3.1.7.2 LOSS-OF-FUNCTION MUTATIONS OF GNAS1:
PSEUDOHYPOPARATHYROIDISM
The first clinical and biochemical description ofpseudohypoparathyroidism (PHP)
was made in 1942 by Albright et al. They described three patients with apparent
hypoparathyroidism (HP) but in whom after treatment with parathyroid extract no
positive response was achieved, showing no phosphate diuresis or increase in
phosphate clearance. Albright et al. (1942) initially used the term "Seabright-Bantam
syndrome" for this entity (in reference to the abnormal feathering pattern of the male
Seabright Bantam, that they believed resulted from failure to respond normally to
testicular hormones). In this they recognized for the first time the existence of
conditions in which they thought the primary disturbance was a failure of response to
hormone(s) by the end-organ, rather than a failure in the nature of the hormone in
itself (Albright et al., 1942, Wilson and Foster, 1992).
3.1.7.2.1 Clinical characteristics
Albright's clinical account of the phenotypic characteristics of these patients
constitutes what is now known as Albright hereditary osteodystrophy (AHO) (OMIM
300800) and includes short stature, round face, cataract, nystagmus, short thick neck,
obesity, reduced intelligence, seizures, hypocalcemic tetany, subcutaneous
calcification or ossification and bone abnormalities such as osteoporosis, shortening
ofmetacarpals and metatarsals. The Chvostek and Trousseau signs are also positive
in these patients, reflecting hypocalcaemia (Albright et al., 1942, OMIM, 2000).
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The clinical laboratory abnormalities seen are a high basal thyroid-stimulating
hormone level and a hyper-response to thyrotropin-releasing hormone, low or absent
antithyroid antibody titres, low serum calcium, high serum phosphate, and high
levels of serum parathyroid hormone (PTH) (Laycok and Wise, 1996).
3.1.7.2.2 Molecular basis ofPHP
Two related observations helped to elucidate the molecular basis for PHP. The first
of them was the clinical observation that the administration ofPTH to these patients
failed to provoke a phosphate diuresis or an increase in serum calcium. The second
observation was made by Chase et al. (1969) who demonstrated that the actions of
PTH on its target organs (bone and kidney) were mediated by cAMP. The
observation that PTH infusion leads to increased urinary excretion ofnephrogenous
cAMP proved to be a reliable diagnostic test for PTH resistance (Wilson and Foster,
1998).
In contrast to patients with idiopathic or postsurgical HP, patients with PHP show a
markedly blunted urinary cAMP response to exogenous PTH, whereas patients with
PPHP showed a normal response. Taken together, these results indicated that the
biochemical defect in PHP was not in PTH itself but rather at or downstream of the
receptor site in the plasma membrane (Wilson and Foster, 1992).
The biochemical defect in PHP patients was eventually shown to be a partially
deficient activity ofGsa. The activity ofGsa in two assay systems was significant
lower (almost 50%) in erythrocyte membranes from PHP patients compared to
normal subjects. The results supported the hypothesis that deficient activity of the
guanine nucleotide regulatory protein was the molecular basis for hormone resistance
in this inherited disorder (Farfel, et al., 1980 and 1981, Levine et al., 1980).
Levine et al. (1986) measured the Gsa activity of erythrocyte membranes both from
AHO patients with clinical hormone resistance (PHP-la) and from family members
with AHO alone (PPHP). Patients with PPHP had reductions in Gsa activity
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comparable to those in patients with PHP-la, despite the fact that unlike patients with
PHP-la, individuals with PPHP did not have obvious endocrine dysfunction. These
findings generated the suggestion that more than one mechanism may be involved in
the presentation of the disease (Levine et ah, 1988).
Subjects with PHP and deficient Gsa activity show a high incidence of resistance to
additional hormones (Wilson and Foster, 1992 and 1998). Normal cAMP response to
PTH has been documented in osteoblasts isolated from patients with PHP-la and
PHP-lb, suggesting that the hypocalcaemia in PHP is not due to skeletal resistance,
but is a consequence of the renal resistance to PTH, resulting in both increased
urinary calcium losses and impaired 25 (OH) D3 1 a-hydroxylation (Wilson and
Foster, 1998).
3.1.7.2.3 Classification ofPHP
The classification ofPHP is based on the clinical and biochemical characteristics of
the patients. In PHP type I both the nephrogenous cAMP and phosphaturic response
to PTH are blunted, whereas in PHP type II, there is a normal nephrogenous cAMP
response to PTH infusion but a diminished phosphaturic response. These findings
suggested that the defect in PHP type I was likely to be in the PTH receptor-adenylyl
cyclase system and the defect in PHP type II was an inability to respond to cAMP.
PHP type I can be subclassified as follows:
1. Patients with PHP type la (PHP-la) have AHO and resistance to multiple
hormones due to a deficiency ofGsa activity.
2. Patients with PHP type lb lack AHO, have normal Gsa activity in
erythrocytes and have hormone resistance that is limited to PTH. This has
been presumed due to a defect in the PTH receptor, but recent studies in some
families at least provide evidence for a tissue-restricted defect ofGsa.
143
3. Patients with PHP type Ic have AHO and resistance to multiple hormones but
Gsa activity is normal.
A diagnostic problem is found in patients presenting with overt hypocalcaemia and
hyperphosphatemia, to discriminate between HP and PHP-I and II. For this purpose,
responses to exogenous PTH-(l-34) (synthetic PTH) are a useful test. Data from HP
patients provide the proper reference group, as the difference between HP and PHP is
enhanced by the fact that the phosphaturic and cAMP excretory responses to PTH are
both greater in HP patients than in normal subjects. PTH (1-34) is a safe and
effective diagnostic agent for the investigation of renal responses to PTH. Patients
with PHP have blunted cAMP and phosphaturic responses to PTH-(l-34) compared
to those of either normal or HP subjects. Induced hypercalcaemia failed to restore a
normal cAMP response to PTH-( 1 -34) infusion in 2 patients with PHP (Mallette et
al., 1988).
Their different clinical presentation and endocrine abnormalities suggested that (at
least) PHP-la and PHP-lb were unrelated disorders and therefore thought to be
caused by distinct molecular defects. The PTH-restricted nature of hormone
resistance in PHP-lb suggested that the defect might lie at the level of the specific
receptor for PTH/PTH-related protein (PTHrP). However, in two studies of the
receptor gene in patients with PHP-lb, no mutations were found by direct sequencing
ofPCR products, suggesting that this was not the mechanism underlying PHP-lb, at
least in the patients analysed (Schipani et ah, 1995, Fukumoto et ah, 1996).
A genome-wide linkage scan using four PHP-lb families with -350 microsatellite
markers mapped the PHP-lb gene to the telomeric region of chromosome 20ql3.3.
Interestingly, in each kindred one or several individuals carried the allele associated
with PHP-lb but showed no biochemical evidence for the disorder; these unaffected
gene carriers were always offspring of obligate male gene carriers. This suggested
that PHP-lb, like PHP-la, was paternally imprinted and maps to the chromosomal
region containing GNAS1 (Juppner et al., 1998). This unexpected finding further
suggests that PHP-la and PHP-lb (at least some cases) are after all allelic disorders.
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It has recently been discovered that PHP-lb patients often have an abnormality of
GNAS1 imprinting (see Discussion section 3.4.5). In one other recent report (Wu et
al., 2001) the GNAS1 mutation Alle382, removing one residue from the C-terminus of
Gsa, was found in a PHP-lb family. Co-transfection experiments showed that this
mutation selectively impairs Gsa coupling to the PTH receptor, but not to the other
Gsa -coupled receptors for TSH and LH, providing an explanation at the level of
receptor-G protein interaction for the selective hormone resistance in PHP-lb.
3.1.7.2.4 Molecular basis for hormone resistance in PHP
The observation that patients with AHO may have either reduced or normal levels of
Gsa mRNA first suggested that Gsa deficiency might arise from a variety of genetic
mutations. Several heterozygous GNAS1 gene mutations that accounts for Gsa
deficiency have been identified in the different families studied. These include an
initiator codon mutation, missense mutations, mutations in sequences necessary for
correct splicing and small deletions (Patten et al., 1990, Weinstein et al., 1990, Miric
et al., 1993, Schwindinger et al., 1994, Farfel et al., 1996 and 1999, Schwindinger
and Levine, 1997, Aldred and Trembath, 2000).
One of the most common mutations found in GNAS1 in PHP-la is a 4 bp deletion in
exon 7 (Yu et al., 1995) that has been found in several unrelated patients, including
some with de novo mutations. This site thus represents a mutational hotspot.
Aldred and Trembath (2000) identified several new mutations in GNAS1, among
them a case of germ-line mosaicism for a de novo in-frame insertion in exon 13. This
was one of three insertions and deletions observed at this site, suggesting that nt
1106-1108 in exon 13 represent a second potential "hot spot" for mutations.
A particularly interesting Gsa mutation was described in two patients showing a
combination of testotoxicosis (a condition caused by autonomous secretion of
testosterone by Leydig cells in the absence of LH, part of the clinical spectrum of
McCune-Albright syndrome) and PHP-la. In both patients, a Gsa mutation replaced
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alanine at position 366 with serine. This mutation constitutively activates adenylyl
cyclase in vitro, causing hormone-independent cAMP accumulation when expressed
in cultured cells, and accounting for the testotoxicosis phenotype (as cAMP
stimulates testosterone secretion). Although Gsa-A366S is stable at testis
temperature, however, it is rapidly degraded at 37°C, explaining the PHP-la
phenotype caused by loss ofGsa activity. In vitro experiments indicated that
accelerated release ofGDP causes both the constitutive activity and the
thermolability ofA366S (Iiri et al., 1994).
Although these mutations provided a molecular basis for the Gsa deficiency, they did
not offer an explanation for why an identical defect in Gsa should have such variable
phenotypic consequences in different tissues or in different individuals (Miric et al.
1993).
3.1.7.2.5 PHP-la PATTERN OF INHERITANCE AND GENOMIC
IMPRINTING
One of the most interesting and puzzling characteristics of PHP-la has been its
pattern of inheritance and the relationship of this to the spectrum of clinical
characteristics observed among the members of the families affected. The pattern of
inheritance was difficult to establish because of an apparent excess of affected
females and the presence within an affected family ofmembers with the same
somatic features (AHO) but no evidence of hormone resistance (PPHP). The
question raised was: "how is possible that the same mutation within one family may
have a different phenotypic expression in different affected individuals?".
Levine et al. (1986) proposed that the expression of the mutations depends partly
upon modifying genes, invoking the concept ofmetabolic interference. This proposes
that two different non-allelic genes, which by themselves may cause no overt
metabolic abnormalities, could interact when present together to cause hormone
resistance. Thus, a patient with PHP-la would not only have reduced Gsa activity,
but might also have inherited non-allelic polymorphisms, resulting in altered activity
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of other subunits of e.g. adenylyl cyclase, cAMP phosphodiesterase or protein
kinase. Conversely, patients with PPHP might inherit only reduced Gsa activity and
thereby escape expression of overt endocrine dysfunction.
Controversially, early clinical studies indicated a female:male ratio of 2:1 among
affected individuals, which led to the suggestion that AHO was an X-linked disorder.
The subsequent description of a family with male-to-male transmission suggested
that PHP-la had an autosomal dominant pattern of inheritance; however the features
exhibited by the proband and his sister were not striking and difficult to explain. The
authors noted that for unknown reasons the pattern of inheritance albeit autosomal
dominant had an enhanced expression in the female (Weinberg et al., 1971).
Nonetheless, the previous observation and the subsequent location of the human
GNAS1 gene to chromosome 20 led to the conclusion that PHP-la must be inherited
in an autosomal dominant fashion (Weinberg et al., 1971, Schwindinger and Levine,
1997).
To explain these differences in clinical presentation, it was suggested that they might
be related to genomic imprinting, depending on the sex of the transmitting parent
(Hall, 1990). In the analysis by Davies and Hughes (1993), a survey of the published
records ofAHO pedigrees showed that in 36 reports of families with AHO in two or
more generations, 33 cases presented maternal transmission and only three were
paternal; of 66 affected offspring, 36 were female and 30 were male (in accordance
with an autosomal dominant inheritance ratio). The 60 offspring who had inherited
the gene from their mother had full expression of the syndrome, with hormone
resistance (PHP); the 6 offspring with paternal transmission all had partial expression
(AHO only, PPHP). The study suggested that full expression ofPHP-la was
associated with inheritance of a maternally transmitted mutation, while inheritance of
a paternally transmitted mutation results in partial expression irrespective of the
degree of expression in the parent. The suggestion was made that GNAS1 might
therefore be an imprinted gene, with loss of a maternally-expressed function
accounting for hormone resistance in PHP-la.
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Further support for this hypothesis came from the study by Wilson et al. (1994), they
studied the origin of a Gsa mutation in apparently sporadic cases ofAHO,
demonstrating that the "switch" in the phenotype was dependent on the sex of the
transmitting parent across two generations. They remarked the fact that simple
monoallelic expression of the GNAS1 gene alone would not explain the clinical
observations in AHO, as equivalent reductions in Gsa bioactivity were found in
bothPHP-Ia and PPHP patients in all tissues tested. However, imprinting at a tissue-
or even cell-specific level could account for these findings.
One contradictory report came from Schuster et al. (1994), who reported a family
with PHP-la that had inherited the disease paternally as well as maternally,
suggesting that mechanisms other than genomic imprinting are responsible for the
full expression of hormone resistance, at least in the case of this family.
At a molecular level, demonstration that GNAS1 was biallelically-expressed came
from the studies by Campbell et al. (1994). They analysed the origin of GNAS1
transcripts in human fetal tissues, and of 75 fetuses genotyped 13 heterozygous for a
Fokl polymorphism in exon 5 of GNAS1 were identified. RNA from up to 10
different tissues from each fetus was analysed by RT-PCR. In all cases expression
from both parental alleles was shown by Fokl digestion of the resulting fragments.
No tissue specific pattern of expression was discerned in these experiments. The
authors stated that if genomic imprinting regulates the expression of the human
GNAS1 gene, the data suggested that the effect must either be subtle and quantitative
or be confined to a small subset of specialised hormone responsive cells within the
target tissues.
As mentioned this paradox could be explained if imprinting alters the expression of
Gsa in a cell-specific fashion. Thus the different phenotypes could result from tissue-
specific combinations of haploinsufficiency and monoallelic expression. The
functional defects found in patients with PHP-la reflect Gsa activity in cells in which
the gene is subject to paternal imprinting but haplosufficient (one allele normally
suffices, for instance in PTH-responsive cells of the kidney). On the other hand, the
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phenotype ofAHO results from deficient signalling function in cells in which the
Gsa gene is haploinsufficient but not imprinted (both alleles are normally expressed).
Finally cAMP-dependent functions that are not affected in either PHP-la or PPHP
are performed by cells in which the Gsa gene is haplosufficient and not imprinted
(Farfel et al., 1999).
As alluded to above in the discussion of GNAS1 gene structure, the imprinting status
of GNAS1 was revaluated following the discovery of a differentially methylated
region approximately 35 kb upstream of exon 1. These new studies began with an
analysis carried out by a collaborating group in Japan (lead by Dr. Y. Hayashizaki).
These investigators used restriction landmark genomic scanning to compare human
parthenogenetic DNA, DNA from non-related female individuals and DNA from
androgenetic complete hydatidiform mole. A differentially methylated spot, named
A20, was identified. When this was cloned and sequenced, analysis of EST databases
demonstrated that A20 was part of a cDNA derived from GNAS1. The knowledge (i)
that imprinted genes carry differences in methylation (ii) that Gnas (the homologous
gene in mice) maps to a known imprinted region and (iii) the pattern of inheritance
observed in families suffering from PHP-la, all prompted the study of this new
differentially methylated region, in order to define its relationship to GNAS1 and
subsequently to assess its imprinting status.
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3.2 MATERIAL AND METHODS
3.2.1 OLIGONUCLEOTIDES
The following oligonucleotides were used in the analysis described in this chapter:
NAME SEQUENCE 5'- 3'
A2 OA ATC TTT GGT GGA TTC GGG TGG
A2 0B GGA CAG GCA GGG GCT TCA GGT
A2 0D GCC TTC CCC AAT GAC CCC AG
A20F2 GTG TGT GTT GGT GTC CAT ATT C
A21F GTT TCC TCA CTT CTC ATT C
A21R CTG TGT GTC TGG TTT TTC AA
A21R2 AGC CCT TCC CAA GTA CAA GTA
XI IF GGA TGC CTC CGC TGG TTT CAG
X12R ACT CTC AGA TCG ACC GAA GCA G
XL 10 GTC GGG ATC TTC TGG GGT T
XL11 TGA CGC CCC AGC CGA T
K06T7 AGC CGG AAA CGA CCT CAG TG
K06-T3 AGA AAA TGG TGC CGA GCG ACA
K06A ACT TAC TCC GCA ACT TTC TC
K06B GTA CCC CTG GCG GAG AAG CG
K06C CGC AGA GAA GAA ACG CAG T
K06D ACT GCG TTT CTT CTC TGC G
K06E CTG AAA CCA GCG GAG GCA TCC
K06F CTC TCA GAT CGA CCG AAG CAG C
lFb CCA TGG GCT GCC TCG GGA ACA
1R TAG ACC TGC TTG TCC TTC TGC A
Gsa2F CCA AAG TGT TAA AAT GCC TCC T
Gsa2R CCC TGC ACA GAT TTG ACA CTT AC
GNASEX3F AGA GGA CCG CAG GCT GCA A
GNASEX3.5R CCT CAG ATA ACA GAA TAG TA
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GNASEX5.5R2 TAG AAG TTC CTA AGA CCG AGC AAT TCC AGC
PHP7F TTG ATG TAG CGC TGT GAA CA
PHP7R TGC CAA TCT AAA GCA AAG GTC
F8BglM13F-1 TTT CCT CGG GGG TTG GTA T
F8BglM13R-1 TCC CTC CTG CCA CCT GCC
F8F2 TAC ATT GCT TAC AGT TCA GGA A
I01F AGG CAA GAG GAC CGG CGG AGG
IOIR GCT CCG CGC CTT GCT TGC CTC
NESP1 TCG GTG TGT GCC TAA GAG GAT
NESP2 CTT GGA TCT TTG TCC TCG GG
NESP3 GTC ACT AAT GGA GGA CGC CGT
NESP4 TGG TGG GCG TTA AGG AAG CT
NESP5 TCG GAA TCT GAC CAC GAG CA
NESP6 CGT CTG CAC GCT CTC AAG TT
NESP7 CAG GCT CGG TCT CGA AGT
NESP8 CGG GGG ACT CAG GGA ATA CC
NESP9 CTC CGA TCC ATC CTC TT
NESPIO CCC GAA CGC ACC CCA GAT
NESP11 AGT GAC GCC GGA TGG GGA
NESP12 ATT TGG GGT GCG TTC GGG
NESP13 TTC CCC TAA CCG CCC GCC G
NESP14 CGG CGG GCG GTT AGG GGA A
NESP15 TTC CTG AAC TGT AAG CAA TGT A
NESP16 TTC CTG AAC TGT AAG CAA TGT A
NESP17 GGG GTC GCG TCT AAC ATC A
NESP18 TGA TGT TAG ACG CGA CCC
NESP21 AAA AAT CTC ATC CGA CTT GG
NESP22 CCA AGT CGG ATG AGA TTT TT
NESP23 AGC CTG AGT TCA CCA AGC A
NESP24 TGC TTG GTG AAC TCA GGC T
NESP25 GTC ATT CAT CTC AAG CCC T
NESP26 CGG CTG CTC TCA CAT CGT
151
3.3 RESULTS
3.3.1 IDENTIFICATION OF EXON A20 OF GNAS1
A screen for genomic regions displaying differential allelic methylation (DMRs) was
carried out in collaboration with the laboratory ofDr. Y. Hayashizaki (Tsukuba,
Japan). This screen used restriction landmark genomic scanning for methylation
differences (RLGS-M), a technique developed in the Hayashizaki laboratory (Hatada
et al., 1991, Hayashizaki et al., 1994, Kamiya et al., 2000). The RLGS-M method
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employs P-end-labelling of rare-cutting methylation-sensitive restriction sites in
genomic DNA, followed by high resolution two-dimensional electrophoresis
separation of end fragments generated by cleavage with a second and third restriction
enzyme.
This method preferentially targets transcription units because of its dependence on
cleavage at rare CpG-containing sites, which are located mostly within CpG islands
at the 5' ends of genes. RLGS-M is dosage sensitive and can distinguish haploid and
diploid intensity of single-copy genes. This important property confers the ability to
screen for imprinted genes by comparing spot intensity in parthenogenetic, normal
and androgenetic DNA, without having to rely on polymorphisms to distinguish the
parental alleles. A spot generated by cleavage at a site within a DMR is predicted to
be of haploid intensity in all normal DNA samples, but to be of either diploid or zero
intensity (or vice-versa) in parthenogenetic and androgenetic DNA, depending on
whether the methylated allele is paternal or maternal, respectively.
In this screen, parthenogenetic DNA (from blood of the chimaeric patient FD, Strain
et al., 1995), DNA from normal non-related female individuals and from a complete
hydatiform mole were compared. Two spots named NV149 and A20 were identified
as candidate imprinted loci. These were excised from the gel, and cloned and
sequenced. The NV149 clone, which is not discussed further here, proved to map to a
region upstream of the ZAC gene (the zinc finger protein which regulates apoptosis
and cell cycle arrest). This allowed the demonstration that ZAC is a paternally
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expressed imprinted gene and most likely the gene that is dysregulated in transient
neonatal diabetes mellitus (Kamiya et al., 2000).
The other differentially methylated spot, named A20, that was absent from the
RLGS-M images from parthenogenetic DNA, but present at haploid intensity in all
control females, was also cloned and sequenced. This Mbol-Ascl fragment was 232
nt in length. Database searching using this sequence resulted in identification of a
match to an EST (Acc. number AJ224867), derived from IMAGE cDNA clone
359933. Alignment of the A20 genomic sequence fragment with the cDNA sequence
revealed that the A20 clone contained a single exon that was 91 nt in length (referred









Figure 3.3. DNA sequence of genomic clone A20. The sequence corresponding to
the exon A20 (as determined by comparing cDNA and genomic sequences) is
shaded. The oligonucleotides used for analysis and their orientations are marked by
arrows and the sequences underlined.
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3.3.1.1 Analysis of the cDNA clone 359933 (827-k06)
The IMAGE cDNA clone 359933 was obtained from the UK HGMP Resource
Centre (under its plate co-ordinates, 827-k06). This cDNA had been cloned in the
vector pT7T3D using the enzymes Notl and EcoRl. Plasmid DNA was therefore
purified and digested with these enzymes. The bands obtained showed that the cDNA
insert of the clone was ~800 bp in length (Figure 3.4).
M 1 2 3
Figure 3.4. Restriction digestion analysis of cDNA clone 359933 (827-k06). Lanes:
M) 1 kb marker ladder; 1) Notl digest 2) EcoRl digest 3) Notl+EcoKl digest. The
arrow marks the insert fragment (the remaining unlabelled lanes correspond to other
clones that were being analysed at the same time).
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3.2.1.2 Sequence analysis of clone 359933
Clone 359933 was then completely sequenced on both strands; it proved to be 834 nt
in length (Figure 3.5). When this complete sequence of the cDNA clone was used to
search the sequence databases it was noted that it consisted of:
(i) A 367-nt upstream region, homologous to part of the 5' portion of the
mRNA encoding the rat Gsa-related protein, XLas (Kehlenbach et ah,
1994).
(ii) The 91 nt corresponding to exon A20.
(Hi) A previously unidentified 67 nt exon (given the name A21).
(iv) GNAS1 exons 2 and 3.
(v) A variant terminal exon (which was given the name 3N) containing a
polyadenylation signal and poly(A) addition site. A similar variant
terminal exon has previously been found in other GNAS1 mRNAs

























Exon 3 Exon 3N
661 ATCCCTAGATGATGGCTACAGTTTCTCATCTTCCCGGCTATGTCCTATCACAATTTGCAT
< GNASEX3 . 5R
721 GCTGGAATTGCTCGGTCTTAGGAACTTCTAATAAGAATACTATTCTGTTATCTGAGGGGG
781 GAGGGGGGATGGGGCCCCTGCTACCTGACCTTAAACGATGATTGAAAAAAAAAA
Figure 3.5. Complete sequence of cDNA clone 359933 (827-k06). The splice
junction positions are marked by vertical lines. The names of the exons identified are
shown. The oligonucleotides used for the analysis and their orientations are marked
by arrows and the sequences underlined. This sequence was deposited in GenBank
under the accession number AJ224867.
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The presence ofXLas-homologous sequences, and of exons 2 and 3 of the GNAS1
gene, indicated that the sequence of clone 359933 represented a bona fide GNAS1
transcript, containing at its 5' end previously undescribed exons, including A20 and
A21. The identification of these new exons showed that the previously reported gene
structure of GNAS1 (Kozasa et al., 1988) was incomplete. Furthermore, since A20
had been identified as a candidate imprinted locus, there was clearly a need to
characterise the structure of the new 5' region ofGNAS1, so as to allow further
analysis of the differential methylation in this region and its implications for
imprinting of the GNAS1 locus. As a first step, the RPCI1 PAC DNA library was
screened in order to identify large genomic clones that contained GNAS1.
3.3.2 SCREENING OF THE RPCI1 PAC LIBRARY FOR CLONES
CONTAINING GNAS1
For screening the RPCI1 human genomic PAC library by PCR, two oligonucleotides
named PHP7F and PHP7R, which match sequences flanking exon 7 of GNAS1 (as
described in Kozasa et al., 1988), were used. Four of the 21 primary pools (named A
to U) were positive for the presence ofGNAS1. These were pools D, E, H and U, all
ofwhich yielded a PCR product of the expected size, 180 bp (Figure 3.6A). The
secondary pools corresponding to the four positive primary pools were screened
using the same PCR primers. Secondary pools D15, E3, H5 and U4 were positive,
corresponding to the PAC clone groups numbers 60, 63, 110 and 309, respectively
(Figure 3.6B).
Screening of the tertiary pools corresponding to each of these four clone groups
identified the following PAC clones as containing exon 7 of GNAS1: dJ60ol6,
dJ63n2, dJ11 Op 14 and dJ309f20 (Figure 3.6C).
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Figure 3.6.
A) PCR screening for GNAS1 exon 7 in the RPCI1 PAC library. Lanes: M) 1 kb
marker ladder; positive pools indicated by the corresponding letter: D, E, H, and
U; 1, 2 and 3) human genomic DNA (positive controls); 4) negative control
(DNA blank).
B) PCR screening of secondary pools of the RPCI1 PAC library. The figure
shows screening of the group H secondary pools. There was only one positive
pool in this group. Lanes: M) 1 kb marker ladder; 1) positive sample
(corresponding to clone group number 110); 2) normal human genomic DNA,
positive control.
C) Tertiary screening of the RPCI1 PAC library. The PCR products
corresponding to PAC clone dJ309f20 are shown. Lanes: M) 1 kb marker ladder;
1) positive sample corresponding to group f; 2) positive sample corresponding to
sample number 20; 3 and 4) positive controls (normal human genomic DNA).
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A) PCR screening of primary pools of the RPCI1 PAC library
M D E H
506 bp 506 bp
iflMH
B) Secondary screening, pool H
M
1





C) Tertiary screening, pool U4
506 bp 06 bp
Figure 3.6. PCR screening of the RPCI1 PAC library
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These four PAC clones were obtained from the UK HGMP Resource Centre and
DNA was extracted. To confirm the presence of GNAS1 in each clone, two different
PCRs were performed. In addition to primers PHP7F and R that flank exon 7,
primers Gsa2F and Gsa2R, that flank exon 2 of GNAS1, were used. The expected
PCR product was 149 nt in length. PCR products of the expected size were obtained
from all the PAC clones with one exception; dJ63n2 was negative for the presence of
exon 2 (Figure 3.7).
In a third PCR, primers A20A and A20D, that match sequences of the recently
identified exon A20 at the 5' end of GNAS1, were used (see Figure 3.3). This time,
only dJ309f20 was positive for the expected 222 nt PCR product, establishing this as
the only one of the four PACs likely to contain the novel 5' exons of GNAS1 (Figure
3.7).
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Exon 2 Exon 7
LANE NAME EXON 2 LANE EXON 7 LANE EXON A20
1 dJ60ol6 + 6 + 11 -
2 dJ63n2 - 7 + 12 -
3 dJ11 Op 4 + 8 + 13 -




Figure 3.7. PCR analysis of the PAC clones for exons 2, 7 and A20 ofGNAS1. Lane
M) 1 kb marker ladder.
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3.3.3 STRUCTURAL ANALYSIS OF THE 5' END OF GNAS1
3.3.3.1 Construction of subclone libraries derived from PAC dJ309f20
The first step taken in order to characterise the 5' end of GNAS1, with respect to the
newly identified exons, was to create a number of different subclone libraries from
PAC dJ309f20. These were then screened to identify subclones containing the new
exons. These subclones were then used to establish the genomic structure of GNAS1
at its 5' end.
Subclone libraries derived from PAC dJ309f20 were constructed using vectors pCRII
(Invitrogen), TVEC (Promega) and pUC18 (Stratagene). PAC dJ309f20 was digested
with the enzymes Not\+Sac\ and Sac\+Asc\ for the subclone libraries using the first
two vectors. /iamHI-digested pUC18 was used to subclone Bglll and BamHl
fragments of the PAC.
3.3.3.1.1 Screeningfor subclones containing the A20 exon
As indicated in Figure 3.3, an AscI site lies just downstream of the A20 exon. From
the TVEC vector library, twenty randomly chosen Sacl-Ascl subclones were
screened by colony PCR (using primers A20A and A20D) for the presence of exon
A20 of GNAS1. Six subclones (numbers 4, 5, 10, 13, 16 and 21) were positive
(Figure 3.8).
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Figure 3.8. Colony PCR screening for exon A20. Lanes: M) 1 kb marker ladder; 4,
5, 10, 13, 16 and 21) subclones positive for the presence of exon A20.
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3.3.3.1.2 Screeningfor subclones containing GNAS1 exon 1
The pCRII subclone library (ofNotl-Sacl fragments) was screened by colony PCR
using primers lFb and 1R. Two subclones were positive (not shown).
3.3.3.1.3 Screeningfor subclones containing exon XLas
Using the BamHl subclone library of dJ309f20, colony PCR was performed using
primers XL1F and K06D, that match sequences in the XLas part of the 359933
cDNA (Figure 3.5). Of 100 subclones analysed, only two, numbers 21 and 33,
yielded the expected 241 nt PCR product. DNA was extracted from both clones and
rescreened for both exons A20 (using primers A20A and A20D) and XLas (primers
XL1F and K06D). Both clones were positive for the presence ofA20 in addition to
XLas.
These two subclones (21 and 33) were further analysed using PCR primers A21F and
A21R, that match sequences of exon A21. A product of the expected size (67 nt) was
again obtained from both subclones. Thus, the XLas, A20 and A21 exons appeared
all to lie on a common BamHl fragment, contained in subclones Bam21 and Bam33.
3.3.3.2 Sequencing analysis ofsubclone Bam21
Digestion of subclone Bam21 with BamHl showed an insert of ~2 kb. The complete
sequence of this insert was then determined on both strands. As expected from the
previously described PCR analyses, this subclone contains the complete sequences of
exons A20 and A21 and also the 3' part of the XLas exon. In order to complete the
sequence of the entire region comprising these three exons, further sequencing of
Sac\-Asc\ subclone 4, containing exon A20 and exon XLas, was also carried out in
our laboratory (Dr. B. E. Hayward). These overlapping subclones yielded a
combined sequence of 2479 nt, which was deposited under accession number
AJ224868 (Figure 3.9).
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Figure 3.9. Sequence assembled from subclone Bam21 and Sacl-Ascl subclone 4
(accession number AJ224868). The exons A20 and A21 are shaded. The intron
sequences are shown in lower case. The translated part of the XLas exon probably
starts at nt 318 and is shaded (see below). Some of the oligonucleotides used for the





































































































The true 5' end of exon XLas remains to be determined, as attempts to map the 5'
end of XLas by RACE were not successful (Dr. B. E. Hayward). However, RT-PCR
products diagnostic ofXLas-exon 2 spliced mRNA could be generated by using
upstream primers as much as 1.1 kb from the 3' end of the XLas exon (nt 375-1482
in Figure 3.9). These experiments indicate that the XLas exon is > 1.1 kb in size, and
it may extend even further 5' because the reading frame remains open beyond the
start of our sequence (Figure 3.9).
3.3.3.3 Identification of exon 3N of GNAS1
As mentioned above, an alternative terminal exon sequence was identified in
IMAGE clone 359933 (827-k06). This exon was located after exon 3, and was given
the name 3N. To establish the genomic distance between exon 3 and exon 3N,
primers GNAS3ExF (exon 3) and GNAS3.5R (exon 3N) were designed and used for
PCR analysis. Another oligonucleotide 3.5FII was also used to screen the BamHl and
Bglll subclone libraries for subclones containing exon 3N, yielding one positive
BamHl subclone (F8).
It was subsequently noticed that primer 3.5FII had been synthesized with a mismatch
in its sequence. Nonetheless, when a new primer with the correct sequence was used
in a PCR reaction for exon 3N, subclone BamF8 was indeed positive for the expected
product of 113 bp. To confirm the presence and sequence of exon 3N, subclone
BamF8 DNA was then used as template for sequencing with primers GNASEx3.5,
GnasEx3.5R and 3.5FII.
These data were used to determine the position and size of exon 3N. The PCR
product obtained using primers in exons 3 and 3N was ~1100 bp (Figure 3.10). Thus,
exon 3N was determined to be 1 kb downstream of exon 3, within the -4.5 kb intron
originally described between exons 3 and 4 (Kozasa et al., 1988). There were no
additional splice junctions within this region of the IMAGE clone downstream of
exon 3.
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Figure 3.10. GNAS3F-3.5R PCR product. Lanes: M) 1 kb marker ladder, 1)
Subclone BamF8 , 2) PAC dJ309f20; 3) human genomic DNA (positive control).
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3.3.3.4 Organisation of novel GNAS1 exons
Based on the previously described results, it was established that the organisation of
the novel exons contained within IMAGE clone 359933 (827-k06) is as follows
(Figure 3.11):
Figure 3.11. Organisation of the novel exons of GNAS1. The exons are in grey or
white for untranslated regions.
A) GNAS1 partial gene structure The exon labeled A has been previously described
(Swaroop et al., 1991), the exon 3N is indicated. Fmarks the polymorphism used for
analysing the RT-PCR products (described in section 3.3.5).
B) The gene structure of GNAS1 including the XLas exon -35 kb upstream of the
originally described exon 1 of GNAS1 is shown.
C) Organisation of the XLas region. The XLas, A20 and A21 exons are shown. The
restriction sites indicated are S, Sacl\ B, BamHI; As, Ascl. The region sequenced in













The distance between the XLas region and the exon 1 region of the gene was
established to be approximately 35 kb by restriction mapping ofPAC dJ309f20,
performed by pulsed-field gel electrophoresis by Dr. B. E. Hayward. Subsequent
sequence data of the entire region, obtained at the Sanger Centre, have confirmed
these analyses; GNAS1 exons 1-13, XLas and NESP55 (section 3.3.6) lie within the
sequence ofPAC clones dJ543j 19 (Acc. number AL109840), dJ309f20 (Acc.
number AL121917), and dJ806m20 (Acc. number AL 132655).
3.3.4 DIFFERENTIAL METHYLATION IN THE XLas REGION OF GNAS1
The genomic sequence obtained in this study shows that the human XLas-
homologous region is encoded in a single large exon (>1.1 kb) ~35kb upstream of
exon 1 of GNAS1. A 1.9 kb Sacl-Ascl probe fragment (see Figure 3.11) was used for
assessing the methylation status of the NotI, FfrvHII and Ascl sites in this region, by
Southern blotting of normal and parthenogenetic lymphoblastoid cell DNA (Dr. L.
Strain). Sacl digestion generates a fragment of ~6 kb containing the XLas exon.
The results of this experiment showed that normal DNA yielded bands indicating the
presence ofboth methylated and unmethylated alleles at all the mentioned restriction
sites. The parthenogenetic DNA, in contrast, was completely methylated at all the
sites. This confirmed that as indicated by the original RLGS-M result, this genomic
region is indeed differentially methylated, the paternal allele being unmethylated and
the maternal methylated. The restriction sites whose methylation analysis was
assessed are shown in Figure 3.12.
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Figure 3.12. Organisation of the XLas region of GNAS1. The map is not to scale.
Grey lines above the exons represent the splicing patterns observed in the majority of
XLas-containing RT-PCR products and below the line the splicing patterns seen in
the 359933 cDNA clone. Italic letters indicate restriction sites: S, Sad; B, BamHl, N,
Notl; As, Asd; Ng, NgoMl; Bs, ffosHII; F, Fokl (polymorphic site). Asterisks
indicate those sites whose methylation status was assessed by Southern blotting. The
coding regions of exons are shaded grey, and the untranslated regions white.
173
Figure3.12.OrganisationofthXL sregiGNAS1andloc tio softhrestriction sitesanalysedfordifferentialme hylation
3.3.5 MONOALLELIC EXPRESSION OF XLas-CONTAINING
TRANSCRIPTS
In order to assess if the differential methylation described in GNAS1 reflects
monoallelic expression of this gene, a series ofRT-PCR analyses of fetal RNA
samples was carried out in our laboratory (Dr. B.E. Hayward). In a previous analysis
of GNAS1 described by Campbell et al. (1994) a large number ofRNA samples from
first trimester fetuses heterozygous for a Fokl polymorphism in exon 5 had been
analysed. RT-PCR analysis using oligonucleotides in exons 2 and 6 of GNAS1 had
demonstrated that this gene was biallelically expressed in all the samples. However,
it was now recognised that these experiments did not distinguish between GNAS1
transcripts containing either exon 1 or the novel differentially methylated XLas
exon.
In the new study, these fetal RNA samples were first reanalysed by RT-PCR between
exon 2 and 6, yielding identical results as previously described, with uniformly
biallelic expression of the gene. However when the RT-PCR analysis was performed
using an upstream oligonucleotide within the XLas exon, the Fokl digests revealed
that all of the XLas-containing transcripts were derived from the paternal allele. In
contrast with this result, an RT-PCR specific for exon 1-derived products showed
that these transcripts were derived from both alleles.
These RT-PCR experiments also showed that the XLas-exon 6 RT-PCR products
were shorter than the 783 bp product predicted from the sequence of the cDNA clone
359933. When these products were sequenced, it was found that as in the rat XLas
mRNA, the human XLas exon is spliced directly onto exon 2, resulting in a mRNA
with an open reading frame continuous with that of exons 2-13.
Interestingly, RT-PCR products containing A20 or A21 were not detected,
suggesting that most XLas-containing transcripts do not contain the A20/A21 exons.
As A20/A21 transcripts also do not have a continuous ORF, they may be aberrant or
functionally unimportant splice forms. However, their RT-PCR analysis (using an
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upstream primer specific for A20) did show that A20-containing transcripts also are
derived exclusively from the paternal allele.
3.3.6 SEQUENCE CONSERVATION AND REPETITIVE ELEMENTS IN
THE XLas REGION
A comparison between the translated human XLas ORF (starting at nt 318 of our
genomic sequence AJ224868) and the peptide sequence predicted by a full-length rat
cDNA (according to Kehlenbach et al., 1994, and in Hayward et al., 1998a)
demonstrates that the extreme N- and C-terminal parts of the XLas segments are
well conserved. The central regions, in contrast, align much less well, but there are
qualitative similarities between the two species' sequences in this region.
As shown in Figure 3.13, this central region includes a repetitive domain. In the rat
XLas protein, there is a tetrapeptide repeat based on EPAA (single-letter amino acid
code). The predicted human protein has a tripeptide repeat motif, again rich in
proline, alanine and an acidic amino acid (though D, aspartate rather than E,
glutamate). A higher order repeat of 9 or 12 amino acids can also be discerned within
this tripeptide repeat region. The overall ratio of (D+E):P:A in this region (20:22:42)
is virtually identical to that in the rat EPAA repeat region.
The fact that the qualitative properties of the repeated XLas domain, but not its
primary structure, are conserved between human and rat, may be significant. It may
indicate selective pressure exerted at the level of the protein, but for the general
chemical nature of the domain rather than its precise sequence. Alternatively, it could
be that the presence of the DNA repeatmotif itself, rather than the encoded protein
sequence, is selected for. This could be the case if the repeat motif has a specific role
in the imprinting process, as has been suggested from the finding of such tandem















Figure 3.13. Internal repeat motifs in the human XLas exon, residues 74 to 225 (as
in Hayward et al., 1998a). The most highly conserved residue at each position of the
repeat is shaded.
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Summarising the information obtained up until this point in the analysis of GNAS1, it
was concluded that this gene was indeed imprinted, and that this imprinting was
promoter-specific. The various promoter-specific transcripts of GNAS1 are
alternatively spliced onto the splice acceptor site of exon 2. In the case of the XLas-
derived transcripts, this yields mRNA species that are derived exclusively from the
paternal allele, including one that encodes a protein homologous to the large Gsa-
related protein XLas of the rat. The XLas promoter is active only on the paternal
allele, even in the same tissue samples in which transcription from the major
promoter (upstream of exon 1) is biallelic.
3.3.7 IDENTIFICATION AND ANALYSIS OF NESP55
The demonstration that GNAS1 was indeed imprinted, in a promoter-specific fashion,
was of considerable interest, but still did not offer an explanation for the imprinted
inheritance pattern ofhormone resistance in PHP-la. The fact that the mutation must
be maternally derived for hormone resistance to develop appeared to indicate that
GNAS1 would be maternally expressed, at least in some tissues. The imprinted XLas
transcript, in contrast, is paternally expressed. Indeed, one would predict that patients
with PPHP as a result of a paternally inherited null mutation of GNAS1 might be
lacking XLas function in addition to their 50% loss of Gsa activity. One possibility
that was suggested by the identification of the novel XLas promoter 35 kb upstream
of the exon 1 promoter was that there might be additional upstream promoters, that
could perhaps be maternally expressed. This prompted a search for GNAS1 mRNAs
with 5' ends that were different from those already known.
Initially, Dr. B. E. Hayward in our laboratory examined all identifiable GNAS1 EST
sequences in the databases. Only one of them (derived from IMAGE cDNA clone
301896) had a 5' end that had not previously been seen. Secondly, a 5'-RACE
analysis was performed on human fetal muscle RNA, using a primer located in
GNAS1 exon 5. Products were size-selected to be larger than expected for exon 1-
containing mRNAs, and then cloned.
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This library of cloned RACE products was then screened for the presence or absence
of the XLas exon. One XLas-negative RACE clone was > 1.3 kb in size and was
characterised further. After sequencing, its 5' end proved to include the entire
unknown 5' sequence of IMAGE clone 301896. However, unlike clone 301896, the
RACE clone also contained an additional 0.9 kb of sequence inserted between the
unknown 5' sequence and exon 2. The analysis of this region demonstrated that it
encoded the human homologue of the bovine NESP55 protein.
Further study of the new NESP55 sequence by PCR assays demonstrated that the
entire cDNA ofNESP55 was encoded by a single exon, contained within the same
PAC clone dJ309f20, that contains the XLas exon and exon 1-13 of GNAS1. After
hybridisation ofNESP55 and XLas-specific oligonucleotide probes to pulse-field gel
electrophoresis-separatedMini and Notl digests, it appeared that the NESP55 and
XLa exons were separated by a small (11 kb) Mlul fragment.
Bovine NESP55 is encoded by mRNAs in which exons 2-13 ofGNAS1 appear to
make up the 3' untranslated region. Just as for bovine NESP55, the stop codon of the
human NESP55 ORF is 5' to the splice junction with exon 2, so that none of the Gsa
coding region is included in the NESP55 ORF (Figure 3.14).
Figure 3.14. Schematic representation ofNESP55 cDNA clones. The 5' and 3'
untranslated regions are indicated by lines (the sequence in the 3' untranslated
mRNA corresponding to Gsa is represented by a broken line). G2-G7 are the
sequences corresponding to exons 2-7 ofGsa. The NESP55 open reading frame
(ORF) is boxed. The four different clones (a, b, c, d) represented were described by
Ischia et al. (1997), and derived from bovine adrenal medulla. Their sequences are
identical in the 5' untranslated region and the ORF but differ in the 3' untranslated
region. The positions of the components of a homologous human EST clone
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Figure3.14.Schematicrepresentat onofNESP55cDNAclones
Next, the dJ309f20 subclone libraries ofBamYll and Bglll fragments were screened
to identify subclones containing the NESP55 exon. One Bglll subclone, 34 F8
(referred to hereafter as subclone Bgl34) was further characterised by restriction
mapping and then by direct sequencing of the entire 5g/II-derived fragment.
3.3.7.1 Restriction mapping of subclone Bgl34
A restriction map of subclone Bgl34 was first constructed. Some representative
digests are shown in Figure 3.15.
1018 bp- ,,,,
506 bp - M
Figure 3.15. Restriction digests of subclone Bgl34. Lanes: M) 1 kb marker ladder;
enzymes used for digestion 1) Kpnl, 2) Mlul, 3) Mlul+Kprtl, 4) AgoMI, 5)
NgoMl+Kpnl, 6) Xhol, 7) Xhol+Kpnl, 8) Hindlll, 9) Hindlll+Kpnl, 10) Fspl, 11)
Fspl+Kpnl.
The restriction map of subclone Bgl34, deduced from these and other digests, is
shown in Figure 3.16.
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Figure 3.16. Restriction map of subclone Bgl34 (to scale).
(a) Map of the original PAC clone dJ309f20. (Left) The SP6 end of the PAC insert.
(Right) Exons 1-13 ofGNAS1 (modified from Hayward et al., 1998b).
(b) Expanded view of the Bgl34 insert; BgRl (B), Mlul (M), TVgoMI (Ng), Pvul (P),
















Figure3.16.Enzymaticrestric ionapofs b loneBgl34
3.3.7.2 Sequence analysis of subclone Bgl34
The Bgl34 subclone was eventually completely sequenced on both strands. Its insert
is 4330 nt in length. The annotated sequence of this subclone is shown in Figure
3.17.
Within this genomic sequence there are at least three regions of interest: (i) the
region containing the upstream sequence common to IMAGE clone 301896 and the
5'-RACE clone previouslymentioned (section 3.3.6); (ii) the NESP55 sequence
itself and finally, (iii) a sequence downstream ofNESP55, later identified as
corresponding to exon IV of the GNAS1 antisense transcript (see section 3.3.8 and
Chapter 4).
The first of these regions, (i), spliced in front of GNAS1 exon 2 in the IMAGE clone
301896 (accession no. W16881) is underlined in Figure 3.17 (nt 567-682). At the end
of this region, the presence of a cryptic splice donor site appears to account for the
splicing to exon 2. This clone had also been identified by Ischia et al. (1997) when
studying the NESP55 bovine sequence (Figure 3.14).
Region (ii) (the NESP55 ORF) is shown in bold in Figure 3.17. As described above
(section 3.3.6), this ORF is contained in a 5' RACE clone, that also contained
upstream sequences, including region (i) from IMAGE clone 301896. The RACE
clone, however, also contained an additional 0.9 kb of sequence, inserted between
region (i) and GNAS1 exon 2. As is the case also for bovine NESP55, the human
NESP55 stop codon is 5' to the splice junction with exon 2, so that none of the Gsa
coding region is included in the NESP55 open reading frame. The putative start
codon at nt 849 in Figure 3.17 is the first (and only) one following an upstream in-
frame stop codon (nt 685, double-underlined).
The characteristics of the human NESP55 protein sequence are further described in
the following section. Further analysis of the genomic sequence of subclone Bgl34
demonstrated that the NESP55 exon is contained within a CpG island that extends
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from nt 822 to nt 2839, basically delimited by two VgoMI sites (nt 820-826 and nt
2775-2780). Several restriction sites corresponding to methylation-sensitive rare-
cutting enzymes were identified within this CpG island.
Region (iii) in the Bgl34 genomic sequence is shaded in Figure 3.17. It represents
exon IV of an antisense transcript which is further described in section 3.3.8 and
chapter 4. This transcript is comprised of 5 exons (numbered I-V) and it has been
demonstrated that is imprinted, being expressed from the paternal chromosome only
(Hayward and Bonthron, 2000).
Figure 3.17. Complete sequence of subclone Bgl34. The sequence was derived from
genomic DNA and initiates at a Bglll site. It is contiguous with the RT-PCR-derived
cDNA sequence as far as the splice donor site (indicated by the change to lowercase
letters at position 1629), 42 nt beyond the NESP55 stop codon. The NESP55 coding
sequence is indicated in bold uppercase letters; the upstream in-frame stop codon is
double-underlined. The positions of the ends of 5' RACE clones, at nt 465, 490 and
517, are indicated by bold underlined nucleotides. The region spliced in front of
GNAS1 exon 2 in IMAGE clone 301896 (Acc. numberW16881) is underlined (nt
567-686). The sequence of the cDNA 088f21 corresponding to the antisense
transcript exon IV (AS-EXON IV) is shaded, nt 2678-2870 (described in section
3.3.8- and in Chapter 4), and the alternative splice site is indicated by a dashed line at
nt 2957 (as described by Hayward and Bonthron, 2000). Some of the restriction sites
















































































































































































3.3.7.3 Predicted NESP55 protein sequence analysis
The predicted translation product of the NESP55 cDNA has a molecular mass of
28,031 Da (Figure 3.18). The sequence ofbovine NESP55 had already been
determined (Ischia et al., 1997) but for further comparative analysis the murine
NESP55 amino acid sequence was also determined. (Dr. B.E. Hayward and Professor
Bonthron). This was done by BLAST searching, identifying an IMAGE cDNA clone
(746837) that contained part of the murine NESP55 homologue, after which the
complete sequence ofmurine NESP55 was determined from this cDNA clone and
from RT-PCR products derived from a pTC3 pancreatic islet-derived cell line.
The predicted human NESP55 translation product has 245 amino acid residues,
compared to 241 amino acids for bovine NESP55 and 253 amino acid for murine
NESP55. Human NESP55 is rich in glutamic acid (15%), arginine (11%) and proline
(11%). The C-terminal two-thirds of the protein (amino acids 75-245) contains a
number of repetitive motifs. One of the repetitive regions lies at the middle of the
predicted protein (amino acid residues 102-143). This sequence is a dipeptide repeat
in which every second residue is glutamic acid (E), of the form E-(T/S/P). Most of
the differences between human, bovine and murine NESP55 sequence occur within
these repetitive regions, whereas the first 50 amino acids are highly conserved
(Figure 3.18).
Analysis of the codon preference of the human NESP55 sequence suggests that
selective pressure is imposed at the DNA and not just at the protein level. Examples
of this are that of 37 Glu codons, 30 are GAG and seven are GAA (the proportion
expected from human codon preference tables is 21 GAG, 16 GAA). Similarly,
another example is that of 14 Thr codons, 12 are ACC, two ACT, 0 ACG, 0 ACA
(expected; five ACC, three ACT, two ACG, four ACA) (as deduced using the protein
sequencing analysis software at the HGMP MRC UK bioinformatics site).
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1 50
bovnesp mdrrsrpqlg rrarhnyndl cppigrraat allwlscsia llralatsst
humnesp mdrrsraqqw rrarhnyndl cppigrraat allwlscsia llralatsna
musnesp mdrrsraqqw rrarhnyndl cppigrraat allwlscsia llralassna
51 100
bovnesp raqqraaa.q rrtflnahhr s aaqv fpeppes... .dhedtdfep
humnesp raqqraaaqq rrsflnahhr s gaqv fpespesesd heheeadlel
musnesp raqqraa..q rrsflnahhr saaaaaaaqv lpessesesd heheevepel
101 150
bovnesp slpecpeyqe eefdyesete s..eseiese tefetesdta pttepetepe
humnesp slpecley.e eefdyetese t..eseiese tdfetepeta pttepetepe
musnesp arpecleydq ddyetetdse tepesdiese teietepete petepetepe
151 200
bovnesp depgpwpkr ptfhqslter lsalrlrspd aspsrappst qesesprqge
humnesp ddrgpwpkh stfgqsltqr lhalklrspd aspsrappst qepqsprege
musnesp derg...prg atfnqsltqr lhalklqsad asprraqptt qepesasege
201 250
bovnesp e....pedkd prdpeeseep keeekqqqhr ckpkkpt.rr dpspespskr
humnesp elk..pedkd prdpeeskep kee..kqrrr ckpkkpt.rr daspespskk








Figure 3.18. Multiple sequence alignment of bovine (bov), human (hum), and mouse
(mus) NESP55 amino acid sequences. The alignment was obtained by the analysis of
the sequences with the Pileup program. Residues in common between two or more
sequences are shaded (modified from Hayward et ah, 1998b).
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3.3.7.4 Allele-speciflc methylation in the region of the NESP55 exon
To assess the methylation status of the region containing the NESP55 exon, its
restriction map was referred to. The subclone Bgl34 was then digested with the
enzymes Kpnl and Fspl. The resulting 2.6 kb fragment (as marked in Figure 3.19)
was used as probe in a Southern blotting analysis (by Dr. L. Strain). This probe was
predicted to detect fragments containing a number of rare-cutting methylation-
sensitive restriction sites (Xhol, NgoMl,Mlul, Fspl and SacII). Parthenogenetic F.D.
or normal female control lymphoblastoid cell line DNA was double-digested with
Bglll and one of the methylation-sensitive enzymes. The analysis showed that for all
of these enzymes, in normal controls the Bglll fragment is partially resistant to
cleavage, indicating methylation of these sites on at least one allele (paternal).
Meanwhile in the parthenogenetic DNA all of the enzymes but Mlul cleaved the
Bglll fragment to completion. Therefore, these restriction sites are unmethylated on
the maternal allele, and methylated on the paternal one (Figure 3.19). It may be noted
that although most of the differentially methylated region lies within the NESP55
exon, one of the paternally methylated TVgoMI sites lies within an exon of the
paternally expressed antisense transcript.
Figure 3.19. Methylation analysis ofNESP55. Restriction sites whose methylation
status was examined are indicated above by - or + to indicate unmethylated or
methylated status, respectively, on maternal and paternal alleles. The hatched bar
indicates the probe used in Southern blotting in the present study. The methylation
indicated for the XLas exon and exon 1 is as described elsewhere (this chapter
section 3.3.4). The restriction enzymes used for the analysis are represented by letters
as described in Figure 3.11 and 3.16. The VgoMI site situated within exon IV of the


















3.3.7.5 NESP55 is expressed only from the maternal allele
As NESP55 and XLas exons were found to have an opposite methylation pattern, it
was also further investigated whether they also show opposite patterns of allele-
specific expression. For this purpose, RT-PCR analysis (by Dr. Hayward) was again
performed using fetal tissues known to be informative for the Fokl polymorphism in
exon 5.
The RT-PCR was made specific for NESP55 using a unique upstream primer. From
a total of 19 tissue samples from 6 informative fetuses, uniform results were obtained
in several tissues. In each case NESP55 transcripts were exclusively derived from the
maternal allele.
3.3.8 ANTISENSE TRANSCRIPT AT THE GNAS1 LOCUS
Once the complete sequence of the Bgl34 subclone had been obtained, the whole
sequence was used for further database searches using BLAST. Besides the NESP55
cDNA sequences identified as matching region (ii) of the genomic clone, region (iii)
of the sequence, as alluded to above, also identified another distinct EST (Ace.
number T84962). This EST had in fact also already been identified during the
analysis of another genomic subclone derived from PAC dJ309f20 (the already
mentioned BamC6, lying further downstream towards XLas). The IMAGE clone
111764 (named 088f21 by the UK HGMP Resource Centre) corresponding to this
EST was then completely sequenced (as described in Chapter 4).
The same transcript was again later identified by further BLAST searching, using the
complete sequence, later obtained in our laboratory, of the region between NESP55
and XLas in human and mouse. Further RT-PCR and 5'-RACE experiments
indicated that the cDNA 111764 was part of a bigger transcript composed of 5 exons,
and 1.1 kb in total length. Comparison of the cDNA sequence to the genomic
sequence showed that this transcript was spliced, and must have been transcribed in
the antisense direction relative to NESP55. Furthermore, it was also later shown that
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this antisense transcript is imprinted, being expressed from the paternal chromosome
only (Hayward and Bonthron 2000).
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3.4 DISCUSSION
In the present chapter, I have described studies carried out on the GNAS1 gene as
part of a project aimed at elucidating new aspects of its genomic structure and its
complex pattern of imprinting. It became clear that the original description of the
GNAS1 gene structure (Kozasa et ah, 1988) was incomplete. Furthermore, the new
information obtained during this study has gone some way towards resolving the
confusion over the imprinting status of GNAS1. In particular, it is now clear that the
conclusions drawn from earlier studies of GNAS1 expression were somewhat
misleading, since these studies (Campbell et ah, 1994, Williamson et ah, 1996) did
not attempt to distinguish the expression of the differently imprinted GNAS1
transcripts.
During the course of the present studies, new exons of GNAS1 were defined, and it
was also shown that the promoters upstream of these novel exons display a complex
pattern of allele-specific expression. The new, extended GNAS1 gene encodes three
different products:
(i) the a subunit of the stimulatory G protein Gs; this is the major product in
most tissues, and was shown by RT-PCR specific for exon 1 to be
biallelically derived in several human fetal tissues. This fact explains the
biallelic expression previously observed using an RT-PCR assay that did not
distinguish the different GNAS1 gene products (Campbell et ah, 1994).
(ii) NESP55, a neuroendocrine secretory granule protein, expressed exclusively
from the maternal allele.
(iii) XLas, a plasma membrane associated, adenylate cyclase-activating Gs
variant protein, that is expressed exclusively from the paternal allele.
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Both NESP55 and XLas display a similar pattern of tissue distribution, being
expressed at highest level in neuroendocrine tissues including the pituitary, the
adrenal medulla, and certain parts of the brain. However, RT-PCR analysis showed
that these proteins are strictlymonoallelically derived, even in tissues with only a
very low level of expression (Hayward et al., 1998a, b).
In addition to these protein-coding transcripts, a novel non-coding antisense
transcript was later identified at the GNAS1 locus. This spliced transcript originates
-2 kb upstream ofXLas, and terminates -20 kb upstream ofNESP55. It is expressed
from the paternal allele, and has been hypothesized to have a role in suppressing the
paternal NESP55 promoter by some cis-acting mechanism (Hayward and Bonthron,
2000). A similar transcript has also been identified in the mouse Gnas gene (Wroe et
al., 2000) and sequence comparisons between human and mouse show the antisense
promoter and first exon to be highly conserved, further suggestive of an important
functional role for the antisense trancript (Hayward and Bonthron, 2000).
Although, as mentioned above, Gsa-encoding transcripts are predominantly biallelic,
it does appear that there is predominantly monoallelic expression in certain cell
types. In our laboratory, for example, it has been recently demonstrated that Gsa is
predominantly maternally derived in the human adult pituitary. This correlates with a
strong maternal bias in the allelic origin of the activating gsp mutations of codon 201
and codon 227 in growth hormone-secreting pituitary adenomas; 21 out of 22 such
mutations were found to occur on the maternal allele (Hayward et al., 2001).
3.4.1 GNAS1 GENE STRUCTURE
As originally described by Kozasa et al. (1988), the human GNAS1 gene comprised
13 exons and 12 introns, spanning -20 kb in 20ql3. However, further studies carried
out by a number of different research groups later identified new exons of this gene.
The first new exon described was named exon A (also referred to as 1A in the
mouse; Liu et al., 2000a) and is located 2.5 kb 5' to the original exon 1 (Ishikawa et
al., 1990, Swaroop et al., 1991).
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The remaining novel GNAS1 exons were identified as described in this thesis. All but
one of these novel exons (the exception being exon 3N, that is located in the intron
between the originally described exons 3 and 4) are located at the 5' end ofGNAS1,
in the order: NESP55-XLas-A20-A21. NESP55, the most 5' of these exons, is
located ~ 49 kb upstream of the original exon 1. The XLas, A20 and A21 exons are
located ~ 35 kb from exon 1 (Figure 3.20).
Like exon 1 and exon 1A, these new exons at the 5' end of GNAS1 are alternatively
spliced onto exon 2 of this gene. Although the original XLas-containing IMAGE
cDNA clone contained also exons A20 and A21, RT-PCR experiments indicate that
most XLas-containing transcripts do not contain the A20/A21 exons. Furthermore,
as A20/A21-containing transcripts do not have a continuous open reading frame,
they may be unimportant splice forms. Like the XLas exon, the NESP55 exon, too,
is spliced onto GNAS1 exons 2-13. However, unlike XLas, the open reading frame
ofNESP55 is contained entirely within its own exon, so that the downstream splicing
events should not affect the function of the encoded protein. NESP55 transcripts
terminating in exon 3N should therefore be functional (whereas XLas transcripts that
use this alternative terminal exon presumably are not).
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Figure 3.20. Genomic structure of the GNAS1 gene.
A) Map (to scale) obtained from the analysis ofPAC clone dJ309f20. (Left) The
SP6 end of the PAC insert and NESP55 and XLas exons. (Right) Exons 1-13 of
GNAS1 (as originally described by Kozasa et al., 1988) are indicated by an
inverted brace. The exon A has been described by other groups (Swaroop et al.,
1991, Liu et al., 2000a).
B) Map (not to scale) showing the organisation of the XLas region of GNAS1 and
the new exons identified. Some of the restriction sites referred to in the text are
shown for reference: S, Sad; B, BamHl; As, Asd. The distance between the two
Asd sites is ~ 30kb. The 2479 bp genomic region that was sequenced is indicated
between the S and B sites. The exon A20 is in black; other exons are grey or


























When the translated open reading frame of human XLas was compared with the
corresponding predicted rat protein sequence, it was noted that there are well-
conserved regions at the N- and C- terminal extremes of the XLas segments. The
central, repetitive part of the protein sequence, however, is much less well conserved,
although qualitatively similar features do appear to be present in both species. As
mentioned previously, the rat XLas protein has a tetrapeptide repeat, based on
EPAA, while the predicted human protein has a tripeptide motif that is again rich in
proline and alanine and in an acidic amino acid residue (aspartate rather than
glutamate as in the rat protein).
The precise significance of such repeats is not clear, although they have been noted
to occur frequently in imprinted genes (Neumann et al., 1995a, b). There are some
interesting parallels between the XLas repeats and those within the p57KIP2 protein
encoded by the imprinted gene CDKN1C (1 lpl5.5). In the mouse, pS?101*2 has four
structurally distinct domains: an amino terminal CDK (cyclin-dependent kinase)
inhibitory domain, a proline-rich domain (25% proline), an acidic repeat domain and
a carboxy-terminal domain. In humans, although a repetitive proline-rich domain is
again present, it is not well conserved in sequence, consisting in this case of a PAPA
(proline-alanine) repeat (Matsuoka et ah, 1995).
In the rat XLas protein, the repeat domains form two of a total of four domains that
have been defined. These are: an EPAA repeat domain (residues 37-104), an ARAA
repeat domain (103-187), a proline-rich domain (205-228) and a cysteine-rich
domain (237-304) (Ugur and Jones, 2000). XLas has been proposed to comprise two
functionally independent units that are connected by the proline rich region. The
cysteine-rich region (which is palmitoylated and contributes to the membrane
attachment ofXLas), the C-terminal region of the XL domain (which is implicated
in the (3y-subunits binding) and the as domain are all suggested to belong to one unit
that exerts all Gsa-type functions ofXLas. The other unit, whose function is as yet
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unknown, comprises the alanine-rich repetitive region of the XL domain (Klemke et
ah, 2000, Pasolli et ah, 2000).
As mentioned, XLas behaves in many but not all ways in a functionally similar
fashion to Gsa: it forms a heterotrimer with Py-subunits, binds GTP and undergoes a
conformational change upon GTP binding. In the GTP-bound state, it also activates
adenylate cyclase. However, XLas does not appear to be activated by known Gsa-
coupled receptors (Pasolli et ah, 2000).
Immunofluorescence and subcellular subtraction analyses demonstrated that XLas
and its truncated splice variant referred to as XLaN 1 (derived from use of exon 3N)
are neuroendocrine-specific proteins expressed in many but not all, neuroendocrine
cells (Klemke et ah, 2000). The main cellular localisation ofXLas is to the plasma
membrane (Klemke et ah, 2000), with a minor proportion being associated with the
Golgi complex (Ugur and Jones, 2000, Klemke et ah, 2000).
As described above, the demonstration that transcription of the XLas mRNA was
exclusively from the paternal allele represented the first molecular confirmation that
GNAS1 was indeed an imprinted gene. Nonetheless, the identification of a transcript
that was paternally expressed was puzzling; it had been expected, given the pattern
of inheritance recognized in PHP-la families, that a maternally, rather than a
paternally expressed transcript, might account for this parent-of-origin dependence.
IfXLas were to be implicated in the pathogenesis of PHP/PPHP, its paternal
monoallelic expression would demand consideration of the following issues: Firstly,
how could a paternally inherited mutation (presumably resulting in reduced function
ofboth Gsa and XLas) have a less severe effect than a maternal one, that
presumably affected Gsa but not XLas?. Secondly, it had been previously shown in
the mouse that the Gnasl paternal allele was preferentially expressed in the renal
glomerulus (Williamson et ah, 1996). It was not clear how or if this reflected
imprinting of the XLas transcript. In contrast, at least at the whole organ level,
GNAS1 in humans showed no evidence for tissue-specific imprinting (at least in the
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fetal tissues examined) (Campbell et al., 1994). However, these earlier studies had
not distinguished transcripts derived from the various different GNAS1 promoters.
Because of the inability to reconcile all these different pieces of evidence, it still
seemed at least possible that there might be yet other classes of transcript derived
from GNAS1 that were exclusively maternally rather than paternally derived, at least
in some tissues. A systematic search for GNAS1 transcripts with alternative 5' ends
resulted in the identification of another novel 5' exon, encoding NESP55.
3.4.3 NESP55 EXON
NESP55, the neuroendocrine secretory protein 55000, was first identified
fortuitously, during screening of cDNA libraries from bovine chromaffin cells with
an antibody against secretogranin II. NESP55 belongs to the group of acidic proteins
known as chromogranins. Chromogranins are expressed in neuronal and endocrine
tissues, and secreted from large dense core vesicles. They have between 200 and 700
amino acid residues, with glutamic acid as their most abundant amino-acid residue.
The chromogranins are classified into five groups: chromogranins A and B,
secretogranins I and II, and the so-called VGF group. Within their primary amino
acid sequences, several pairs of basic amino acids are found that are used as cleavage
sites for endopeptidases. An example is the C-terminal octapeptide GAIPIRRH
isolated from bovine chromaffin granules and from adrenal gland where 40% of
NESP55 is processed to the peptide GAIPIRRH (Bauer et al., 1999).
The evidence that supports the classification ofNESP55 as a member of the
chromogranins is as follows: like other chromogranins NESP55 is characterised by a
high abundance of acidic amino acids (21%); it is heat stable, and it is localised to
the soluble content of the large dense core vesicles of the adrenal medulla, brain and
endocrine tissues (Ischia et al., 1997). As mentioned above, cDNA clones containing
the NESP55 sequence were first isolated from bovine chromaffin cell libraries. One
of these clones was 1499 nt in length with an open reading frame coding for a protein
of 241 amino acids with a predicted molecular mass of 27, 494 D (Ischia et al.,
1997).
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NESP55 was localised within the cell to the large dense secretory vesicles, and in
terms of its tissue distribution, is most highly expressed in the adrenal medulla, in the
anterior and posterior pituitary and in various regions of the brain. In the rat,
NESP55 was not detected in any of the cortical areas of the brain, but it was present
in the basal ganglia, hypothalamus and midbrain, particularly those areas rich in
noradrenergic, adrenergic and serotonergic neurons (Bauer et al., 1999).
In our studies on human NESP55, we assigned the initiation codon as the first ATG
occurring after an in-frame upstream stop codon at nt 685 of our sequence. This
indicated that the predicted NESP55 protein product is 245 amino acid residues in
length (vs 241 for bovine and 253 residues for murine NESP55), with a predicted
molecular mass of 28, 031 Da. Human NESP55 is rich in glutamic acid, arginine and
proline. The C-terminal two thirds of the protein (including amino acids 75-245)
contains a number of repetitive motifs, and it is within this region that most of the
differences between human, bovine and murine NESP55 occur.
It is noteworthy that on sucrose gradient centrifugation, NESP55 was found to
copurify with secretogranin II, as had also been reported for XLas, and also that both
NESP55 and XLas have a similar tissue distribution. Both of these proteins are
encoded by the GNAS1 gene, and yet they do not share any protein-coding
sequences, since their open reading frames do not overlap. Furthermore, their
respective promoters are oppositely imprinted.
One additional consideration that results from the opposite imprinting patterns of the
overlapping NESP55 and XLas transcripts relates to splicing specificity. In
particular, it would appear necessary to propose that the splicing ofNESP55 to exon
2 must be strongly dominant over XLas splicing to the same acceptor site. This
conclusion can be reached because the maternally derived nascent transcripts from
the NESP55 promoter must contain all the exons NESP55, XLas and 1-13. If any
splicing ofXLas to exon 2 occurred in these transcripts, it would show up in RT-
PCR experiments as maternally expressed XLas mRNA, and yet none is identifiable.
Possibly therefore, the splicing of the NESP55 transcript occurs in a strictly
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directional 5' to 3' fashion, whereby selection of the most upstream splice donor site
by some form of "scanning" mechanism results in removal of the XLas exon during
the first splicing event, before any XLas-exon 2 splicing can occur.
One additional unusual feature of the NESP55 mRNA is that exons 2-13 do not form
any part of its coding region, but rather are entirely contained within the 3'
untranslated region of the mRNA. The presence ofmultiple introns within 3'
untranslated regions is otherwise unusual in mammalian genes.
Bovine NESP55 appears to be proteolytically processed within the chromaffin
granule to smaller peptides that have been proposed to be physiologically active. One
peptide in particular, comprising the residues Leu-Ser-Ala-Leu (LSAL), a
tetrapeptide sequence which has been named 5-hydroxytryptamine-moduline and is
flanked by arginine residues, was thought suitable for cleavage by prohormone
convertases. LSAL is an endogenous antagonist of the serotonergic 5-
hydroxytryptamine IB receptor subtype, and (before the sequence of human NESP55
described here was known) it had been considered that the LSAL peptide in humans
might contribute to the pathophysiology of serotonergic transmission disorders
(Ischia et al., 1997, Kim et al., 2000).
However, in our human NESP55 sequence, we have found that the amino acid
sequence corresponding to the LSAL tetrapeptide in bovine NESP55 is not
conserved, being LHAL in humans (as is also the case in mouse). It is therefore far
from clear whether NESP55 is the physiological precursor for the LSAL peptide,
which also calls into question its postulated involvement in modulating serotonergic
transmission. One genetic association study has been performed to address the
proposed involvement ofNESP55 in patients suffering from autistic and obsessive
compulsive disorders (Kim et al., 2000). In this study, six polymorphisms that do not
change the amino acid sequence were identified, as well as a deletion of 24 bp in the
coding region that results in the in-frame deletion of 8 amino acid residues. In the
family under analysis (suffering from obsessive compulsive disorder) only
heterozygotes for the deletion were identified, they got the mutated alleles from their
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mothers and had a variable clinical presentation with no specific symptoms or
phenotype and even one clinically normal individual was described.
The finding of a phenotypically normal subject who has a mutated allele ofmaternal
origin may suggests the possibility that the deletion does not critically compromise
NESP55 function or that it may have a supplementary role as a risk factor (Kim et
al., 2000).
3.4.4 ANTISENSE TRANSCRIPTS AND REGULATION OF IMPRINTING
OF THE GNAS1 LOCUS
Only 14 kb separates the maternally active NESP55 promoter from the exclusively
paternally active promoter that directs the synthesis ofXLas. The proximity of these
promoters suggests the possibility of co-ordinate regulation in a reciprocally,
mutually exclusive allele-specific manner. One hypothesis to explain how NESP55
and XLas promoters may regulate each other invokes mutual suppression in cis. This
might be exerted as a consequence of transcription originating at one promoter and
extending across the other promoter region. Such a mechanism has been shown to be
involved in regulating the maternally expressed Igf2r gene. In this system, a
paternally expressed antisense transcript originates from a differentially methylated
region within intron 2 of the gene and is transcribed across the upstream sense Igf2r
promoter. Deletion of the intronic DMR results in loss of the antisense transcript and
biallelic transcription from the sense promoter, providing direct evidence for a cis-
effect of the antisense transcript (Wutz et al., 1997).
A specific search for transcripts within the NESP55-XLas genomic interval
(Hayward and Bonthron, 2000) resulted in the demonstration that the maternally
methylated region 2-3 kb upstream of the XLas exon gives rise to a spliced
polyadenylated antisense transcript which spans the upstream NESP55 region. This
antisense transcript was shown to be imprinted and expressed only from the paternal
allele (Hayward and Bonthron, 2000) (Figure 3.21).
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Figure 3.21. Map of the region of the GNAS1 locus containing the antisense exons.
A) The exons NESP55, XLas and the originally described Gsa exons 1 to 13 are
shown for orientation (map to scale). B) The antisense exons (roman numerals) are
shown as open rectangles and the NESP55 and XLas exons as filled rectangles. The
arrows show the direction of the transcription and the respective active chromosome
is indicated bypat (paternal-specific transcription) or mat (maternal-specific
transcription). Some of the splicing patterns observed for the antisense transcript are




















The mechanism of action of such putatively regulatory antisense transcripts has not
been defined. However, the importance ofRNA as a regulatory molecule for
imprinting may lie in its ability to act genetically in cis, unlike proteins which must
be translated in the cytoplasm and then reimported into the nucleus before acting.
This kind of direct link between imprinting and cA-inactivation has also been studied
in the context ofX-inactivation. In mammals, X inactivation requires the action of a
control switch called the "X inactivation centre" (XIC). The cis-acting silencing
function of the XIC requires the action ofXist, an XIC gene that produces an
untranslated RNA which appears to "coat" the inactive X (Lee and Lu, 1999).
In addition to Xist, an antisense gene named Tsix (downstream ofXist) has also been
identified within the XIC, and is thought to act as an Xist regulator. Targetted
deletions of Tsix in female and male mouse cells have shown that despite a
deficiency of Tsix RNA, female cells still inactivate one X, while in male cells X
inactivation is blocked. Thus, X chromosome counting remains intact in the absence
of Tsix. However, heterozygous female cells showed skewedXist expression and
primary non-random inactivation of the mutant X. Therefore, it appears that Tsix
regulates Xist in cis and determines X chromosome choice without affecting
silencing (Lee and Lu, 1999).
Antisense transcripts have been described to be associated with a number of other
imprinted genes, including for example: human KVLQT1 and UBE3A, and mouse
Igf2r and Igf2. KVLQT1 is a potassium channel gene, mutations within which cause
the long QT syndrome. The KVLQT1 gene also encompasses a cluster of Beckwith-
Wiedemann syndrome (BWS) chromosomal rearrangement breakpoints in 1 lpl5.5.
As discussed in the identification of a paternally expressed transcript in an antisense
orientation within KVLQT1 has revealed that abnormal imprinting of this transcript,
named LIT1, occurs in some cases of BWS (Figure 3.22) (Lee MP et al., 1999a,
Mitsuyaet al., 1999).
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Figure 3.22. KVLQT1 antisense transcript. The diagram shows the exon-intron
structure ofKVLQT1 and the position of the intronic, differentially methylated CpG
island KVDMR1. The directions of transcription of the maternally expressed
KVLQT1 gene and of the paternally expressed antisense transcript KVLQT1-AS (or
LIT1) are indicated by a grey and a dark arrow, respectively. Map to scale (modified












Figure3.22.KVLQTlantisensetra script(KV QT1-ASorLI 1)
Methylation analysis revealed that a CpG island associated with LIT1 was
specifically methylated on the silent maternal allele. Furthermore, it was
demonstrated that a high proportion of patients with sporadic BWS showed complete
loss ofmaternal methylation at this CpG island, together with biallelic LIT1
expression. This suggested that the antisense transcript might be involved in the
development ofBWS. Precisely how this aberration of imprinted antisense
transcription results in BWS has not been demonstrated, although it is possible that a
pathway involving suppression of the activity of the nearby CDKN1C gene is
involved (the latter is mutated in a high proportion of familial BWS cases). The
mechanism whereby LIT1 transcription is activated is also not clear. It has been
proposed that the LIT1 CpG island may serve as an insulator between KVLQTI and
its enhancer; according to this model, methylation of the CpG island would interfere
with both insulator function and LIT1 expression (as has also been suggested for a
CpG island near H19 and IGF2). When the CpG island is unmethylated, as it is on
the paternal chromosome, it effectively blocks KVLQTI from its enhancer, both
competing for the enhancer on the same chromosome (Figure 3.22) (Lee MP et al.,
1999a, Mitsuya et al., 1999).
In the case of the antisense transcript described at the UBE3A locus 15ql 1 -ql 3, the
transcript displays a pattern of imprinting that is opposite to that of UBE3A, with
preferential expression from the paternal allele in brain. Their location, orientation
and expression profile may indicate that the sense and antisense transcripts compete
for common regulatory elements. The tissue specificity of the imprinting of UBE3A
could thus be regulated indirectly by the expression of the antisense transcript. This
model would suggest that in tissues where the antisense transcript is monoallelically
(paternally) expressed (such as brain), UBE3A can only be expressed from the
antisense-silent maternal chromosome (Figure 3.23) (Rougeulle et al., 1998).
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Figure 3.23. UBE3A antisense transcript. Map (to scale) of the 3' end and the
downstream region of the UBE3A gene. Coding exons 11, 12, 15 and 16 of UBE3A
are represented by the dark grey boxes, and the downstream transcript by the
narrower marbled grey box. The antisense transcript is represented by the dark box
below the UBE3A locus. This transcript is intronless, and covers at least the 3' half of
UBE3A (from exon 11 to the 3' end) and additional sequence downstream; its 5' end
is 6.5 kb from the stop codon of UBE3A. The arrows indicate the direction of














The non-coding imprinted transcripts seem to be located at least partly within
protein-coding imprinted genes (the exception being HI9), and are transcribed in the
antisense direction relative to the coding transcript. Their sizes range from 1 -2 kb to
more than 100 kb (Lyle et al., 2000), but a common feature seems to be that they
traverse one or more sense exons of the gene with which they are associated. Also
noteworthy is the fact that so far all the antisense transcripts described within
imprinted genes are expressed from the paternal chromosome, although the small
number described so far means that this may be due to chance. As far as the antisense
transcript in the upstream region of GNAS1 is concerned, its importance for the
regulation of the locus seems to be indicated by the fact that its putative promoter
region is highly conserved in the mouse, presumably due to selective constraints
(Hayward and Bonthron, 2000). Aspects of the mouse Gnas locus are discussed
below.
3.4.5 GNAS1 LOCUS IN MOUSE
The Gnas locus on distal chromosome 2 in the mouse has, like its human
counterpart, recently been subjected to detailed scrutiny from an imprinting point of
view. Besides the Nesp and Gnasxl exons, in locations corresponding to those of the
human gene, an antisense transcript, named Nespas, has been identified. In addition,
exon 2 of Gnas has been used as the target for an insertional knockout, and
observations of this mouse have lead to several new hypotheses regarding the
regulation of this locus.
By using representational difference analysis (RDA) to search for regions of
differential methylation, Kelsey et al. (1999) identified a sequence that was highly
homologous (98.4%) to the bovine cDNA for NESP55. They also identified the
murine Gnasxl exon (corresponding to human XLas) in this screen and showed that
Nesp and Gnasxl were exclusively maternally and paternally expressed, respectively,
as in humans. As in human, despite their opposite imprinting Gnasxl and Nesp are
part of the same transcription unit as Gnas, the Gnasxl and Nesp transcripts being
alternatively spliced onto exon 2 of Gnas.
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In addition to this imprinting of the upstream promoters, evidence from the Gnas
knockout suggests that Gsa-encoding transcripts of Gnas are monoallelically
expressed in a tissue-specific manner, in proximal renal tubules (Yu S et al., 1998),
and also in brown and white adipose tissue (Yu S et al., 2000). This appears to be the
case since in these tissues, the Gsa protein and mRNA levels are much lower in mice
in which the null allele is maternal, than in those in which it is paternal.
The Gnas/GNAS1 locus was the first example of a cluster of imprinted genes in
which two oppositely imprinted transcripts share the same exons. As in humans, the
possibility was suggested of an expression competition model, in which methylation
regulates the availability in cis of shared regulatory elements. This could account for
the opposite imprinting ofNesp and Gnasxl, and might furthermore involve the
activity of an antisense transcript named Nespas, which as in the human gene, was
identified in the region between Gnasxl and Nesp (Li et al., 2000, Wroe et al., 2000).
Specifically, it was postulated that Nespas (paternally expressed), may repress the
expression ofNesp in cis from the paternal allele. Nespas in that sense could be
regarded as an "imprintor" and Nesp as the imprinted target. This situation could lead
to non-expression of the sense transcript by any of the following mechanisms:
occlusion of the sense promoter, inactivation of the paternal allele by localised
"heterochromatinisation", or competition for shared transcription factors or
enhancers between the sense and antisense promoter. An expression competition
model in which methylation regulates the availability of shared regulatory elements
also could account for the expression ofNesp and lack of expression ofGnasxl from
the maternal allele (Wroe et al., 2000).
The phenotypes described for mice heterozygous for a Gnas knockout denote further
effects of imprinting at this locus. In particular, it was observed that when the
knockout is inherited paternally, the resulting mice have a hypoactive phenotype
resembling that found with the maternal disomy, whereas in contrast when the null
allele is maternally inherited, the mice have a hyperactive phenotype similar to that
found with the paternal disomy (Yu S et al., 2000).
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It has been also observed that the heterozygous knockout mutation in Gnas (an
insertional disruption of exon 2) leads to opposite effects upon energy metabolism,
resulting in obesity when present on the maternal allele (m-/+) and to leanness when
present on the paternal allele. The homozygotes (-/-) all die during early postnatal
implantation development. It is interesting that like the m-/+ mice, humans with
PHP-la develop obesity, although the physiological mechanism causing obesity in
these patients is not defined yet. Overall, the phenotypes resulting from Gnas
knockout were felt to support the hypothesis of conflicting parental goals driving the
evolution of imprinting, since disruption of the paternal allele leads to decreased
prenatal growth, failure to suckle at birth and markedly reduced accumulation of
energy store postnatally, whereas disruption of the maternal allele leads to opposite
effects (Yu et al., 2000).
More recently, those transcripts originating in the exon 1A region (2-3 kb upstream
of exon 1) have been studied in both the mouse and human by Liu et al. (2000b).
These authors have shown that exon 1A generates mRNAs only from the paternal
allele. Furthermore, this region comprises a new DMR, being methylated exclusively
on the maternal allele. The methylation in this region is established during
gametogenesis and maintained through pre-and postimplantation development and
therefore this upstream region can be considered as a methylation imprint mark. The
suggestion was made that the exon 1A region may act as a centre that controls or
initiates imprinting of the Gnas locus, including the tissue-specific imprinting of the
exon 1 transcripts. However, these authors also showed that the exon 1A DMR is
methylated in all somatic tissues, while Gsa is only imprinted in some. One
possibility is that exon 1A contains binding sites for tissue-specific repressors that
can bind to the paternal allele but are unable to bind to the maternal allele because its
binding site is methylated. An alternative model would be that exon 1A contains a
boundary element that blocks activation of the Gsa promoter by an upstream tissue-
specific enhancer on the paternal allele but does not block promoter activation on the
maternal allele because it is methylated (Liu et al., 2000a).
216
Additional evidence suggesting the regulatory importance of the exon 1A region
came from analysis ofpatients with PHP-lb, in which there is a tissue-restricted
hormone resistance, involving the PTH target tissues but not the other endocrine
targets that are affected in PHP-la. All the PHP-lb patients examined had abnormal
methylation of the exon 1A region, such that both alleles appeared to have a paternal
methylation pattern (Liu et al., 2000b). In some but not all patients the abnormal
methylation also involved the far upstream NESP/XLas region. The precise nature of
the mutation underlying this epigenetic alteration has not yet been defined. However,
it is proposed that the presence of a paternal epigenotype on the maternal allele
results in loss of the normally monoallelic expression ofGsa transcripts in the
proximal renal tubule. This tissue would be selectively sensitive to this imprinting
defect, since in other tissues Gsa transcripts are normally biallelic and hence
transcription would not be lost.
Evidence that Gsa transcripts are imprinted in another tissue, the human pituitary
gland, has also recently been obtained (Hayward et al., 2001). Using normal
pituitaries from individuals heterozygous for the polymorphism in exon 5 of GNAS1,
RT-PCR products from exon 10 to each of the unique first exons were generated.
These RT-PCR products were thus specific for the Gsa, XLas and NESP55
transcripts. It was clear from this analysis that the Gsa transcript in the pituitary,
unlike those other tissues that had been previously assessed, has a mono-allelic
(maternal) expression.
Relaxation of this imprinting of Gsa was further observed in analyses of growth
hormone-secreting pituitary adenomas. While some 40% of such tumours possess
gsp mutations that constitutively activate Gsa (see section 3.1.7.1.2) 60% of
somatotroph adenomas do not possess gsp mutations. In normal human pituitary and
non-functional adenomas, it was found that Gsa was either expressed exclusively
maternally or very strongly biased towards the maternal allele; in contrast in pituitary
somatotroph adenomas it was shown that the Gsa expression was often
approximately biallelic, indicating that relaxation of the Gsa imprinting had occurred
during tumorigenesis (Hayward et al., unpublished results).
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As described in this chapter, the regulation ofGNAS1 has proved far more
complicated that originally thought, as this gene has been proved not only to be
imprinted but also to have a particularly complex pattern of expression, with
paternally (XLas), maternally (NESP55 and Gsa- pituitary) and biallelically derived
products (Gsa in most tissues). Furthermore, the presence of the possibly regulatory
imprinted antisense and exon 1A transcripts adds further complex possibilities to the
mechanisms of regulation of this locus. Further experimental studies are needed to
assess the specific roles of the antisense transcript and exon DMR A1 in the
regulation of the Gnasl/GNASl locus.
The splicing patterns observed for the GNAS1 transcriptional unit are shown in
Figure 3.24.
218
Figure 3.24. Splicing patterns observed for the GNAS1 transcriptional unit (not to
scale). The GNAS1 locus on chromosome 20ql3 is shown at the centre (B) of the
figure. The translated regions are shown in grey. The arrows indicate transcriptional
active promoters. The figure shows the allele-specific methylation and expression
patterns of the transcripts on the maternal (A) and paternal (C) alleles. The grey lines
above and below the exons represent the splicing patterns observed for the region.
A) Maternal allele.- The XLas and exon A regions are methylated. The maternally
expressed NESP55 entire coding region is located in its first exon, the stop codon of
the ORF is 5' to the splice junction with exon 2, so that none of the Gsa coding
region is included in NESP55. The asterisk above the arrow corresponding to the
transcriptional active promoter of exon 1 is to indicate that although Gsa is
biallelically expressed in most tissues, its expression is preferentially maternal in
human pituitary gland.
B) GNAS1 locus.- At the right of the figure the original gene structure of GNAS1
formed by exons 1 to 13 is shown; the exon A (~2kb 5' to exon 1) is also shown .The
newly described exons NESP55 and XLas are indicated as dark rectangles. The
antisense exons (roman numerals) are shown as open rectangles. The arrow shows
the direction of the transcription of the antisense transcript indicated bypat (paternal-
specific transcription). Some of the splicing patterns observed for the antisense
transcript are shown.
C) Paternal allele. On the paternal allele the NESP55 region is methylated, and
there is transcription starting at the promoters of exons XLas, A and 1. XLas and
Gsa proteins have identical COOEl-terminal domains, while their unique NH2-
terminal domains are encoded within their respective first exons. The information in
the figure is derived and/or modified from Kozasa et al., 1988, Ishikawa et al., 1990,
Swaroop et al., 1991, Hayward et al., 1998a and b, Hayward and Bonthron, 2000,







































SCREENING FOR NEW GENES IN SUBCLONE LIBRARIES
DERIVED FROM PAC DNA CLONES THAT MAP TO
CHROMOSOME 20q13
CHAPTER 4. SCREENING FOR NEW GENES IN SUBCLONE LIBRARIES
DERIVED FROM PAC DNA CLONES THAT MAP TO CHROMOSOME
20ql3
4.1 INTRODUCTION
There is considerable evidence that one characteristic of chromosomal regions
regulated by genomic imprinting is the presence of clusters of imprinted genes. A
further intriguing aspect, that must be of central relevance to the mechanisms for
regulating imprinting in such regions, is the presence in at least two of the best
characterised of these clusters (chromosomes 1 lpl 5 and 15ql 1 -q 13) of non-
imprinted genes interspersed with imprinted genes (Buiting et al., 1995, Lee MP et
al., 1999b, Ohta et ah, 1999a and b).
How these imprinted genes are co-ordinately regulated is not entirely clear at present,
but nonetheless the available information does clearly indicate that the chromosomal
distribution of imprinted genes is non-random. As a consequence, several imprinted
genes have been identified purely by positional criteria. It remains to be explained,
however, why other genes mapping within these same regions (and even,
furthermore, located between a pair of two similarly imprinted genes) nevertheless
escape imprinting (Yuan et al.,1996, Zubair et ah, 1997, Lee MP et ah, 1999b, Ohta
et ah, 1999a and b).
One hypothesis that is often invoked to explain the coordinate regulation of an
imprinted gene cluster involves the action of a long distance control mechanism in
these regions. Regardless of the precise control mechanisms, though, a direct
implication of the existence of these co-regulated clusters is that once a new gene has
been characterised as imprinted, the likelihood that there may be other imprinted
genes in the same chromosomal region can be investigated (Caspary et ah, 1998, Lee
et ah, 1999b, Bell and Felsenfeld, 2000, Hark et ah, 2000). We pursued this line of
investigation in the case of distal chromosome 20ql3. After characterising GNAS1 as
a complex imprinted gene (Hayward et ah, 1998a and b), there was considerable
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interest in identifying any other genes that may be in this region, upstream and
downstream of GNAS1, in order to assess whether they might form additional
components of a larger co-regulated imprinted gene cluster.
The approach that was taken to identifying new genes in this region was first to
identify overlapping PAC clones that contained GNAS1 and the regions upstream and
downstream of it, and then to construct plasmid subclone libraries derived from these
PAC clones. The inserts of a representative number of these subclones were then
sequenced at both ends and used to search EST databases using the BLAST
algorithm. The sequences were also analysed using the HGMP NIX interface to a
variety of programs for predicting structural features ofDNA sequences. In the
longer term, once a putative novel gene was identified, further cDNA and genomic
structure analyses were pursued, in order to determine the gene structure and address
its imprinting status.
Initially, it was known from the screening of the RCPI1 PAC library that four clones
(dJ60ol6, dJ63n2, dJ11 Op 14 and dJ309f20) contained sequences from GNAS1. Only
one of these (PAC dJ309f20) contained the complete gene sequence, while the other
three clones overlapped the downstream region of GNAS1 (corresponding to the TV-
end of dJ309f20). Subclone libraries in the vector pUC18 were constructed, with
inserts derived from digestion ofPAC dJ309f20 DNA with the restriction enzymes
BamHl or Bglll. In addition, the sequences at the T7 (downstream) and SP6
(upstream ofGNAS1) ends ofPAC dJ309f20 were determined. Based on these
sequences, oligonucleotides were designed for use in further PCR screening of the
RCPI1 PAC library, in order to identify other clones that overlapped dJ309f20.
Following this, further sequence analysis of subclone libraries constructed from these
clones was carried out.
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4.2 MATERIAL AND METHODS
4.2.1 POLYMERASE CHAIN REACTION
All PCRs and RT-PCRs were carried out with one of six different buffer conditions,
as described in Chapter 2, Materials and Methods.
4.2.2 OLIGONUCLEOTIDES
The following oligonucleotides were used for PCR, and sequencing:
NAME SEQUENCE 5'- 3'
SEQUENCE ANALYSIS OF M13F/R ENDS OF SUBCLONES
119-1R/A1 TGG ATG GCA GCA GGC AAA G
12ORl/114 GCT GTG AAC TGT CCA TTT
34F8/114 GGA TGG TAA CTT CGG GCA G
1476-a GGA GCC TTC GTT CTG TGC
4FHdF-a CTT AGC CAT CCT GAG AGT CC
D7BgF-a GCC TTC TGT GGG TTC TGT AGT TT
COMPLETE SEQUENCE ANALYSIS OF BamHI SUBCLONE Gil
THF AAC AGC CCT GCA TCT GCC GT
THF2 AGG GGA ACA GAA AAC TTA GGC
G11THF3B TAA AAA GGA AGG GGA TAC AGA T
THF4 CAA AGC CCC ACC ACC GT
7F TTG ATG TGA GCG CTG TGA ACA
G117F2 CTG GAA TCT TTG AGA CCA AG
7R TGC CAA TCT AAA GCA AAG GTC
7R2 AGA AGG TTA GGG CAA ACA GGA
7R3 GGT AAT GCC TGA CAA AAA CA
7R4 TTG GGG TAA TTA ATA TGG AA
G117R5 AGC CAG CCA AAC CCC AGC
G117R6 CCC GAC AAA ATT CAA CAA
COMPLETE SEQUENCE ANALYSIS OF cDNA CLONE 1430
1430R2 CAT CGT CTG GGC TGA ATA A
1430R3 TAA GAC CTG TGG CAT CCC C
1430R4 ACT TTG GGA GGC CGA GGC
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1430F2 TAG CCC TCT CCT TGT GGC A
1430F3 TGG GGA CAC ACT GGT TGC CT
COMPLETE SEQUENCE ANALYSIS OF cDNA CLONE 088f21
88f21R2 ATC CAA CAC CTT TCC CCA GC
8 8 f21R3 GGG GCG TAT CTA GTG TTG AA
88f21F4 GGA AGC TGA CAG GGA CCA A
8 8 f21F3 GCC CCA TCT CCA ATT CTA AT
88f21R5 TGC CTC CTT TTC GAC GAC TGA T
8 8 f21F5 TTG GAA GCA GCA GGG ACC
COMPLETE SEQUENCE ANALYSIS OF CDNA CLONE NX11
NX11-EST1 GTT GGC GGT CAT CAT CA
NX11-EST2 GAA AGT TCT CCC ATT GAG AGC AC
NX11-3 TCT CTC TGA TGC CAC AAC A
NX11-4 GCA AAT GCA GGC TGA TGG CGC
NX11-5 TGT TGT GGC ATC AGA GAG A
NX11-6 GCG CCA TCA GCC TGC ATT TGC
NX11-7 TCT CCT GGC CAT ATC TAG C
NX11-9 CAG CTG CTG GGC CAC TCT TTG
NX11-11 CCG TGT TCA GGG TCG TTT CT
NX11-12 TTC CAA TCA TGC CAT TCT T
NX11-13 CCT GGA TGT GGG CTC TGC A
NX11-14 AAG AGG GAG CAG GGA GGA TC
NX11-15 GTT GGC GGT CAT CAT CA
NX11-16 GGA ACA CGT AGG GAG CAG AG
NX11-17 GCA CAA ACA TGC AGC CAA GT
4.2.3 PULSED-FIELD GEL ELECTROPHORESIS (PFGE)
For PFGE analysis the PAC clones were digested with rare cutting restriction
enzymes, and electrophoresis was performed in 1% agarose gel using a CHEF-DRII
apparatus (BioRad). The voltage was set at 200 volts, with a temperature of 14°C for
16 hours. Thereafter, the separated fragments were transferred to a nylon membrane
(Hybond N+, Amersham) by capillary blotting and then hybridised to 32P-labelled
probe as described in Chapter 2, Materials and Methods.
225
4.2.4 ANALYSIS OF SUBCLONE LIBRARIES FROM PAC CLONES
dJ309f20, dJ96n2 AND dJ654c22
PAC DNA was purified and used for the construction of the subclone libraries.
Sequencing of plasmid subclones from the libraries was performed using either a 33P-
labelled dideoxy terminator kit (Amersham USB) or dye terminator chemistry on an
ABI377 automatic sequencer. The sequences obtained were used for database
searching with the BLAST algorithm, and further analysis using the HGMP NIX
interface to multiple sequence analysis programs, as described in Chapter 2,
Materials and Methods.
For screening of the subclone libraries by hybridization, the subclones were
replicated from 96-well plates onto nylon filters. These filters were hybridized using




Four PAC clones (dJ60ol6, dJ63n2, dJl 1 Op 14, dJ309f20) had originally been
identified in the RPCI1 library by PCR screening for exon 7 of GNAS1. However,
further analysis indicated that of these four clones, dJ309f20 was the only one that
contained all the exons of GNAS1. It was therefore chosen for further sequence
analysis, and as the starting point for extending the PAC contig.
4.3.1 SCREENING OF PAC dJ309f20 SUBCLONE LIBRARIES
A subclone library in the pUC18 vector was constructed from PAC dJ309f20,
digested with the restriction enzymes BamHI or Bglll. 50 subclones from each of the
BamHl and Bglll libraries were picked at random and both ends were sequenced
using the oligonucleotide primers M13F and M13R. The sequences obtained were
used to search (using the BLAST algorithm at NCBI) four different databases: non-
redundant GenBank, human ESTs, mouse ESTs and other (non-human or mouse)
ESTs. From these initial 100 subclones analysed the results were as follows:
Seven subclones contained insert sequences identical to various exons of the GNAS1
gene; four contained ESTs other than GNAS1; 21 had sequences similar to E. coli
(presumably as a result of the presence ofE. coli genomic DNA contaminating the
preparations ofPAC DNA); one had a sequence similar to S. cerevisiae; ten insert
sequences were not of good quality for analysis and the remaining 57 subclones
identified sequences without matching EST or related to repetitive elements type LI
or Alu (Table 4.1).
NAME GNAS1 ESTs E. coli S. cerevisiae Rep. elements Other
NUMBER 7 3 21 1 57 11
Table 4.1. dJ309f20 subclone library screening results.
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The three novel ESTs identified in this initial round of sequencing were in the inserts
of subclones Al, G11 and C6 in the BamWl library and these subclones were
therefore further analysed.
4.3.2 ANALYSIS OF SUBCLONE BamAl
The insert in subclone AXBamUl group 1 (referred to hereafter as BamAl) was
sequenced at both ends. The sequence obtained from the M13R end was 300 nt in
length and contained no EST matches. The sequence obtained from its M13F end
was 520 nt and had a significant match to the EST AA159229, representing an
mRNA derived from human pancreas.
The IMAGE cDNA clone corresponding to EST AA159229 was obtained from the
UK HGMP Resource Centre under its identifier 1430-d08, (referred to hereafter as
cDNA clone 1430). This cDNA had been cloned into the pBluescript SK vector
using the enzymes EcoKl and Xhol and was therefore digested with both enzymes,
showing that its insert was ~lkb in length (Figure 4.1). DNA from the genomic








Figure 4.1. Restriction digests of cDNA clone 1430 and genomic subclone BamAl.
Lanes: 1) 1 kb ladder, 2) Clone 1430 uncut, 3) Clone 1430, EcoK\+Xho\ digested, 4)
Subclone BamAl uncut, 5) Subclone BamAl, BamHl digested. The arrows mark the
insert bands.
The insert of cDNA clone 1430 was then completely sequenced on both strands. Its






















911 TGATGAAACACCATCTCTACTAAAAATACAAAAAAAAAAAAAAAAAAACTCGAG Xhol (M13F)
Figure 4.2. Complete sequence of cDNA clone 1430. The EcoKl and Xhol sites
(corresponding to the M13R and M13F end of the subclone) are marked in bold italic
letters. The position and orientation of the oligonucleotides used for sequencing are
indicated by the arrows and are underlined.
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The genomic insert in BamAl was also further sequenced from its M13F end and the
sequence obtained was compared with the complete sequence of cDNA clone 1430.
It was found that the sequences were oppositely orientated at their M13 ends and that
a probable intron-exon junction was present. The alignment of these sequences is












Figure 4.3. Comparison of the M13R end of cDNA 1430 with the matching part of
genomic subclone BamAl. The ZscoRI cloning site of the cDNA is in bold letters and
underlined and the adaptor sequence using for cloning is underlined. The intron-exon
junction in the genomic sequence is marked by a vertical line and is in bold letters.
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1 2
Figure 4.4. Autoradiograph showing partial sequences of a region from the genomic
subclone BamAl (sequence 1) with the matching part of the EST clone 1430 M13F
end (sequence 2) derived using the primer 1430R4. The partial sequences indicated
by the brace are compared on the right of the figure. The site where the sequences
diverge is marked by a vertical line and the Xhol cloning site of the cDNA clone is
underlined.
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Further genomic sequence analysis ofPAC dJ309f20 was later carried out by Dr. B.
E. Hayward, including determination of the complete sequence of the 12 kb genomic
insert in subclone BamAl (Hayward and Bonthron, 2000). This data indicated that
the putative transcript represented by cDNA 1430 lies within a region ~19kb
upstream ofNESP55 (discussed in Chapter 3).
4.3.3 ANALYSIS OF SUBCLONE BamGll
Sequencing of the insert of dJ309f20 subclone G1 IBamRl (referred to hereafter as
BamGl 1) identified ESTs at both M13-ends. The sequence obtained from its M13R
end was 271 nt in length and included part of exon 9 and the whole of exon 8 of
GNAS1. The sequence obtained from the M13F end was 352 nucleotides in length
and had 3 significant EST database alignments: AA195902, an mRNA derived from
muscle, H72932, an mRNA from fetal liver and spleen, and D81936, a mRNA from
fetal brain. The sequence of EST AA195902 was used for a further BLAST search,
identifying another three ESTs, AA284401, AA278187 and AA253299.
These EST sequences were also used to search the TIGR database, identifying the
1255 nt consensus sequence THC205478 as a significant match, with a percentage of
identity of 97.8%. Based on the existence of this apparent EST contig, it was decided
to characterise in more detail the insert of genomic subclone BamGl 1. BamGl 1
DNA was digested with BarnWl, showing that its insert was ~2kb in length (not
shown).
From the known genomic structure of GNAS1, the position of the BamHl site in exon
9 made it clear that the 2 kb insert in BamGl 1 must also contain exons 7 and 8 of the
gene. To establish the distance separating the sequence in BamGl 1 that matches
THC205478 from exon 7 ofGNAS1, a PCR was performed with primers named
THC (THC sequence) and PHP7R (exon 7 of GNAS1). As template, BamGl 1 DNA,
PAC dJ309f20 DNA and human genomic DNA were used. The PCR product
obtained in each case was -1200 bp (Figure 4.5).
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Figure 4.5. THC-PHP7R PCR products. Lanes 1) 1 kb ladder, 2) BamGl 1 DNA
template, 3) dJ309f20 PAC DNA template, 4) human genomic DNA template and 5)
no template (control blank).
Finally, the BamGl 1 insert was completely sequenced on both strands. The sequence
was 2103 nt in length (Figure 4.6).
Figure 4.6. Complete sequence of genomic subclone BamGl 1. The BamHl sites are
underlined. The sequence contained in THC313290 (the most recent version of the
original cDNA contig THC205478) is in bold letters and GNAS1 exons 7 to 9 are
highlighted in grey and labelled. The arrows mark the positions and orientations of





















































This completed sequence was used to perform further database searches using
BLAST, showing that it contained the entire sequence ofputative cDNA contig
THC205478, as well as GNAS1 sequences corresponding to part of intron 6, exon 7,
intron 7, exon 8, intron 8 and part of exon 9 (Figure 4.7).
Figure 4.7. Subclone BamGl 1. A) GNAS1 partial gene structure (not to scale), as in
Kozasa et al. (1988). Exons are represented by grey boxes and are numbered. The
BamHl sites are indicated. B) Genomic subclone BamGl 1, showing the position of
the THC313290 contig sequence within intron 6 of GNAS1 and the GNAS1 exons






More recently, the THC205478 entry has been replaced by an updated contig,
THC313290. The sequences of genomic subclone BamGl 1 and THC313290 were
compared using BLAST 2. The sequences were 99% identical, with minor
differences between them probably representing sequencing errors. As shown in
figure 4.6, (a) there is a single contiguous region ofmatch between the genomic
sequence and THC313290 (b) the genomic sequence has a poly(A) stretch
corresponding in position to that of the putative EST contig. The results suggest that
THC313290 actually represents a genomic sequence, represented in the EST
databases as a result of priming from a (dA)-rich region ofDNA. However, it is also
possible that the THC313290 ESTs represent a genuine unspliced transcript, which
could also be part of a larger transcript. The 3' end of the sequence THC313290 is
336 nt away from exon 7 of GNAS1.
4.3.4 ANALYSIS OF SUBCLONE BamC6
The sequence obtained from the insert in subclone C6 BamHl (referred to hereafter
as BamC6) was 158 nt in total length. This sequence showed a significant match to a
human EST T84962/11764, derived from a fetal liver and spleen cDNA library.
4.3.4.1 Clone 088f21 enzymatic digestion analysis
The corresponding IMAGE cDNA clone was obtained from the UK HGMP
Resource Centre under its identifier 088f21. The cDNA insert was cloned between
Pacl and EcoRl sites in the vector pT7T3D. Plasmid DNA was extracted and
digested with Pad and EcoRX, yielding a band of-700 bp .
4.3.4.2 Sequence analysis of clone 088f21























Figure 4.8. Sequence of the insert of cDNA clone 088f21. The BamHl, Pacl, EcoRl
and the poly(A) signal sites are marked in bold. The sequence contained in subclone
BamC6 is highlighted in grey and the position and orientation of the oligonucleotides
used for the analysis are marked by arrows. The splice junction (described in section
4.3.5) is marked by a vertical line.
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When the sequence from clone 088f21 and subclone BamC6 inserts were compared,
it was noticed that they had the same orientation with respect to their M13-ends and







Figure 4.9. Alignment of partial sequences from cDNA clone 088f21 and genomic
subclone BamC6. The intron-exon splice junction is marked by a vertical line, and
the intron sequence in subclone BamC6 is in lower case. The BamHl site is in bold.
A further hybridisation screen of the dJ309f20 genomic subclone libraries was
performed to identify subclones containing the remaining part of the sequence of
cDNA clone 088121. For this purpose, a PCR product was generated using
oligonucleotides 88f21F3 and M13R, purified from a 1% low-melting-point agarose
gel, and labelled as described in Chapter 2, Materials and Methods for use as a
hybridisation probe.
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Several subclones were identified in this screen (Figure 4.10). Among them, as
expected, were BamC6 (positive control) and, unexpectedly, the subclones BamAl
and Bgl34. The subclone BamAl was mentioned above because it contained
sequences corresponding to the cDNA 1430 (section 4.3.2) and was sequenced
completely later in our laboratory. The subclone Bgl34 was known to contain the
NESP55 sequence (Chapter 3) and its sequence was also completed in totality later.
The oligonucleotide 88121F3 itselfwas also used for a further round of screening of
the subclone libraries. Since it corresponds to a sequence adjacent to the poly(A)
signal in cDNA clone 088121, the genomic subclones identified by it should contain






Figure 4.10. dJ309f20 subclone library screening for clones containing exons of the
antisense transcript 088f21. The M13R-088f21F3 PCR product was used as probe.
Duplicate membranes were hybridized; both master and copy membranes are shown.
The positive subclones, BamAl, BamD12 and BamF6 (in this group) are marked by
block arrows.
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4.3.5 Analysis of subclone BglC2
From the several subclones positive for the 3' end of the antisense transcript 88f21,
subclone C2 from the Bglll library (referred to hereafter as subclone BglC2) was
further analysed. By PCR with the M13F and M13R primers an insert length of ~2.7
kb was determined.
Primer 88f21F3 (see Figure 4.8) was used for sequencing on this new genomic
subclone. When the 301 nt genomic sequence obtained was compared to the 088f21
cDNA sequence the two sequences were identical as far as the already identified
intron-exon splice junction (Figure 4.11; sequences shown on reverse strand to
correspond to Figure 4.8). Immediately beyond this point the sequences diverge, with
a consensus —AG/ splice acceptor site being present in the BglC2 sequence.






Figure 4.11 Comparison of part of the sequences of genomic subclone BglC2 and
cDNA clone 088f21. The intron-exon splice junction is marked by a vertical line.
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As mentioned, the large (12 kb) subclone BamAl was also positive on screening
with oligonucleotide 88f21F3, and from its size, it was expected that it would contain
the complete 2.7 kb Bglll insert of subclone BglC2. In order to establish the position
of the 088f21 cDNA sequence (later identified as exon V of the antisense transcript
at the GNAS1 locus, Hayward and Bonthron, 2000) within these two genomic
subclones and also their respective orientations relative to the Ml 3 primers, PCRs
were set up using the M13F or M13R primers with 88f21F3 or 88f21R3. The
deduced map of these genomic clones is shown in Figure 4.12.
Figure 4.12. Diagram to show relative positions and orientation of subclones BamAl
and BglC2. The orientation of the vector relative to the subclone inserts ends is
indicated by M13F and M13R. The BamHl and Bglll sites are shown (in subclone
BglC2 the Bglll sites are shown in brackets, as they were destroyed during cloning
into the BamHl site of pUC18). The oligonucleotides used for sequencing and PCR
analysis and their orientation are indicated as arrows. Exon V of the antisense
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4.3.6 ANALYSIS OF SUBCLONE BAMF3
The original sequence of genomic subclone BamC6 (which had identified the 088f21
cDNA in the EST databases) consisted only of a small insert of 158 bp between two
BamHl sites. Subsequent screens for other genomic clones containing parts of cDNA
088f2l identified among others subclone Bgl34. This subclone had already been
analysed, and was known to contain the NESP55 exon (described in Chapter 3).
However, restriction mapping and then later complete sequencing of Bgl34 revealed
only one BamHl site corresponding to the site at one end ofBamC6. The position of
this site indicated a discrepancy between the structures ofBamC6 and Bgl34.
To resolve this discrepancy in the presence or absence of the second BamHl site
between the two clones, another BamHl subclone that was positive on screening for
088f21 was analysed. This was subclone F3 (referred to hereafter as subclone
BamF3).
Digestion of subclone BamF3 with BamHl showed that unlike BamC6, its insert was
~7kb (data not shown). It was sequenced at both ends using M13F and M13R
primers. The sequence obtained from the M13R end of this clone was identical to
that of BamC6 as far as the position of the discordant second BamHl site. At this
point, no BamHl site was present in subclone BamF3, consistent with the data
obtained from sequencing of subclone Bgl34 (Figure 4.13).
It therefore appeared that the small insert ofsubclone BamC6 was artefactually















Figure 4.13. Sequence comparison of subclones BamC6 and Bgl34. The partial
sequence (sequence A) of subclone Bgl34 is shown as in Figure 3.17, from nt 2574
to 2774, and it is compared to the complete sequence of subclone BamC6 (sequence
B). The sequences are identical from nt 2584 to nt 2731 (region delimited by vertical
lines, including the itamHI-restriction site marked in bold letters and upper case-
present in both subclones). This sequence comprises part of an intron (lower case
letters) and part of exon IV of the GNAS1 antisense transcript (marked in upper case
letters and in grey). The sequences differ from nt 2574 to 2573 (marked in bold
letters), where an artefactual BamHI site is present in BamC6 (shown in brackets).
This result was also verified by sequencing on subclone BamF3.
4.3.6.1 Further sequence analysis of subclone BamF3
A 333 nt sequence read was obtained from the M13F end of subclone BamF3. This
sequence yielded two significant alignments in the EST databases, to accession
numbers AA179082 and AA176863, whose sequences overlap. The IMAGE clone
corresponding to EST AA179082 was obtained from the UK HGMP Resource
Centre under its identifier 1476-kl 1.
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4.3.6.1.1 Analysis ofIMAGE clone 1476-kl 1
The cDNA insert of 1476-kl 1 had been cloned into a pBluescript vector with the
enzymes EcoKl and Xhol. An EcoRl+Xhol digest of this clone showed that the insert
size was only ~250 bp. The insert in clone 1476-kl 1 was completely sequenced from





Figure 4.14. Clone 1476-kl 1 insert sequence. TheiscoRI and Xhol sites are
underlined and in bold.
The insert sequences from clone 1476-kl 1 and subclone BamF3 were then
compared. As can be noted in Figure 4.15, clone 1476-kl 1 is included almost in its
totality in subclone BamF3 and it may be part of a bigger transcript. The putative
cDNA sequence of clone 1476-kl 1 was completely colinear with the genomic
sequence of subclone BamF3 apart from its first 7 nt (Figure 4.15). These 7 nt are in
fact derived from a linker used for library construction. In addition, the Xhol site at
the other end of the cDNA clone appears not to be linker derived, but to correspond
to anXhol site present in the genomic sequence at this point. It is therefore possible






Figure 4.15. Sequence alignment ofEST clone 1476-kl 1 and subclone BamF3. The
Xhol site is in bold and underlined. The site where the sequences diverge is marked
by a vertical line.
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